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ABSTRACT 
MATTHEW T. MARTIN: Using High Throughput Screening For Predictive Modeling of 
Reproductive Toxicity 
(Under the direction of Dr. David J. Dix) 
 
Traditional reproductive toxicity testing is inefficient, animal intensive and expensive 
with under a thousand chemicals ever tested among the tens of thousands of chemicals in our 
environment. Screening hundreds of chemicals through hundreds high-throughput biological 
assays generated a validated model predictive of rodent reproductive toxicity with potential 
application toward large-scale chemical testing prioritization and chemical testing decision-
making. Chemical classification for model development began with the uniform capturing of 
the available animal reproductive toxicity test information utilizing an originally developed 
relational database and reproductive toxicity ontology. Similarly, quantitative high-
throughput screening data were consistently processed, analyzed and stored in a relational 
database with gene and pathway mapping information. Chemicals with high quality in vivo 
and in vitro data comprised the training, test, external and forward validation chemical sets 
used to develop and assess the predictive model based on eight selected features generally 
targeting known modes of reproductive toxicity action. In three case studies, the forward 
validated predictive model reduced the overall costs of reproductive toxicity testing by 
roughly twenty percent. The model provides a starting point for the future of reproductive 
toxicity testing. 
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CHAPTER 1 
INTRODUCTION 
Reproductive Physiology 
 Successful reproduction involves a complex orchestration of behavioral, 
physiological, biochemical, and molecular events requiring optimal timing and are driven 
primarily by the integration of signals along the hypothalamic-pituitary-gonadal (HPG) axis 
in both males and females (Perreault, 2008) (Figure 1.1). Normal male physiological 
processes revolve, primarily, around the testis which controls male development, sexual 
behavior, and reproductive capability. Specifically, the hypothalamus releases neuro-
hormones including gonadotropin-releasing hormone (GnRH), stimulating the release of 
follicle stimulating hormone (FSH) and lutenizing hormone (LH) from the pituitary to 
regulate functions of seminiferous tubules (via Sertoli cells) and the interstitium (via the 
Leydig cell) in the testis, respectively (Johnson et al., 2010). Leydig cells in the testis are 
then responsible for the excretion of testosterone and secondary metabolites including 
estrogen, which provide regulatory feedback to the hypothalamus and pituitary, androgen- 
and estrogen-mediated effects on target organs, and  regulate sexual development and 
function (Swerdloff et al., 2009). Spermatogenesis is one such biological process triggered 
by well orchestrated HPG signals as indicated by the balance of LH and testosterone in the 
serum. The mass balanced nature of the HPG axis, including both positive and negative 
feedback mechanisms, creates a compensatory system able to withstand ever changing 
dynamics from internal and external signals. However, chronic stressors and susceptible 
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developmental and life-stages can cause deleterious changes in sex hormone levels leading to 
sexual decrements. 
 Much of the same neuroendocrine control along the HPG axis regulates female 
reproduction and, in fact, the namesake for such hormones as FSH and LH were based on 
their function in the female reproductive system. The role of neuroendocrine function in 
females extends beyond that in males of reproductive tissue development, gametogenesis, 
and sexual behavior to also include menstrual cyclicity, offspring birthing and future 
development, and even milk production for lactation (Hoyer, 2010). Much like the testis, the 
ovary functions both as a gonad, developing and delivering oocytes, and as an endocrine 
gland producing important hormones such as inhibin, estradiol, and progesterone which 
allow the development of female secondary sexual characteristics and support pregnancy 
(McGee and Hsueh, 2000). Ovarian follicular development is induced by FSH followed by a 
surge of LH leading to the development of a mature follicle and release of the oocyte, but 
FSH is truly only indispensable to the final maturation process by rescuing a minority of 
follicles from atresia, or ovarian apoptosis (Chabbert Buffet et al., 1998;  Richards et al., 
1995). The majority of early ovarian follicular development have been shown to be 
independent of the larger HPG signaling processes with intra-ovarian paracrine signaling 
playing a major role (Richards and Pangas, 2010). Neuroendocrine regulation and ovarian 
function provide the necessary physiological environment with well choreographed processes 
to enable pregnancy, but the reproductive tract is the physical site of menstruation, 
implantation, pregnancy development and maintenance, and eventual birth. Alterations to the 
neuroendocrine system or reproductive tract can have profound effects on reproductive 
performance. 
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Chemically-induced Reproductive Toxicity 
The HPG axis provides the key controls and functions to normal reproductive 
development and performance, although altering the HPG axis is not the only means to 
reproductive impairment and toxicity, including neuromuscular and systemic target organ 
toxicities.  However, much of the research in molecular mechanism of reproductive toxicity 
in focused on the key molecular and hormonal targets within the HPG axis. Using animal 
models, a limited number of chemicals have well elucidated mechanisms of action in terms 
of effects on reproductive development or performance.  For example, vinclozolin is a 
dicarboximide fungicide and recognized to exert antiandrogenic activity (Gray et al., 1994). 
The ability of vinclozolin to displace the androgen receptor’s natural ligands, i.e., 
testosterone and dihydrotestosterone, leads to reduction in testosterone biosynthesis and 
disrupts androgen dependent mechanisms. The reduction in testosterone and disruption of 
androgen mediated mechanisms leads to reductions in sperm production, demasculinization, 
and sexual development, including delayed anogenital distance and preputial separation 
(Gray, et al., 1994;  Kubota et al., 2003). As with many environmental chemicals, the 
reproductive toxicity profile includes additional endpoints related and unrelated to its 
antiandrogenic mode of action. Additionally, vinclozolin’s antiandrogenic activity is not 
solely exerted in its parent form but generates metabolites with increased antiandrogenic 
potencies (Kelce et al., 1994). Vinclozolin provides a good example of the broad phenotypic 
consequences of disrupting key hormone levels that interact with many nodes in the HPG 
axis. 
Prochloraz, a conazole fungicide, causes relatively specific effects on steroidogenesis 
and malformations in androgen-dependent tissues. In contrast to vinclozolin that causes 
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testosterone reduction via androgen receptor antagonism, prochloraz inhibits the conversion 
of progesterone to testosterone through the inhibition of CYP17, a key protein in the 
steroidogenic pathway (Blystone et al., 2007). Inhibition of CYP17 causes significant 
reductions in testosterone and prochloraz specifically inhibits steroidogenesis at the protein, 
not genomic, level (Laier et al., 2006;  Vinggaard et al., 2002). The complexity and 
compensatory nature of the HPG axis make identifying the specific mechanism of action for 
particular chemicals difficult purely from a phenotypic perspective. The adverse outcomes of 
vinclozolin and prochloraz appear similar but in fact are driven primarily by two distinct 
mechanisms, androgen receptor antagonism and CYP17 inhibition, respectively. Androgen 
receptor antagonism appears to cause more direct effects on sexual development and 
differentiation with secondary effects on steroidogenesis, while inhibition of CYP17 and 
other steroidogenic pathway proteins cause primary effects on sperm production and 
secondary effects on sexual development via reduced testosterone. 
Environmental chemicals have also been shown to cause male and female 
reproductive toxicity through direct cytotoxic actions in the reproductive tract. For example, 
4-vinylcyclohexene and its diepoxide metabolite cause ovarian toxicity by damaging ovarian 
follicles. Additionally, 4-vinylcyclohexene causes ovarian cancer in long-term rodent studies 
and has demonstrated increased risk in humans (IARC, 1994).  The primary mode of action 
for 4-vinylcyclohexene ovotoxicity is the induction of follicular apoptosis (Hoyer et al., 
2001). 4-vinylcyclohexene is an example of a chemical acting primarily at a physiological 
level within the HPG axis. However, the relative sensitivity of 4-vinylcyclohexene can be 
mitigated through changes in metabolism, e.g., differences between rat and mouse, and 
through specific molecular oxidative stress sensors such as nuclear factor erythroid 2-related 
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factor 2 (Nrf2) (Hu et al., 2006). The wide range of modes and mechanisms of action leading 
to reproductive toxicity demonstrate the complexity of developing alternative toxicity tests 
that can efficiently evaluate a chemical complete reproductive toxicity potential. However, 
the diverse set of phenotypes that arise from the potentially finite numbers of mechanisms 
may make it possible to develop a battery of more efficient tests that adequately cover the 
known modes of action. As opposed to pure animal tests observing gross phenotypes, a 
battery of tests evaluating modes of action would better enable the evaluation of a chemical’s 
human reproductive toxicity potential. 
Human Reproductive Impairment 
One in ten to one in six couples seek medical help due to subfertility with 20-25% of 
the problem being due to the male partner, 30-40% due to the female partner, roughly 30% 
due to potentially both partners, and roughly 15% with no specific factor identified  (De 
Kretser and Baker, 1999). Infertility throughout most literature is described or defined as a 
couple who have never been able to become pregnant after at least one year of unprotected 
intercourse. Infertility statistics may be skewed based on the research demonstrating that 
about 25% of all pregnancies are lost prior to clinical recognition and were only detectable 
through urinary concentrations of human chorionic gonadotropin (hCG) (Wilcox et al., 1999;  
Wilcox et al., 1988). Therefore, the combination of male infertility, female infertility, and 
impaired fecundity (e.g., miscarriage or pregnancy loss) are all components in assessing 
overall human reproductive health decrements, but have diverse etiologies spanning genetic, 
disease, age, lifestyle, and environmental factors.  
 Estimating environmental/chemical-exposure contributions to human reproductive 
impairment and infertility has been shown to be difficult to assess due to many confounding 
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factors (Sharpe, 2000). For instance, male infertility, as compared to female infertility, may 
appear to be the more straightforward assessment because one can simply measure sperm 
count and quality as a major indicator of male infertility. Unfortunately, humans are naturally 
inefficient at spermatogenesis and have high inter- and intra-individual variability forcing 
studies to require high sample sizes and other study design considerations which make these 
studies less feasible and desirable (Sharpe, 2010). Nonetheless, lifestyle-related and 
environmental factors, such as smoking, obesity, traffic exhaust, dioxins, and combustion 
products, appear to negatively affect the perinatal and adult testes while there is suggestive, 
but generally unconfirmed, evidence that pesticide, food additive, persistent pollutant, and 
polychlorinated biphenyl exposure affect spermatogenesis in the general population (Sharpe, 
2010). Many confounders, including age, lifestyle, and disease background must be 
accounted for in studying female fertility and fecundity levels due to environmental 
exposures. Recently a study of 1240 women found that environmental exposures to 
perfluorinated compounds significantly increased the time to pregnancy (Fei et al., 2009). 
These findings demonstrate that environmental relevant exposure levels to common 
industrial chemicals are linked to adverse reproductive performance in the general 
population. However, the ability to identify chemicals that affect human reproduction 
remains limited because of inadequate methodology spanning analytical chemistry to 
epidemiological measurements, small sample sizes, inappropriate endpoints, and the many 
confounders previously discussed and in many cases positive study findings are controversial 
and often are refuted in follow-up studies (Sharara et al., 1998). Epidemiological studies may 
be the most direct link to human relevant findings, but have shown limited success and only 
provide relevant information based on already exposed populations. The risk assessment 
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process attempts to characterize human risk of chemical exposure and the primary tool for 
doing such assessments are laboratory animal studies.  
Reproductive Toxicity Testing 
The chemical risk assessment process differs across regulatory bodies and chemical 
use classes. In the case of most environmental chemicals, multiple studies are used to assess 
the reproductive cycle in full (Figure 1.2). Prenatal developmental toxicity studies generally 
evaluate systemic toxicities to the pregnant female and fetal malformations and survival. 
Chronic and cancer long –term bioassays have the capacity to evaluate post-reproductive 
health, specifically male and female reproductive organ cancers. Specific and primary to the 
assessment of reproductive toxicity potential, the multigeneration reproductive toxicity study 
used by USEPA in the pesticide registration process assesses the performance and integrity 
of the male and female reproductive systems in the rat (USEPA, 1996) including assessment 
of gonadal function, the estrous cycle, mating behavior, conception, gestation, parturition, 
lactation, weaning, and on the growth and development of the offspring (Figure 1.3). The 
multigeneration study also provides information about the effects of the test substance on 
neonatal morbidity, mortality, target organs in the offspring, and data on prenatal and 
postnatal developmental toxicity. Two historical test guidelines have been used for the 
multigeneration studies. Multigeneration studies according to the 1982 Reproductive and 
Fertility Effects guideline (USEPA, 1982) have been conducted on over 700 chemicals and 
submitted to EPA. Multigeneration studies according to the newer 1998 guideline (USEPA, 
1998) have been conducted on over 90 chemicals and submitted. Information on data 
submissions to EPA was drawn from the Office of Pesticide Programs (OPP) Information 
Network- the OPPIN database (Bouve, 2002). The 1998 guideline was harmonized by EPA’s 
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Office of Pollution Prevention & Toxic Substances (OPPTS) to meet testing requirements of 
the EPA’s Office of Pollution Prevention and Toxics (OPPT) and OPP, as well as 
international guidelines published by the Organization for Economic Cooperation and 
Development (OECD). Both of the guidelines call for a two-generation study in which 
continuously treated male and female rats are mated to produce first generation offspring, 
and in turn the adult offspring are mated to produce a second generation (Figure 1.3.A).  In 
the United States, only food-use pesticide active ingredients are run routinely through a two-
generation reproductive toxicity study. 
Industrial chemicals, regulated under Toxics Substance Control Act (TSCA), rarely 
have a reproductive toxicity test performed and most studies found for industrial chemicals 
have been performed independent of TSCA (Aso et al., 2005;  Fujii et al., 2005;  Tyl et al., 
2008;  York et al., 2010). The European Union’s Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) regulation and potential TSCA reform may change the 
amount of reproductive toxicity tests routinely run on industrial chemicals, but the efficiency, 
practicality, and capacity to run thousands of industrial chemicals through such time-
consuming and expensive tests has been questioned (Hartung and Rovida, 2009). The pre-
clinical chemical safety assessment of pharmaceuticals with respect to reproductive toxicity 
have been historically divided into three segments with segment one and three addressing 
fertility and pre-/post-natal toxicity, respectively (Lumley, 1991). The International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) has evaluated the three-segment strategy and 
numerous proposals for revised testing protocols (Barrow, 2009;  Lumley, 1991). A similar 
effort to revise the two-generation reproductive protocol used for most environmental 
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chemicals has been under evaluation and attempts to reduce animal use by going to an 
extended one-generation protocol and using cohorts to evaluate developmental neurotoxicity 
and immunotoxicity potential (Piersma et al., 2010). The two-generation study data has been 
used to retrospectively evaluate the ability of a one-generation protocol to adequately assess 
a chemical’s reproductive toxicity potential by comparing classes of effects across the first 
and second generations (Figure 1.3B). Adapting and progressing reproductive toxicity testing 
study designs will reduce, to some extent, animal use and provide additional toxicological 
information. However, these new study designs do not and will not address the chemical 
testing bottleneck. The United States Environmental Protection Agency (EPA) has identified 
roughly 10,000 environmentally relevant chemicals that have been or may need to be 
assessed for their human exposure and toxicity potential (Judson et al., 2009). Past and 
current traditional reproductive toxicity testing has tested roughly 1,000 environmental 
chemicals in forty years. This testing strategy trajectory cannot be maintained, while 
claiming to be protective of human health and is being recognized around the world with 
regulatory changes such as the European Union’s Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) regulation and research initiatives such as the 
interagency program called Tox21 (Collins et al., 2008). The basic premise is to have all 
chemicals evaluated for toxicity potential, but the methods for arriving at this goal is less 
well defined in the regulatory context. Research initiatives, such as Tox21 and the EPA’s 
ToxCast program, have proposed large scale high-throughput screening assays to probe 
biological pathways to ascertain a chemical’s toxicity potential using computational 
modeling. 
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Predictive Toxicology using Computational and Alternative Methods 
 The medical and health community have been in search for indicators of human 
disease since the dawn of medicine. From demons and bad omens, to fevers and rash, to key 
measurement devices like the blood pressure cuff or x-ray machine, to the heart attack 
decision tree, these indicators of disease range from being associative, symptomatic, 
diagnostic, or prognostic. Just as twentieth century medicine was not focused on prevention, 
human disease indicators were not generally predictive. Two key scientific advancements 
have begun to change this. Advancements in molecular biology and computer science 
provide physicians, scientists, and researchers the tools to become preventative and 
predictive. Much like what the blood pressure cuff did for accurate measurement of blood 
pressure and thus the ability to causally associate high blood pressure with increased risk of 
heart disease and other adverse health outcomes, the mapping of the human genome has 
produced an entire generation of biological assays that allow for the accurate measurement of 
gene, protein, and cellular changes. These advancements have changed all health research 
fields, including drug discovery, epidemiology and toxicology. 
 Toxicology has the appearance of being reluctant to incorporating advances in 
molecular biology and computer science into its everyday practice and from a regulatory 
perspective this may be the case. On the other hand, toxicology does not have the luxury of 
testing adverse chemicals effects to humans in most cases and highly observational animal 
studies have been the primary measurement tool of toxicologists. Therefore, species 
extrapolation and mechanistic understanding have been primary themes in toxicology leading 
to the use of advanced molecular biology tools including genomics. Additionally, there has 
been an emphasis on reducing animal use in testing and increasing testing efficiency, which 
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has led to the use of advanced computational tools such as machine learning in structure 
activity relationship (SAR) modeling. The major difference between toxicology and other 
medical science disciplines is that toxicology has not taken advantage of the combined power 
of molecular biology and computer science. The focus from observational and descriptive 
toxicology has changed to an emphasis on mechanistic, predictive and high-throughput 
toxicology. Incorporating information and lessons from the last fifty years of toxicology into 
modern computing and biological tools include traditional toxicology studies being captured 
in databases, mechanistic studies, dose response modeling, and structure-based modeling. 
Toxicity Databases 
 Therefore, computational toxicology is an emerging field that combines in vitro and 
computationally-generated data on chemicals, information on biological targets (genes, 
proteins), pathways and processes, and informatics methods to model and understand the 
mechanistic basis of chemical toxicity (Judson, 2011). One of the key informatics methods 
applied is relational database and knowledgebase creation capable of storing, aggregating and 
analyzing large previously unsearchable data and information. The amount of reference 
toxicity information on environmental chemicals, including primary studies, study reviews 
and summarized reports, quickly diminishes beyond pesticide active ingredients, Integrated 
Risk Information System (IRIS) chemicals, NTP nominated chemicals and a few other 
sources (Judson et al., 2008;  Judson, et al., 2009). Efforts to digitize and structure the vast 
stores of open literature and unpublished industry-submitted studies have provided the 
information in a context amenable to using the data as anchoring endpoints for predictive 
toxicology applications. The currently available chemical-induced toxicity databases vary 
widely in breadth and depth of information (Bitsch et al., 2006;  Knudsen et al., 2009;  
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Martin et al., 2009a;  Martin et al., 2009b;  Richard et al., 2008;  Yang et al., 2006). IRIS is a 
good example of a database that has large content, covering greater than 500 chemicals and 
multiple toxicities, but lacks the standardization and detailed relational structure to provide 
accurate and efficient read-across (USEPA, 2011). ToxML, and related Food and Drug 
Administration (FDA) databases, ToxRefDB (U.S. EPA’s Toxicity Reference Database), and 
REPDOSE are examples of relational formats that currently house hundreds of chemicals and 
multiple study types in a standardized format using controlled vocabularies (Bitsch, et al., 
2006;  Martin, et al., 2009a;  Yang, et al., 2006). Web accessible toxicological data sources 
have been previously characterized (Felsot, 2002;  Gold et al., 1991;  Russom, 2002;  
Wolfgang and Johnson, 2002). These internet resources range from food and drug toxicity to 
environmental and ecological toxicity. Some of the internet sources provide fairly detailed 
summaries from cancer-related and genotoxicity studies. However, the information from 
these various sources is dispersed across the internet and in a wide variety of formats. 
Systems such as TOXNET, DSSTox, ACToR and PUBCHEM have made many of these 
resources available in a compiled format able to be searched based on chemical structure 
(Judson, et al., 2008;  USEPA, 2007). The utility of chemical toxicity databases range from 
regulatory retrospective analyses (Piersma, et al., 2010), toxicity data gap analyses (Judson, 
et al., 2009), species concordance (Gold, et al., 1991), and toxicity classification modeling 
(Judson et al., 2010a;  Zhu et al., 2009). Chemical toxicity information from structured, 
relational and searchable databases has provided a renewable resource for previously 
unachievable, unrepeatable, or non-updatable analyses, as well as setting the stage for 
measurable impacts that computational toxicology can make on chemical toxicity testing. 
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Chemical Structure-based Modeling in Toxicology 
 In addition to and in conjunction with chemical toxicity database efforts, 
computational approaches using structure-based classification and regression methods, 
including quantitative structure activity relationship (QSAR) models, have pushed the 
boundary on the amount of data and information required to assess a chemical’s toxicity 
potential. Can a chemical’s toxicity potential be predicted only using chemical structure? 
Historically the answer has be ‘no’; QSAR and other structure-based modeling approaches 
have had limited success in gaining regulatory acceptance or application due to three primary 
reasons; a lack of well annotated reference chemical toxicity information, the complexity and 
multi-modality of toxicity endpoints, and limited focus on modeling best practices especially 
with regard to model quality and applicability metrics. Recently, efforts to develop modeling 
best practices and workflow have enabled appropriate evaluation of QSAR models before 
and after publication. QSAR modeling efforts have too often focused on “introspective” 
indicators of model accuracy and quality (Tropsha and Golbraikh, 2007) and in most cases 
were explanatory in nature.  
QSAR publications often internal measures of model accuracy and quality, but until 
recently, the “modern QSAR” era, little effort or emphasis has been placed on rigorous 
model validation, including external validation, determination of the domain of applicability, 
and targeted chemical selection (Golbraikh et al., 2003;  Golbraikh and Tropsha, 2002;  
Tropsha and Golbraikh, 2007). There are many potential reasons for the increased attention 
to external validation, including larger chemical sets, expanded applications and journal 
publication standards, but nonetheless modern QSAR model validation should and has begun 
to focus on external validation. In general, current practices generally include a clear 
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definition of the training and test set, external validation set, measures of accuracy at all 
levels of model development, and a clearly defined domain of applicability. 
Structure-activity relationships (SAR) have been used for a number of regulatory 
actions and decisions in the past, including but not limited to: chemical groupings (e.g., High 
Production Volume chemical categories), bridging of toxicity data (e.g., antimicrobial re-
registration; iodine and iodine complexes were all registered together with a single reference 
dose using data on representative compounds), supporting in vivo outcome calls (e.g., cancer 
assessment, using results of chemicals in same class to bolster argument for cancer 
classification), and study design requirements (e.g., organophosphates required to perform 
AChE testing). These applications of SAR have been fairly limited to simplistic analogy 
models or based solely on structure similarity and are not generalizable or externally 
predictive of biological or toxicological activity. QSAR models, alone, may never be broadly 
used for predictive toxicology, but the experiences gained from years of research in 
developing classification models of toxicity, developing best modeling practices and 
identifying data gaps where predictive toxicology is most needed has and will continue to 
push forward computational toxicology. 
Experimental Predictive Toxicology 
Approaches for predicting toxicity using computational methods and alternative test 
data has advanced our understanding of the molecular basis of toxicity. Iconix’s Drug 
Matrix® stored experimental information from genomic studies including detailed pathology 
and developed genomic signatures or classifiers predictive of toxicity (Fielden et al., 2005;  
Fielden and Kolaja, 2008;  Ganter et al., 2005) and showed promise in predicting toxicities of 
environmental chemicals (Martin et al., 2007). Importantly, the use of reference toxicity 
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information was used in the development of the classifiers in all studies. Similar 
governmental efforts to create the data management tools for storing genomic and phenotypic 
information has created the computational environments for the analysis of large genomic 
datasets with corresponding toxicity or phenotypic data. NIEHS’s Chemical Effects in 
Biological Systems (CEBS) has been developed to store diverse biological information 
resulting from various toxicity and biological studies (Waters et al., 2003;  Waters et al., 
2008;  Xirasagar et al., 2006). Systems-based toxicology in the world of drug discovery and 
drug safety assessment has begun to take hold and used as a viable approach both early in the 
discovery process and later in assessing toxicological information (Mayne et al., 2006). 
Additional informatics approaches including pathway-based analysis linking in vitro assay 
results to drug label information and adverse effect data provided mechanistic insight into 
purported toxicities and side-effects of drugs (Fliri et al., 2005). Similar system-based and 
pathway-based approaches for toxicity prediction to limit the high attrition rate of 
pharmaceuticals in the pipeline have produced other tools and products (Apic et al., 2005). 
These analytical tools required extensive curation of the biological literature, expensive 
laboratory-based data generation, and resulted in large databases for storing the information. 
Systems-biology approaches, including in vivo genomic studies, can provide detailed 
biological mechanistic information, but often lack in throughput and animal efficiency. In 
contrast, QSAR has nearly unlimited throughput and requires no animals, but lacks the 
mechanistic underpinnings often required for regulatory acceptance. To begin to obtain the 
advantages of both worlds, computational toxicology has elicited the use of high-throughput 
in vitro biological assays, previously used heavily in lead drug discovery within the 
pharmaceutical industry (Bleicher et al., 2003;  Mayr and Bojanic, 2009). The toxicological 
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community has turned the paradigm upside down by attempting to broadly profile the 
biological activity of a chemical to then develop fingerprints of activity predictive of 
toxicities and to better understand a chemical’s mechanism of action (Dix et al., 2007;  
Kavlock et al., 2008). Combining in vitro biological assay data into the QSAR modeling 
framework has shown improvement in predicting in vivo toxicological outcomes (Zhu et al., 
2008) and serves as a good example of integrating data across many domains.  
In Vitro Assays in Toxicology 
In vitro biological assays have existed for many years and have been run routinely in 
the toxicological testing process, including the Ames mutagenicity assay (Ames, 1973;  
Ames et al., 1973a;  Ames et al., 1973b). In vitro assay systems have advanced primarily due 
to innovations and advancements in gene/protein sequencing, computer /robotic systems, and 
cell culturing capacity. These innovations have enabled the creation of two focus areas of in 
vitro systems, high throughput screening (HTS) and high content screening (HCS). HTS 
generally focuses on techniques that efficiently measure chemical interactions with proteins 
or cells using 96-, 384-, or 1536-well plates in single concentration screening or 
concentration response formats. HTS assays can be characterized on being cell-free or cell-
based, the cell type when applicable, the intended target or targets, and the readout.  HTS is 
often intended to provide a specific response output covering a specific gene, protein, 
pathway or cell while testing hundreds to thousands of chemicals. The National Institutes of 
Health (NIH) Chemical Genomics Center (NCGC) took HTS one step further by created a 
robotic and assay platform system capable of screening thousands of chemicals in 12-15 
concentration response format, coined Quantitative HTS (qHTS) and using further analysis 
automation to process the outputted data (Inglese et al., 2006;  Inglese et al., 2007). In 
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contrast, HCS focuses on the dynamics (e.g., measurements over time and space) of the 
biological system and are almost exclusively cell-based or model organism-based (e.g., 
zebrafish) systems primarily using imaging techniques (Bullen, 2008;  Giuliano et al., 2005;  
Giuliano et al., 2006). As computational power and robotics systems become cheaper and 
better, HTS and HCS will continue to merge with HTS investigating highly dynamic systems 
across time and producing highly multiplexed results and HCS increasing the throughput 
capacity and the molecular specificity of the target readouts. In addition to running assays in 
concentration response, the U.S. EPA’s ToxCast research program has focused on covering 
as much biology as possible with commercially available assays and those assays available 
through internal and external collaborations (Judson, et al., 2010a). The product of running 
hundreds of diverse assays across thousands of chemicals in full concentration response 
format is millions of data points that require management, analysis and synthesis. 
The field of toxicology has specialized in dose response modeling and has 
characterized dose response relationships across many toxicities and chemicals (Andersen et 
al., 2005;  Cox, 1987;  Leroux et al., 1996;  Setzer et al., 2001;  Swenberg et al., 2008), but 
the vast amount of data generated in HTS and the need for generalizable and extensible 
approaches across datasets remains a challenge for the toxicological community. Limited 
information is available on HTS dose response modeling best practices and appropriate dose 
response modeling techniques to be used for large HTS datasets (Parham et al., 2009). The 
U.S. EPA ToxCast program has released the fifty-percent activity concentrations (AC50), 
full concentration response, and summary calls for over 500 assays and provided both 
detailed and summary data analysis methodologies (Judson et al., 2010b). Generally, a four-
parameter hill model can be fit to the data producing a model that estimates the baseline 
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response (B), maximal or top response (T), the slope of the response (W), and the AC50. Pre-
processing, parameter constraining, confounding, statistical and biological considerations all 
play a role into the final set of conditions used to define active or inactive concentrations of a 
particular chemical-assay combination. Specific considerations include, but are not limited 
to; data normalization methods, positive and negative control performance and availability, 
baseline response adjustments, plate or well variations, response saturation (e.g., full versus 
partial agonist), active concentration extrapolation, outlier detection and removal, response 
directionality, non-monotonic response detection, cytotoxicity filtering and interpretation, 
fluorescence and other artifact detection, and statistical versus biological significance. Taking 
into account many of these considerations enables summary statistical outputs to be 
compared appropriately across assays and assay technologies and to be used in downstream 
modeling applications. 
HTS and HCS, in the toxicological modeling context, requires the integration of 
results across a broad biological activity profile as compared to specific targeted HTS assay 
results. There have been limited efforts toward the development of models predictive of 
toxicity solely using bioactivity profiling data, primarily due to the fact that public research 
programs such as ToxCast and Tox21 programs are still in early stages of data generation 
and subsequent model development. Additionally, the assay coverage for specific biological 
pathways linked to toxicities, where known, varies when using commercially available 
vendors, because many of the assays were developed in the pharmaceutical industry and, for 
instance, have greater coverage of cancer pathways due to drug discovery efforts in cancer 
therapeutics. One focus area in environmental toxicology that helped progress assay 
development has been in the area of endocrine disruption, due in large part to the regulatory 
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creation of the Endocrine Disrupter Screening Program (EDSP) within the U.S. EPA based 
on the 1996 Food Quality and Protection Act (FQPA) and the Safe Drinking Water Act 
(SDWA). EDSP mandates environmental chemicals be evaluated for endocrine disruption 
and therefore a testing battery was developed resulting in large scale assay development and 
validation efforts spanning in vitro and in vivo tests (Goldman et al., 2000;  Harding et al., 
2006). Assay coverage of biological pathways is ever increasing and may enable 
computational modeling in areas that have either been understudied, such as immunotoxicity, 
or have proven to be difficult from a modeling perspective, such as reproductive toxicity.  
 
Reproductive Toxicity Alternative Testing Methods 
Reproductive toxicity is a prime example of a toxicity that has had limited effort and 
success in predictive toxicity, due in part to the lack of reference data in which to model and 
the physiological complexity of general reproductive impairment. One resource for 
predictive models have come from structure based methods (i.e., Quantitative Structure 
Activity Relationship (QSAR) models) and the accuracy and predictivity of the resultant 
models has been limited. A comprehensive effort toward the prediction of reproductive and 
developmental toxicity was undertaken by the FDA (Matthews et al., 2007). The resultant 
QSAR models were developed for endpoints such as sperm effects, female reproductive 
toxicity and male reproductive toxicity and were generally highly specific models with an 
average specificity across all generated models being 88%. Based on the summary statistics 
extracted from the publications, the average balanced accuracy across all models was 58%, 
with the maximum balanced accuracy for any single model being 68% for trans-species 
female reproductive toxicity. It is difficult to assess the true accuracy and forward 
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predictivity of the models based solely on the summary statistics. Most likely, the limitation 
lies in the physiological complexity of reproductive toxicity and structural diversity of 
reproductive toxicants. Additional international efforts are underway with the goal of using 
alternative testing approaches in the detection of reproductive toxicants and on limited 
chemical sets have shown promise (Schenk et al., 2010). Previous international efforts such 
as ReproTect have shed light on the need for alternative test methods and predictive models 
for reproductive toxicity (Hareng et al., 2005), which focuses both on developmental and 
reproductive toxicity. The following table summarizes alternative test methods for assessing 
reproductive toxicity, specifically areas of fertility and fecundity, male and female 
reproductive tract, and reproductive development, as is studied in the two-generation 
reproductive test most often used for environmental chemical reproductive toxicity 
assessment (Table 1.1). Currently, no in vitro test or set of tests would be considered an 
adequate alterative to the two-generation reproductive study and, in most cases, would not 
drastically increase testing efficiency. The goal of the following research is to develop a 
predictive model of general reproductive toxicity using bioactivity profiling data from HTS 
assays for applications towards chemical testing prioritization and with the eventual capacity 
to be used in an integrated testing strategy for reproductive toxicity testing.  
 
  
 21
 
Ta
bl
es
 
Ta
bl
e 
1.
1.
 A
lte
rn
at
iv
e 
re
pr
od
uc
tiv
e 
to
xi
ci
ty
 te
st
 m
et
ho
ds
, t
he
ir 
ta
rg
et
 g
en
de
r, 
cu
rr
en
t m
ax
im
al
 a
ss
ay
 th
ro
ug
hp
ut
 a
nd
 e
xa
m
pl
e 
re
fe
re
nc
e(
s)
 a
re
 su
m
m
ar
iz
ed
 s
ho
w
in
g 
th
e 
lim
ite
d 
hi
gh
-th
ro
ug
hp
ut
 a
ss
ay
 s
ys
te
m
s c
ur
re
nt
ly
 a
va
ila
bl
e.
 
A
lte
rn
at
iv
e 
Te
st
 M
et
ho
d 
Ta
rg
et
 
G
en
de
r 
Sy
st
em
 
Ty
pe
 
Th
ro
ug
h-
pu
t 
R
ef
er
en
ce
 
In
 V
itr
o 
Fe
rti
lis
at
io
n 
as
sa
y 
(I
V
F)
  
Fe
m
al
e 
Ex
 V
iv
o/
 
In
 V
itr
o 
Lo
w
 
 (B
er
ge
r e
t a
l.,
 2
00
0)
 
O
va
ria
n 
Fo
lli
cl
e 
B
io
A
ss
ay
 (F
B
A
)  
Fe
m
al
e 
In
 V
itr
o 
Lo
w
 
 (W
an
 e
t a
l.,
 2
01
0)
 
G
ra
nu
lo
sa
 a
nd
 T
he
ca
 C
el
l C
ul
tu
re
 S
ys
te
m
s 
Fe
m
al
e 
In
 V
itr
o 
Lo
w
 
 (A
lb
er
tin
i a
nd
 A
kk
oy
un
lu
, 2
01
0)
 
In
 V
itr
o 
M
at
ur
at
io
n 
as
sa
y 
(I
V
M
)  
Fe
m
al
e 
In
 V
itr
o 
Lo
w
 
 (L
uc
ia
no
 e
t a
l.,
 2
01
0)
 
M
ou
se
 O
va
ria
n 
Tu
m
or
 C
el
l A
ss
ay
 
Fe
m
al
e 
In
 V
itr
o 
Lo
w
 
 (B
lu
m
en
th
al
 e
t a
l.,
 1
98
8)
 
O
va
ria
n/
Fo
lli
cl
e 
C
ul
tu
re
 S
ys
te
m
s 
Fe
m
al
e 
In
 V
itr
o 
Lo
w
 
 (C
or
tv
rin
dt
 a
nd
 S
m
itz
, 2
00
2)
 
H
um
an
 O
va
ria
n 
G
ra
nu
lo
se
-L
ik
e 
Tu
m
or
 C
el
l L
in
e 
(K
G
N
) 
cu
ltu
re
 a
ss
ay
 
Fe
m
al
e 
In
 V
itr
o 
M
ed
iu
m
 
 (M
or
in
ag
a 
et
 a
l.,
 2
00
4)
 
U
te
ro
tro
ph
ic
 A
ss
ay
 
Fe
m
al
e 
In
 V
iv
o 
Lo
w
 
 (K
im
 e
t a
l.,
 2
00
5)
 
B
in
di
ng
 A
ss
ay
s (
Es
tro
ge
n 
an
d 
A
nd
ro
ge
n 
R
ec
ep
to
r)
 
M
al
e 
&
 
Fe
m
al
e 
In
 V
itr
o 
H
ig
h 
 (F
re
yb
er
ge
r e
t a
l.,
 2
01
0)
 
Tr
an
sa
ct
iv
at
on
 A
ss
ay
s (
C
el
l-b
as
ed
 H
or
m
on
e 
R
ec
ep
to
r 
A
ct
iv
at
io
n)
 
M
al
e 
&
 
Fe
m
al
e 
In
 V
itr
o 
H
ig
h 
 (P
ee
kh
au
s e
t a
l.,
 2
00
3)
 
A
m
ph
ib
ia
n 
m
et
am
or
ph
os
is 
as
sa
y 
M
al
e 
&
 
Fe
m
al
e 
In
 V
iv
o 
Lo
w
 
(G
ut
le
b 
et
 a
l.,
 2
00
7)
 
Es
tro
ge
n-
/A
nd
ro
ge
n-
re
sp
on
si
ve
 c
el
l p
ro
lif
er
at
io
n 
as
sa
ys
 
(e
.g
., 
M
C
F-
7)
 
M
al
e 
&
 
Fe
m
al
e 
In
 V
itr
o 
H
ig
h 
 (L
yk
ke
sf
el
dt
 a
nd
 S
or
en
se
n,
 1
99
2)
 
Ex
te
nd
ed
 o
ne
-g
en
er
at
io
n 
M
al
e 
&
 
Fe
m
al
e 
In
 V
iv
o 
Lo
w
 
 (P
ie
rs
m
a,
 e
t a
l.,
 2
01
0)
 
21 
 
22
 
Pu
be
rta
l A
ss
ay
 (M
al
e 
an
d 
Fe
m
al
e)
 
M
al
e 
&
 
Fe
m
al
e 
In
 V
iv
o 
Lo
w
 
 (M
ar
ty
 e
t a
l.,
 1
99
9;
  M
ar
ty
 e
t a
l.,
 
20
01
) 
Sp
er
m
 C
hr
om
at
in
 S
tru
ct
ur
e 
A
ss
ay
 a
nd
 re
la
te
d 
in
 v
itr
o 
D
N
A
 d
am
ag
e 
as
sa
ys
 
M
al
e 
Ex
 V
iv
o/
 
In
 V
itr
o 
Lo
w
 
 (E
ve
ns
on
 a
nd
 W
ix
on
, 2
00
5)
 
Sp
er
m
 A
ct
iv
at
io
n 
A
ss
ay
 
M
al
e 
Ex
 V
iv
o/
 
In
 V
itr
o 
Lo
w
 
 (S
aw
ye
r a
nd
 B
ro
w
n,
 1
99
5)
 
Sp
er
m
 M
ot
ili
ty
 A
ss
ay
 
M
al
e 
Ex
 V
iv
o/
 
In
 V
itr
o 
Lo
w
 
 (B
et
an
co
ur
t e
t a
l.,
 2
00
6)
 
N
eu
tra
l C
om
et
 A
ss
ay
 in
 S
pe
rm
 (R
eP
ro
C
om
et
) 
M
al
e 
In
 V
itr
o 
Lo
w
 
 (C
or
de
lli
 e
t a
l.,
 2
00
7)
 
Is
hi
ka
w
a 
ce
ll 
te
st
 
M
al
e 
In
 V
itr
o 
M
ed
iu
m
 
 (S
ch
ae
fe
r e
t a
l.,
 2
01
0)
 
H
29
5R
 S
te
ro
id
og
en
es
is 
as
sa
y 
 
M
al
e 
In
 V
itr
o 
M
ed
iu
m
 
 (H
ec
ke
r a
nd
 G
ie
sy
, 2
00
8)
 
Le
yd
ig
/S
er
to
li/
Se
m
in
ife
ro
us
 T
ub
ul
e/
G
er
m
 C
el
l C
ul
tu
re
 
&
 C
o-
cu
ltu
re
 s
ys
te
m
s  
M
al
e 
In
 V
itr
o 
M
ed
iu
m
 
  (
B
ru
n 
et
 a
l.,
 1
99
1)
 
H
er
sh
be
rg
er
 A
ss
ay
 
M
al
e 
In
 V
iv
o 
Lo
w
 
 (S
hi
n 
et
 a
l.,
 2
00
7)
 
 
22 
 23 
Figures 
Figure 1.1 Overview of the key controls and functions of the hypothalamic-pituitary-gonadal 
axis, including gonadotropin-releasing hormone (GnRH), follicle stimulating hormone 
(FSH), and lutenizing hormone (LH) controls of testosterone (T), progesterone and estradiol 
production leading to gametogenesis in the female ovary and male testis. 
 
 
Figure 1.2. Schematic of the reproductive cycle in comparison to guideline toxicity studies 
performed most often for environmental chemical regulation. The multigeneration 
reproductive toxicity test spans portion of fetal development through juvenile development 
and back to the mating male and female and the pregnant female.  In contrast, the prenatal 
developmental toxicity test focuses on the pregnant female and fetal development, 
particularly malformations. The chronic/cancer bioassay does identify systemic and 
carcinogenic reproductive organ effects. 
 24 
 
Figure 1.3. (A) Schematic of the two-generation reproductive study design mapped to terms 
used in ToxRefDB, in particular the definition and separation of parental, offspring and 
reproductive effects. (B) To simplify downstream analyses, terms were often binned based on 
the high level categories and compared across generations. 
 25 
 
 26 
 
References 
Albertini, D. F. and Akkoyunlu, G. (2010). Ovarian follicle culture systems for mammals. 
Methods Enzymol 476, 107-21, S0076-6879(10)76007-9 [pii] 
10.1016/S0076-6879(10)76007-9. 
 
Ames, B. N. (1973). Carcinogens are mutagens: their detection and classification. Environ 
Health Perspect 6, 115-8. 
 
Ames, B. N., Durston, W. E., Yamasaki, E. and Lee, F. D. (1973a). Carcinogens are 
mutagens: a simple test system combining liver homogenates for activation and bacteria for 
detection. Proc Natl Acad Sci U S A 70, 2281-5. 
 
Ames, B. N., Lee, F. D. and Durston, W. E. (1973b). An improved bacterial test system for 
the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci U S A 70, 
782-6. 
 
Andersen, M. E., Thomas, R. S., Gaido, K. W. and Conolly, R. B. (2005). Dose-response 
modeling in reproductive toxicology in the systems biology era. Reprod Toxicol 19, 327-37, 
S0890-6238(04)00217-5 [pii] 
10.1016/j.reprotox.2004.12.004. 
 
Apic, G., Ignjatovic, T., Boyer, S. and Russell, R. B. (2005). Illuminating drug discovery 
with biological pathways. FEBS Lett 579, 1872-7, S0014-5793(05)00225-5 [pii] 
10.1016/j.febslet.2005.02.023. 
 
Aso, S., Ehara, H., Miyata, K., Hosyuyama, S., Shiraishi, K., Umano, T. and Minobe, Y. 
(2005). A two-generation reproductive toxicity study of butyl benzyl phthalate in rats. J 
Toxicol Sci 30 Spec No., 39-58, JST.JSTAGE/jts/30.S39 [pii]. 
 
Barrow, P. C. (2009). Reproductive toxicity testing for pharmaceuticals under ICH. Reprod 
Toxicol 28, 172-9, S0890-6238(09)00072-0 [pii] 
10.1016/j.reprotox.2009.03.013. 
 
Berger, T., Miller, M. G. and Horner, C. M. (2000). In vitro fertilization after in vivo 
treatment of rats with three reproductive toxicants. Reprod Toxicol 14, 45-53, S0890-
6238(99)00062-3 [pii]. 
 
Betancourt, M., Resendiz, A. and Fierro, E. C. (2006). Effect of two insecticides and two 
herbicides on the porcine sperm motility patterns using computer-assisted semen analysis 
(CASA) in vitro. Reprod Toxicol 22, 508-12, S0890-6238(06)00061-X [pii] 
10.1016/j.reprotox.2006.03.001. 
 
 27 
Bitsch, A., Jacobi, S., Melber, C., Wahnschaffe, U., Simetska, N. and Mangelsdorf, I. (2006). 
REPDOSE: A database on repeated dose toxicity studies of commercial chemicals--A 
multifunctional tool. Regul Toxicol Pharmacol 46, 202-10, S0273-2300(06)00097-3 [pii] 
10.1016/j.yrtph.2006.05.013. 
 
Bleicher, K. H., Bohm, H. J., Muller, K. and Alanine, A. I. (2003). Hit and lead generation: 
beyond high-throughput screening. Nat Rev Drug Discov 2, 369-78, 10.1038/nrd1086 
nrd1086 [pii]. 
 
Blumenthal, R. D., McLaughlin, W. H., Jordan, J. J., Cryan, E. V. and Bloomer, W. D. 
(1988). Mouse ovarian tumor cells: an experimental model for progestin-mediated 
radiotherapy. J Surg Oncol 39, 96-100. 
 
Blystone, C. R., Lambright, C. S., Howdeshell, K. L., Furr, J., Sternberg, R. M., Butterworth, 
B. C., Durhan, E. J., Makynen, E. A., Ankley, G. T., Wilson, V. S., Leblanc, G. A. and Gray, 
L. E., Jr. (2007). Sensitivity of fetal rat testicular steroidogenesis to maternal prochloraz 
exposure and the underlying mechanism of inhibition. Toxicol Sci 97, 512-9, kfm055 [pii] 
10.1093/toxsci/kfm055. 
 
Bouve, K. S. (2002). Electronic data submission: Pilot efforts in the Office of Pesticide 
Programs, US Environmental Protection Agency. Acs Sym Ser 824, 188-197. 
 
Brun, H. P., Leonard, J. F., Moronvalle, V., Caillaud, J. M., Melcion, C. and Cordier, A. 
(1991). Pig Leydig cell culture: a useful in vitro test for evaluating the testicular toxicity of 
compounds. Toxicol Appl Pharmacol 108, 307-20, 0041-008X(91)90120-4 [pii]. 
 
Bullen, A. (2008). Microscopic imaging techniques for drug discovery. Nat Rev Drug Discov 
7, 54-67, nrd2446 [pii] 
10.1038/nrd2446. 
 
Chabbert Buffet, N., Djakoure, C., Maitre, S. C. and Bouchard, P. (1998). Regulation of the 
human menstrual cycle. Front Neuroendocrinol 19, 151-86, S0091302298901674 [pii]. 
 
Collins, F. S., Gray, G. M. and Bucher, J. R. (2008). Toxicology - Transforming 
environmental health protection. Science 319, 906-907, DOI 10.1126/science.1154619. 
 
Cordelli, E., Fresegna, A. M., D'Alessio, A., Eleuteri, P., Spano, M., Pacchierotti, F. and 
Villani, P. (2007). ReProComet: a new in vitro method to assess DNA damage in mammalian 
sperm. Toxicol Sci 99, 545-52, kfm191 [pii] 
10.1093/toxsci/kfm191. 
 
Cortvrindt, R. G. and Smitz, J. E. (2002). Follicle culture in reproductive toxicology: a tool 
for in-vitro testing of ovarian function? Hum Reprod Update 8, 243-54. 
 
Cox, C. (1987). Threshold dose-response models in toxicology. Biometrics 43, 511-23. 
 
 28 
De Kretser, D. M. and Baker, H. W. G. (1999). Infertility in men: Recent advances and 
continuing controversies. J Clin Endocr Metab 84, 3443-3450. 
 
Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W. and Kavlock, R. J. 
(2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. 
Toxicol Sci 95, 5-12, kfl103 [pii] 
10.1093/toxsci/kfl103. 
 
Evenson, D. P. and Wixon, R. (2005). Environmental toxicants cause sperm DNA 
fragmentation as detected by the Sperm Chromatin Structure Assay (SCSA). Toxicol Appl 
Pharmacol 207, 532-7, S0041-008X(05)00241-3 [pii] 
10.1016/j.taap.2005.03.021. 
 
Fei, C., McLaughlin, J. K., Lipworth, L. and Olsen, J. (2009). Maternal levels of 
perfluorinated chemicals and subfecundity. Hum Reprod 24, 1200-5, den490 [pii] 
10.1093/humrep/den490. 
 
Felsot, A. S. (2002). WEB resources for pesticide toxicology, environmental chemistry, and 
policy: a utilitarian perspective. Toxicology 173, 153-66, S0300483X0200029X [pii]. 
 
Fielden, M. R., Eynon, B. P., Natsoulis, G., Jarnagin, K., Banas, D. and Kolaja, K. L. (2005). 
A gene expression signature that predicts the future onset of drug-induced renal tubular 
toxicity. Toxicol Pathol 33, 675-83, T06867K6170G4R68 [pii] 
10.1080/01926230500321213. 
 
Fielden, M. R. and Kolaja, K. L. (2008). The role of early in vivo toxicity testing in drug 
discovery toxicology. Expert Opin Drug Saf 7, 107-10, 10.1517/14740338.7.2.107. 
 
Fliri, A. F., Loging, W. T., Thadeio, P. F. and Volkmann, R. A. (2005). Analysis of drug-
induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 1, 389-
97. 
 
Freyberger, A., Wilson, V., Weimer, M., Tan, S., Tran, H. S. and Ahr, H. J. (2010). 
Assessment of a robust model protocol with accelerated throughput for a human recombinant 
full length estrogen receptor-alpha binding assay: protocol optimization and intralaboratory 
assay performance as initial steps towards validation. Reprod Toxicol 30, 50-9, S0890-
6238(10)00003-1 [pii] 
10.1016/j.reprotox.2010.01.001. 
 
Fujii, S., Yabe, K., Furukawa, M., Hirata, M., Kiguchi, M. and Ikka, T. (2005). A two-
generation reproductive toxicity study of diethyl phthalate (DEP) in rats. J Toxicol Sci 30 
Spec No., 97-116, JST.JSTAGE/jts/30.S97 [pii]. 
 
Ganter, B., Tugendreich, S., Pearson, C. I., Ayanoglu, E., Baumhueter, S., Bostian, K. A., 
Brady, L., Browne, L. J., Calvin, J. T., Day, G. J., Breckenridge, N., Dunlea, S., Eynon, B. 
P., Furness, L. M., Ferng, J., Fielden, M. R., Fujimoto, S. Y., Gong, L., Hu, C., Idury, R., 
 29 
Judo, M. S., Kolaja, K. L., Lee, M. D., McSorley, C., Minor, J. M., Nair, R. V., Natsoulis, G., 
Nguyen, P., Nicholson, S. M., Pham, H., Roter, A. H., Sun, D., Tan, S., Thode, S., Tolley, A. 
M., Vladimirova, A., Yang, J., Zhou, Z. and Jarnagin, K. (2005). Development of a large-
scale chemogenomics database to improve drug candidate selection and to understand 
mechanisms of chemical toxicity and action. J Biotechnol 119, 219-44, S0168-
1656(05)00151-3 [pii] 
10.1016/j.jbiotec.2005.03.022. 
 
Giuliano, K. A., Cheung, W. S., Curran, D. P., Day, B. W., Kassick, A. J., Lazo, J. S., 
Nelson, S. G., Shin, Y. and Taylor, D. L. (2005). Systems cell biology knowledge created 
from high content screening. Assay Drug Dev Technol 3, 501-14, 10.1089/adt.2005.3.501. 
 
Giuliano, K. A., Johnston, P. A., Gough, A. and Taylor, D. L. (2006). Systems cell biology 
based on high-content screening. Methods Enzymol 414, 601-19, S0076-6879(06)14031-8 
[pii] 
10.1016/S0076-6879(06)14031-8. 
 
Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y. D., Lee, K. H. and Tropsha, A. (2003). Rational 
selection of training and test sets for the development of validated QSAR models. J Comput 
Aided Mol Des 17, 241-53. 
 
Golbraikh, A. and Tropsha, A. (2002). Predictive QSAR modeling based on diversity 
sampling of experimental datasets for the training and test set selection. J Comput Aided Mol 
Des 16, 357-69. 
 
Gold, L. S., Slone, T. H., Manley, N. B., Garfinkel, G. B., Hudes, E. S., Rohrbach, L. and 
Ames, B. N. (1991). The Carcinogenic Potency Database: analyses of 4000 chronic animal 
cancer experiments published in the general literature and by the U.S. National Cancer 
Institute/National Toxicology Program. Environ Health Perspect 96, 11-5. 
 
Goldman, J. M., Laws, S. C., Balchak, S. K., Cooper, R. L. and Kavlock, R. J. (2000). 
Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and 
thyroid activity in the female rat. A focus on the EDSTAC recommendations. Crit Rev 
Toxicol 30, 135-96, 10.1080/10408440091159185. 
 
Gray, L. E., Jr., Ostby, J. S. and Kelce, W. R. (1994). Developmental effects of an 
environmental antiandrogen: the fungicide vinclozolin alters sex differentiation of the male 
rat. Toxicol Appl Pharmacol 129, 46-52, S0041-008X(84)71227-0 [pii] 
10.1006/taap.1994.1227. 
 
Gutleb, A. C., Schriks, M., Mossink, L., Berg, J. H. and Murk, A. J. (2007). A synchronized 
amphibian metamorphosis assay as an improved tool to detect thyroid hormone disturbance 
by endocrine disruptors and apolar sediment extracts. Chemosphere 70, 93-100, S0045-
6535(07)00832-6 [pii] 
10.1016/j.chemosphere.2007.06.048. 
 
 30 
Harding, A. K., Daston, G. P., Boyd, G. R., Lucier, G. W., Safe, S. H., Stewart, J., Tillitt, D. 
E. and Van Der Kraak, G. (2006). Endocrine disrupting chemicals research program of the 
U.S. Environmental Protection Agency: summary of a peer-review report. Environ Health 
Perspect 114, 1276-82. 
 
Hareng, L., Pellizzer, C., Bremer, S., Schwarz, M. and Hartung, T. (2005). The integrated 
project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reprod 
Toxicol 20, 441-52, S0890-6238(05)00092-4 [pii] 
10.1016/j.reprotox.2005.04.003. 
 
Hartung, T. and Rovida, C. (2009). Chemical regulators have overreached. Nature 460, 
1080-1081, Doi 10.1038/4601080a. 
 
Hecker, M. and Giesy, J. P. (2008). Novel trends in endocrine disruptor testing: the H295R 
Steroidogenesis Assay for identification of inducers and inhibitors of hormone production. 
Anal Bioanal Chem 390, 287-91, 10.1007/s00216-007-1657-5. 
 
Hoyer, P. B. (2010). Female Reproductive Toxicology. pp. 339-345. Elsevier, Oxford. 
 
Hoyer, P. B., Devine, P. J., Hu, X., Thompson, K. E. and Sipes, I. G. (2001). Ovarian toxicity 
of 4-vinylcyclohexene diepoxide: a mechanistic model. Toxicol Pathol 29, 91-9. 
 
Hu, X., Roberts, J. R., Apopa, P. L., Kan, Y. W. and Ma, Q. (2006). Accelerated ovarian 
failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. Mol Cell Biol 26, 940-
54, 26/3/940 [pii] 
10.1128/MCB.26.3.940-954.2006. 
 
IARC (1994). 4-vinylcyclohexene. IARC Monogr Eval Carcinog Risks Hum 60, 347-59. 
 
Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W. and 
Austin, C. P. (2006). Quantitative high-throughput screening: a titration-based approach that 
efficiently identifies biological activities in large chemical libraries. Proceedings of the 
National Academy of Sciences of the United States of America 103, 11473-8. 
 
Inglese, J., Johnson, R. L., Simeonov, A., Xia, M., Zheng, W., Austin, C. P. and Auld, D. S. 
(2007). High-throughput screening assays for the identification of chemical probes. Nature 
chemical biology 3, 466-79, nchembio.2007.17 [pii] 
10.1038/nchembio.2007.17. 
 
Johnson, L., Welsh Jr, T. H., Curley Jr, K. O. and Johnston, C. E. (2010). Anatomy and 
Physiology of the Male Reproductive System and Potential Targets of Toxicants. pp. 5-59. 
Elsevier, Oxford. 
 
Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., Cathey, T., Transue, T. 
R., Spencer, R. and Wolf, M. (2008). ACTOR - Aggregated Computational Toxicology 
Resource. Toxicol Appl Pharm 233, 7-13, DOI 10.1016/j.taap.2007.12.037. 
 31 
 
Judson, R., Richard, A., Dix, D. J., Houck, K., Martin, M., Kavlock, R., Dellarco, V., Henry, 
T., Holderman, T., Sayre, P., Tan, S., Carpenter, T. and Smith, E. (2009). The Toxicity Data 
Landscape for Environmental Chemicals. Environ Health Persp 117, 685-695, Doi 
10.1289/Ehp.0800168. 
 
Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. 
M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M. and Dix, D. J. (2010a). In Vitro 
Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast 
Project. Environ Health Perspect 118, 485-92, 10.1289/ehp.0901392. 
 
Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. 
M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M. and Dix, D. J. (2010b). In Vitro 
Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast 
Project. Environ Health Persp 118, 485-492, Doi 10.1289/Ehp.0901392. 
 
Judson, R. S., Reif, D.M., Houck K. (2011). Computational Toxicology In Principles of 
Toxicology: Environmental and Industrial Applications, 3rd Edition [In Preparation]. 
 
Kavlock, R. J., Ankley, G., Blancato, J., Breen, M., Conolly, R., Dix, D., Houck, K., Hubal, 
E., Judson, R., Rabinowitz, J., Richard, A., Setzer, R. W., Shah, I., Villeneuve, D. and 
Weber, E. (2008). Computational toxicology - A state of the science mini review. Toxicol Sci 
103, 14-27, DOI 10.1093/toxsci/kfm297. 
 
Kelce, W. R., Monosson, E., Gamcsik, M. P., Laws, S. C. and Gray, L. E., Jr. (1994). 
Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is 
mediated by antiandrogenic metabolites. Toxicol Appl Pharmacol 126, 276-85, S0041-
008X(84)71117-3 [pii] 
10.1006/taap.1994.1117. 
 
Kim, H. S., Kang, T. S., Kang, I. H., Kim, T. S., Moon, H. J., Kim, I. Y., Ki, H., Park, K. L., 
Lee, B. M., Yoo, S. D. and Han, S. Y. (2005). Validation study of OECD rodent uterotrophic 
assay for the assessment of estrogenic activity in Sprague-Dawley immature female rats. J 
Toxicol Environ Health A 68, 2249-62, G128388372141862 [pii] 
10.1080/15287390500182354. 
 
Knudsen, T. B., Martin, M. T., Kavlock, R. J., Judson, R. S., Dix, D. J. and Singh, A. V. 
(2009). Profiling the activity of environmental chemicals in prenatal developmental toxicity 
studies using the US EPA's ToxRefDB. Reprod Toxicol 28, 209-219, DOI 
10.1016/j.reprotox.2009.03.016. 
 
Kubota, K., Ohsako, S., Kurosawa, S., Takeda, K., Qing, W., Sakaue, M., Kawakami, T., 
Ishimura, R. and Tohyama, C. (2003). Effects of vinclozolin administration on sperm 
production and testosterone biosynthetic pathway in adult male rat. J Reprod Dev 49, 403-12. 
 
 32 
Laier, P., Metzdorff, S. B., Borch, J., Hagen, M. L., Hass, U., Christiansen, S., Axelstad, M., 
Kledal, T., Dalgaard, M., McKinnell, C., Brokken, L. J. and Vinggaard, A. M. (2006). 
Mechanisms of action underlying the antiandrogenic effects of the fungicide prochloraz. 
Toxicol Appl Pharmacol 213, 160-71, S0041-008X(05)00618-6 [pii] 
10.1016/j.taap.2005.10.013. 
 
Leroux, B. G., Leisenring, W. M., Moolgavkar, S. H. and Faustman, E. M. (1996). A 
biologically-based dose-response model for developmental toxicology. Risk Anal 16, 449-58. 
 
Luciano, A. M., Franciosi, F., Lodde, V., Corbani, D., Lazzari, G., Crotti, G., Galli, C., 
Pellizzer, C., Bremer, S., Weimer, M. and Modina, S. C. (2010). Transferability and inter-
laboratory variability assessment of the in vitro bovine oocyte maturation (IVM) test within 
ReProTect. Reprod Toxicol 30, 81-8, S0890-6238(10)00018-3 [pii] 
10.1016/j.reprotox.2010.01.015. 
 
Lumley, C. E. (1991). Proposal for international guidelines for reproductive and 
developmental toxicity testing for pharmaceuticals. Adverse Drug React Toxicol Rev 10, 143-
53. 
 
Lykkesfeldt, A. E. and Sorensen, E. K. (1992). Effect of estrogen and antiestrogens on cell 
proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 
and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31, 131-8. 
 
Martin, M. T., Brennan, R. J., Hu, W. Y., Ayanoglu, E., Lau, C., Ren, H. Z., Wood, C. R., 
Corton, J. C., Kavlock, R. J. and Dix, D. J. (2007). Toxicogenomic study of triazole 
fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals 
based on mechanisms of toxicity. Toxicol Sci 97, 595-613, DOI 10.1093/toxsci/kfm065. 
 
Martin, M. T., Judson, R. S., Reif, D. M., Kavlock, R. J. and Dix, D. J. (2009a). Profiling 
Chemicals Based on Chronic Toxicity Results from the US EPA ToxRef Database. Environ 
Health Persp 117, 392-399, Doi 10.1289/Ehp.0800074. 
 
Martin, M. T., Mendez, E., Corum, D. G., Judson, R. S., Kavlock, R. J., Rotroff, D. M. and 
Dix, D. J. (2009b). Profiling the Reproductive Toxicity of Chemicals from Multigeneration 
Studies in the Toxicity Reference Database. Toxicol Sci 110, 181-190, DOI 
10.1093/toxsci/kfp080. 
 
Marty, M. S., Crissman, J. W. and Carney, E. W. (1999). Evaluation of the EDSTAC female 
pubertal assay in CD rats using 17beta-estradiol, steroid biosynthesis inhibitors, and a thyroid 
inhibitor. Toxicol Sci 52, 269-77. 
 
Marty, M. S., Crissman, J. W. and Carney, E. W. (2001). Evaluation of the male pubertal 
onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats. Toxicol Sci 
60, 285-95. 
 
 33 
Matthews, E. J., Kruhlak, N. L., Daniel Benz, R., Ivanov, J., Klopman, G. and Contrera, J. F. 
(2007). A comprehensive model for reproductive and developmental toxicity hazard 
identification: II. Construction of QSAR models to predict activities of untested chemicals. 
Regul Toxicol Pharmacol 47, 136-55, S0273-2300(06)00174-7 [pii] 
10.1016/j.yrtph.2006.10.001. 
 
Mayne, J. T., Ku, W. W. and Kennedy, S. P. (2006). Informed toxicity assessment in drug 
discovery: systems-based toxicology. Curr Opin Drug Discov Devel 9, 75-83. 
 
Mayr, L. M. and Bojanic, D. (2009). Novel trends in high-throughput screening. Curr Opin 
Pharmacol 9, 580-8, S1471-4892(09)00128-3 [pii] 
10.1016/j.coph.2009.08.004. 
 
McGee, E. A. and Hsueh, A. J. (2000). Initial and cyclic recruitment of ovarian follicles. 
Endocr Rev 21, 200-14. 
 
Morinaga, H., Yanase, T., Nomura, M., Okabe, T., Goto, K., Harada, N. and Nawata, H. 
(2004). A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce 
aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology 
145, 1860-9, 10.1210/en.2003-1182 
en.2003-1182 [pii]. 
 
Parham, F., Austin, C., Southall, N., Huang, R., Tice, R. and Portier, C. (2009). Dose-
response modeling of high-throughput screening data. J Biomol Screen 14, 1216-27, 
1087057109349355 [pii] 
10.1177/1087057109349355. 
 
Peekhaus, N. T., Ferrer, M., Chang, T., Kornienko, O., Schneeweis, J. E., Smith, T. S., 
Hoffman, I., Mitnaul, L. J., Chin, J., Fischer, P. A., Blizzard, T. A., Birzin, E. T., Chan, W., 
Inglese, J., Strulovici, B., Rohrer, S. P. and Schaeffer, J. M. (2003). A beta-lactamase-
dependent Gal4-estrogen receptor beta transactivation assay for the ultra-high throughput 
screening of estrogen receptor beta agonists in a 3456-well format. Assay Drug Dev Technol 
1, 789-800, 10.1089/154065803772613426. 
 
Perreault, S. D., Klinefelter G.R., Clegg E. (2008). Assessment of Male Reproductive 
Toxicity. Informa Healthcare, USA. 
 
Piersma, A. H., Rorije, E., Beekhuijzen, M. E., Cooper, R., Dix, D. J., Heinrich-Hirsch, B., 
Martin, M. T., Mendez, E., Muller, A., Paparella, M., Ramsingh, D., Reaves, E., Ridgway, 
P., Schenk, E., Stachiw, L., Ulbrich, B. and Hakkert, B. C. (2010). Combined retrospective 
analysis of 498 rat multi-generation reproductive toxicity studies: on the impact of 
parameters related to F1 mating and F2 offspring. Reprod Toxicol, S0890-6238(10)00351-5 
[pii] 
10.1016/j.reprotox.2010.11.013. 
 
 34 
Richard, A. M., Yang, C. and Judson, R. S. (2008). Toxicity data informatics: supporting a 
new paradigm for toxicity prediction. Toxicol Mech Methods 18, 103-18, 
10.1080/15376510701857452. 
 
Richards, J. S., Fitzpatrick, S. L., Clemens, J. W., Morris, J. K., Alliston, T. and Sirois, J. 
(1995). Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and 
regulated genes. Recent Prog Horm Res 50, 223-54. 
 
Richards, J. S. and Pangas, S. A. (2010). The ovary: basic biology and clinical implications. J 
Clin Invest 120, 963-72, 10.1172/JCI41350 
41350 [pii]. 
 
Russom, C. L. (2002). Mining environmental toxicology information: web resources. 
Toxicology 173, 75-88, S0300483X02000239 [pii]. 
 
Sawyer, D. E. and Brown, D. B. (1995). The use of an in vitro sperm activation assay to 
detect chemically induced damage of human sperm nuclei. Reprod Toxicol 9, 351-7, 
0890623895000212 [pii]. 
 
Schaefer, W. R., Fischer, L., Deppert, W. R., Hanjalic-Beck, A., Seebacher, L., Weimer, M. 
and Zahradnik, H. P. (2010). In vitro-Ishikawa cell test for assessing tissue-specific chemical 
effects on human endometrium. Reprod Toxicol 30, 89-93, S0890-6238(10)00019-5 [pii] 
10.1016/j.reprotox.2010.02.002. 
 
Schenk, B., Weimer, M., Bremer, S., van der Burg, B., Cortvrindt, R., Freyberger, A., 
Lazzari, G., Pellizzer, C., Piersma, A., Schafer, W. R., Seiler, A., Witters, H. and Schwarz, 
M. (2010). The ReProTect Feasibility Study, a novel comprehensive in vitro approach to 
detect reproductive toxicants. Reprod Toxicol 30, 200-218, DOI 
10.1016/j.reprotox.2010.05.012. 
 
Setzer, R. W., Lau, C., Mole, M. L., Copeland, M. F., Rogers, J. M. and Kavlock, R. J. 
(2001). Toward a biologically based dose-response model for developmental toxicity of 5-
fluorouracil in the rat: a mathematical construct. Toxicol Sci 59, 49-58. 
 
Sharara, F. I., Seifer, D. B. and Flaws, J. A. (1998). Environmental toxicants and female 
reproduction. Fertility and Sterility 70, 613-622, Doi: 10.1016/s0015-0282(98)00253-2. 
 
Sharpe, R. M. (2000). Lifestyle and environmental contribution to male infertility. Br Med 
Bull 56, 630-42. 
 
Sharpe, R. M. (2010). Environmental/lifestyle effects on spermatogenesis. Philos T R Soc B 
365, 1697-1712, DOI 10.1098/rstb.2009.0206. 
 
Shin, J. H., Moon, H. J., Kang, I. H., Kim, T. S., Lee, S. J., Ahn, J. Y., Bae, H., Jeung, E. B. 
and Han, S. Y. (2007). OECD validation of the rodent Hershberger assay using three 
 35 
reference chemicals; 17alpha-methyltestosterone, procymidone, and p,p'-DDE. Arch Toxicol 
81, 309-18, 10.1007/s00204-006-0174-1. 
 
Swenberg, J. A., Fryar-Tita, E., Jeong, Y. C., Boysen, G., Starr, T., Walker, V. E. and 
Albertini, R. J. (2008). Biomarkers in toxicology and risk assessment: informing critical 
dose-response relationships. Chem Res Toxicol 21, 253-65, 10.1021/tx700408t. 
 
Swerdloff, R. S., Wang, C. and Sinha Hikim, A. P. (2009). Hypothalamic-Pituitary-Gonadal 
Axis in Men. pp. 2357-2393. Academic Press, San Diego. 
 
Tropsha, A. and Golbraikh, A. (2007). Predictive QSAR modeling workflow, model 
applicability domains, and virtual screening. Curr Pharm Des 13, 3494-504. 
 
Tyl, R. W., Myers, C. B., Marr, M. C., Sloan, C. S., Castillo, N. P., Veselica, M. M., Seely, J. 
C., Dimond, S. S., Van Miller, J. P., Shiotsuka, R. N., Beyer, D., Hentges, S. G. and 
Waechter, J. M., Jr. (2008). Two-generation reproductive toxicity study of dietary bisphenol 
A in CD-1 (Swiss) mice. Toxicol Sci 104, 362-84, kfn084 [pii] 
10.1093/toxsci/kfn084. 
 
USEPA (1982). OPP Guideline 83–4: Reproductive and Fertility Effects. Pesticide 
Assessment Guidelines, Subdivision F, Hazard Evaluation: Human and Domestic Animals. 
Office of Pesticides and Toxic Substances, Washington, DC.EPA–540/9–82–025 
 
USEPA (1996). Reproductive Toxicity Risk Assessment Guidelines. Fed. Regist 61, 56274–
56322. 
 
USEPA (1998). Health Effects Test Guidelines  
OPPTS 870.3800 Reproduction and Fertility Effects. Office of Pesticides and Toxic 
Substances, Washington, DC.EPA 712–C–98–208 
 
USEPA (2007). Distributed Structure-Searchable Toxicity (DSSTox) Database 
Network.http://www.epa.gov/ncct/dsstox/index.html 
 
USEPA (2011). Integrated Risk Information System (IRIS) 
Homepage.http://www.epa.gov/IRIS/ 
 
Vinggaard, A. M., Nellemann, C., Dalgaard, M., Jorgensen, E. B. and Andersen, H. R. 
(2002). Antiandrogenic effects in vitro and in vivo of the fungicide prochloraz. Toxicol Sci 
69, 344-53. 
 
Wan, X., Zhu, J., Zhu, Y., Ma, X., Zheng, Y., Wang, F., Liu, Z. and Zhang, T. (2010). Rat 
ovarian follicle bioassay reveals adverse effects of cadmium chloride (CdCl2) exposure on 
follicle development and oocyte maturation. Toxicol Ind Health 26, 609-18, 
0748233710375949 [pii] 
10.1177/0748233710375949. 
 
 36 
Waters, M., Boorman, G., Bushel, P., Cunningham, M., Irwin, R., Merrick, A., Olden, K., 
Paules, R., Selkirk, J., Stasiewicz, S., Weis, B., Van Houten, B., Walker, N. and Tennant, R. 
(2003). Systems toxicology and the Chemical Effects in Biological Systems (CEBS) 
knowledge base. EHP Toxicogenomics 111, 15-28. 
 
Waters, M., Stasiewicz, S., Merrick, B. A., Tomer, K., Bushel, P., Paules, R., Stegman, N., 
Nehls, G., Yost, K. J., Johnson, C. H., Gustafson, S. F., Xirasagar, S., Xiao, N., Huang, C. C., 
Boyer, P., Chan, D. D., Pan, Q., Gong, H., Taylor, J., Choi, D., Rashid, A., Ahmed, A., 
Howle, R., Selkirk, J., Tennant, R. and Fostel, J. (2008). CEBS--Chemical Effects in 
Biological Systems: a public data repository integrating study design and toxicity data with 
microarray and proteomics data. Nucleic Acids Res 36, D892-900, gkm755 [pii] 
10.1093/nar/gkm755. 
 
Wilcox, A. J., Baird, D. D. and Weinberg, C. R. (1999). Time of implantation of the 
conceptus and loss of pregnancy. N Engl J Med 340, 1796-9, 
10.1056/NEJM199906103402304. 
 
Wilcox, A. J., Weinberg, C. R., Oconnor, J. F., Baird, D. D., Schlatterer, J. P., Canfield, R. 
E., Armstrong, E. G. and Nisula, B. C. (1988). Incidence of Early Loss of Pregnancy. New 
Engl J Med 319, 189-194. 
 
Wolfgang, G. H. and Johnson, D. E. (2002). Web resources for drug toxicity. Toxicology 
173, 67-74, S0300483X02000227 [pii]. 
 
Xirasagar, S., Gustafson, S. F., Huang, C. C., Pan, Q., Fostel, J., Boyer, P., Merrick, B. A., 
Tomer, K. B., Chan, D. D., Yost, K. J., 3rd, Choi, D., Xiao, N., Stasiewicz, S., Bushel, P. and 
Waters, M. D. (2006). Chemical effects in biological systems (CEBS) object model for 
toxicology data, SysTox-OM: design and application. Bioinformatics 22, 874-82, btk045 [pii] 
10.1093/bioinformatics/btk045. 
 
Yang, C., Benz, R. D. and Cheeseman, M. A. (2006). Landscape of current toxicity databases 
and database standards. Curr Opin Drug Disc 9, 124-133. 
 
York, R. G., Kennedy, G. L., Jr., Olsen, G. W. and Butenhoff, J. L. (2010). Male 
reproductive system parameters in a two-generation reproduction study of ammonium 
perfluorooctanoate in rats and human relevance. Toxicology 271, 64-72, S0300-
483X(10)00094-6 [pii] 
10.1016/j.tox.2010.03.005. 
 
Zhu, H., Martin, T. M., Ye, L., Sedykh, A., Young, D. M. and Tropsha, A. (2009). 
Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. 
Chem Res Toxicol 22, 1913-21, 10.1021/tx900189p. 
 
Zhu, H., Rusyn, I., Richard, A. and Tropsha, A. (2008). Use of cell viability assay data 
improves the prediction accuracy of conventional quantitative structure-activity relationship 
models of animal carcinogenicity. Environ Health Perspect 116, 506-13, 10.1289/ehp.10573. 
 37 
 
 
 
 
CHAPTER 2 
PROFILING PHENOTYPIC ACTIVITY OF CHEMICALS FROM MULTIGENERATION 
REPRODUCTION STUDIES IN TOXREFDB1
 
 
Abstract 
 Multigeneration reproduction studies are used to characterize parental and offspring 
systemic toxicity, as well as reproductive toxicity of pesticides, industrial chemicals and 
pharmaceuticals. Results from 329 multigeneration studies on 316 chemicals have been 
digitized into standardized and structured toxicity data within the Toxicity Reference 
Database (ToxRefDB). An initial assessment of data quality and consistency was performed 
prior to profiling these environmental chemicals based on reproductive toxicity potential and 
generated toxicity endpoints for predictive modeling within the EPA’s ToxCast™ research 
program. Unsupervised hierarchical clustering of the lowest effect levels for 75 effects 
generated chemical-phenotype relationships and provided chemical clusters for predictive 
modeling. Comparative analysis across the 329 studies identified chemicals with sensitive 
reproductive effects, based on comparisons to chronic and subchronic toxicity studies, as 
well as cross-generational comparisons within the multigeneration study. The unsupervised 
clustering and comparative analyses identified 19 parental, offspring and reproductive effects 
with a high enough incidence to serve as targets for predictive modeling in ToxCast. These 
                                               
1 Previously published as Martin, M. T., Mendez, E., Corum, D. G., Judson, R. S., Kavlock, R. J., Rotroff, D. 
M. and Dix, D. J. (2009b). Profiling the Reproductive Toxicity of Chemicals from Multigeneration Studies in 
the Toxicity Reference Database. Toxicol Sci 110, 181-190, DOI 10.1093/toxsci/kfp080. 
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toxicity endpoints included specific reproductive performance indices, male and female 
reproductive organ pathologies, offspring viability, and parental systemic toxicities. 
Capturing this reproductive toxicity data in ToxRefDB supports ongoing retrospective 
analyses, test guideline revisions, and computational toxicology research. 
Introduction 
 The U.S. Environmental Protection Agency (EPA) and other regulatory agencies are 
investigating novel approaches for predicting chemical toxicity, with the goal of rapidly 
screening the thousands of environmental chemicals with limited toxicity data (Judson et al., 
2008). Building predictive models of chemical toxicity requires high quality in vivo toxicity 
data, in order to develop and validate new in vitro and in silico approaches. In support of 
EPA’s ToxCast™ predictive toxicology effort (Dix et al., 2007), we have created the 
Toxicity Reference Database (ToxRefDB) for capturing information from in vivo toxicity 
studies. ToxRefDB includes endpoints from multiple study types, including chronic rat and 
mouse carcinogenicity two-year bioassays that have been previously reported and made 
publicly available (Martin et al., 2009;  USEPA, 2009b). ToxRefDB is being used to build 
computational models linking whole animal toxicity, and specific tissue and cellular 
phenotypes, to specific chemical-biological interactions detected by cellular, genomic and 
biochemical in vitro assays. The in vivo toxicity data captured in ToxRefDB is facilitating a 
transition to the National Research Council’s vision for “Toxicity Testing in the 21st Century: 
A Vision and a Strategy” (Collins et al., 2008;  Gibson, 2010), by linking toxicity endpoints 
from animal studies to molecular targets and pathways relevant to humans. 
 The multigeneration study data entered into ToxRefDB provides anchoring in vivo 
reproductive toxicity data for the EPA ToxCast™ research program (USEPA, 2009a). Within 
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the ToxCast program, bioactivity profiles for hundreds of environmental chemicals are being 
derived from hundreds of in vitro assays (Dix, et al., 2007;  Houck and Kavlock, 2008). 
Phase I of ToxCast is focused on chemicals with known in vivo toxicity data, supporting the 
development of in vitro data signatures predictive of these in vivo outcomes(Judson et al., 
2010). It is worth noting that for environmental chemicals, unlike pharmaceuticals, 
quantitative in vivo toxicity data is essentially restricted to animal species. Nearly all of the 
ToxCast Phase I chemicals are food-use pesticide active ingredients that have undergone 
numerous mammalian toxicity tests, including guideline multigeneration studies. This highly 
standardized dataset provided in ToxRefDB facilitates profiling ToxCast Phase I chemical 
toxicity based on parental, offspring and reproductive effects.  
 Traditional toxicity testing for the risk assessment of environmental compounds or 
groups of compounds can cost millions of dollars and take years of effort. Since 1970, EPA 
has accumulated a vast store of high quality regulatory toxicity information on hundreds of 
compounds, most of which has been inaccessible to computational analyses. The curation 
and structuring of this chemical toxicity information into ToxRefDB has created a valuable 
resource for both retrospective and prospective toxicological studies (Martin, et al., 2009). In 
addition to the chronic/cancer rat and cancer mouse studies and multigeneration studies 
reported here, we are also extracting developmental toxicity studies in the rat and rabbit. The 
multigeneration reproductive toxicity dataset- studies used by EPA in the pesticide 
registration process to assess the performance and integrity of the male and female 
reproductive systems (USEPA, 1996) include assessment of gonadal function, the estrous 
cycle, mating behavior, conception, gestation, parturition, lactation, weaning, and on the 
growth and development of the offspring. The multigeneration study also provides 
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information about the effects of the test substance on neonatal morbidity, mortality, target 
organs in the offspring, and data on prenatal and postnatal developmental toxicity.  
 Two historical test guidelines have been used for the multigeneration studies in 
ToxRefDB. Multigeneration studies according to the 1982 Reproductive and Fertility Effects 
guideline (USEPA, 1982) on over 700 chemicals have been conducted and submitted to 
EPA. Multigeneration studies according to the newer 1998 guideline (USEPA, 1998) on over 
90 chemicals have been conducted and submitted, including 40 studies extracted into 
ToxRefDB. Information on data submissions to EPA was drawn from the Office of Pesticide 
Programs (OPP) Information Network- the OPPIN database. The 1998 guideline was 
harmonized by EPA’s Office of Pollution Prevention & Toxic Substances (OPPTS) to meet 
testing requirements of the EPA’s Office of Pollution Prevention and Toxics (OPPT) and 
OPP, as well as international guidelines published by the Organization for Economic 
Cooperation and Development (OECD). Both of the guidelines call for a two-generation 
study in which continuously treated male and female rats are mated to produce first 
generation offspring, and in turn the adult offspring are mated to produce a second 
generation. 
 Methods 
Data Characteristics  
 Reviews of registrant-submitted multigeneration reproductive toxicity studies, known 
as Data Evaluation Records (DER), were collected for roughly 300 chemicals from EPA’s 
Office of Pesticide Programs (OPP). File types of DER include TIFF, Microsoft Word, Word 
Perfect and PDF formats, some of which are not directly text-readable. Approximately 500 
multigeneration reproductive toxicity DER were reviewed, and based on data quality a subset 
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of 329 were selected for curation into ToxRefDB. The first portion of the DER outlines the 
test substance, purity, lot/batch numbers, MRID (Master Record Identification), study 
citation, OPPTS test guideline (USEPA, 1982;  USEPA, 1998) and reviewers of the study. 
The executive summary captures all of the basic study design information, including species 
and strain, doses, number of animals per treatment group and any deficiencies in study 
protocol. All dose levels were stored in ToxRefDB as ‘mg/kg/day’ and, where possible, 
recorded or calculated from food consumption data as an average over the entire dosing 
period. The executive summary also describes treatment-related effects observed at various 
dose levels in the study. The body of the DER provides detailed test material and animal 
information, and full dose response data in text and tables for all measured and observed 
endpoints. All treatment-related effects were captured for each study in ToxRefDB.  
 Multigeneration study DER contain all the information necessary to infer Lowest 
Effect Level (LEL) values for all treatment-related effects that were statistically or 
biologically significant. Typically the DER also designated ‘critical’ effects for each study, 
and Lowest Observed Adverse Effect Level (LOAEL) and No Observed Adverse Effect 
Level (NOAEL) for each study. If provided by the DER, ToxRefDB captured these study-
level NOAEL, LOAEL and critical effect data. However, it is important to note that the 
critical effects used to establish NOAEL, LOAEL and a reference dose (RfD) for a 
conventional chemical pesticide active, and to make regulatory risk assessment and 
management decisions, are based on a toxicological review of multiple studies across many 
study types.  
 Treatment-related effects were further identified as either a ‘Parental’, ‘Offspring’, or 
‘Reproductive’ effect. Consistent with DER, ‘Parental’ endpoints were defined as systemic 
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toxicity observed in the male or female adult parents, and exclude effects directly related to 
reproduction (e.g., reproductive organ toxicity). ‘Offspring’ endpoints were defined as 
systemic toxicity observed in the pre-weaning and juvenile animals, and exclude birthing 
indices up to post-natal day (PND) four (e.g., litter size and live birth index). ‘Reproductive’ 
endpoints were defined as observed effects on the reproductive performance or capacity of 
the animals and included all reproductive organ toxicities, effects on estrous cyclicity, sperm 
parameters, fertility, and mating, and pre-natal and early post-natal viability. 
 A small number of ToxCast Phase I chemicals were not pesticide active chemicals, 
such as some perfluorinated compounds and phthalates. Though DER and pesticide 
registration studies were not available for these chemicals, there was often high quality, 
standardized reproductive toxicity studies available from the National Toxicology Program, 
peer-reviewed literature, or other sources. When data from such studies were available, it was 
curated into ToxRefDB consistent with information taken from DER.  
Data Model and Quality Control 
 The relational data model for ToxRefDB was previously described (Martin, et al., 
2009) in a diagram showing the data model and field-level. A Data Entry Tool was 
developed for database population, including a controlled vocabulary for reproductive and 
other test data (available for download at http://actor.epa.gov/toxrefdb/). Additional data 
entry and quality control procedures for ToxRefDB have been previously described (Martin, 
et al., 2009). 
 Full descriptions of the available data and conclusions as to the potential for the 
pesticides to cause harm to humans or the environment, risk mitigation measures, and the 
regulation of pesticides can be found at U.S. EPA Office of Pesticide Programs website 
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(http://www.epa.gov/pesticides). The study-level critical effects captured in ToxRefDB and 
taken from individual DER and studies cannot be correlated directly to regulatory 
determinations or RfDs without additional information and analysis. 
Data Output and Analysis 
 The structured toxicity information stored within ToxRefDB can be extracted in 
various formats utilizing SQL™ queries. For the purpose of providing computable outputs, 
i.e. quantitative outputs amenable to statistical analysis, a consistent data output was used. 
The cross-tabulated data output consisted of rows of chemical information (e.g., Chemical 
Abstracts Service Registry Number, chemical name), by columns of toxicity endpoints with 
the value entered being the lowest dose at which the endpoint was observed (i.e., LEL) in 
‘mg/kg/day’. Even though NOAEL/LOAEL values for each study’s ‘Parental’, ‘Offspring’, 
or ‘Reproductive’ effect can be queried from the database, the current analyses for ToxCast 
only utilized LEL. Log transformed potency values were derived using –log2 of LEL. A 
constant value of 12 was then added to zero-center the data allowing for zero to represent no 
observed effect. Therefore, a value of 1 would be equivalent to an effect at 2048 mg/kg/day 
and 18 would be equivalent to 0.015625 mg/kg/day. The log transformed values are 
predominantly used in the current analysis. However, millimolar concentrations 
(mmol/kg/day) were calculated for each endpoint using the molecular weight of tested 
chemical and the LEL in mg/kg/day. The resulting data formats are highly amenable to 
statistical data analysis, including descriptive and predictive data mining algorithms. These 
data tables are available on the ToxRefDB homepage: http://www.epa.gov/ncct/toxrefdb/. 
 Unsupervised two-way hierarchical clustering across all the chemicals, of all effects 
with incidence greater than five, was carried out based on log transformed potency values 
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and using Pearson’s dissimilarity measure for both chemicals and effects. This analysis used 
Ward’s method for linkage and the agglomerative clustering method and was implemented in 
R version 2.6.1 (Gentleman and Hornik, 2002). Clusters of chemicals were identified based 
on a distance height cutoff of five. The proportion of positive effects in each respective 
cluster to the proportion of effects out of the respective cluster was used as a measure of the 
weight of an endpoint in deriving the cluster classes.  
Results 
Summary Characterization of Multigeneration Study Results 
 This analysis focused on reproduction-related endpoints culled from 329 
multigeneration rat studies on 316 unique chemicals entered into ToxRefDB (Table 2.1). The 
vast majority of studies (294 of 329) were performed using a two-generation protocol. There 
were seven one-generation studies, for which four were supplementary studies to longer-term 
two- or three-generation studies. Of the 28 three-generation studies, only first and second 
generation effects were used in subsequent analyses while third generation effects were 
excluded. In total, there were 11 chemicals with more than one study in this dataset. Four 
chemicals had an additional study run to satisfy study guideline requirements. Two chemicals 
had an additional study to test at additional dose levels. Five chemicals had two studies 
performed at similar dose levels and the conclusions between each pair of studies were 
similar.  
 Across all studies and treatment groups 12,230 treatment-related effects were 
observed, corresponding to 458 different, unique types of effects. Nearly twice as many total 
effects were observed in the F1 generation compared to the P1 or F2 generations. However, 
the F1 generation includes both juvenile (i.e., offspring) and adult effects, whereas P1 and F2 
 45 
generations only represent adult or juvenile life-stages, respectively. In order to enable cross-
generation comparisons, the count of chemicals and treatment-related effects across life-
stage, endpoint category, and generation are presented in Table 2.2. Parental effects were 
associated with 275 of the 316 chemicals for both the P1 and F1 generation, whereas 
reproductive effects were associated with only 100 or 129 chemicals in the P1 and F1 
generations, respectively. Besides more chemicals, there were 73% more adult effects within 
the reproductive endpoint category in the F1 generation, than in the P1. A similar number of 
chemicals and offspring category effects were observed in the F1 and F2 generation. 
Hierarchical Clustering for Identification of Chemical-Phenotype Classes 
 Identification of chemical clusters with similar profiles of phenotypic activity was 
achieved by unsupervised two-way hierarchical clustering of 75 target-level effects (Figure 
2.1). These 75 effects were selected based on an occurrence with greater than five of the 316 
chemicals. These were defined as target-level effects because specific descriptive terms were 
aggregated to the target organ (i.e., liver) or measured index (e.g., lactation index), rather 
than all possible outcomes for each target (e.g., hypertrophy, hyperplasia, degeneration, etc.). 
Six chemical clusters were identified based on a distance height cutoff of five. Each cluster 
description in Figure 2.1 is derived from the mostly heavily weighted endpoints in forming 
the respective chemical cluster and does not mean that every chemical in the cluster causes 
the endpoint. Cluster 1 consists of the 14 chemicals with no observed toxicities across the 75 
effects in this analysis. Cluster 2 contains 115 chemicals for which general systemic 
toxicities are driving the formation of the cluster. Interestingly, this cluster is also heavily 
weighted with endpoints relating to sperm counts and morphology, endocrine-related organ 
pathologies and weight changes, and delays in sexual maturation. Of the 115 chemicals, all 
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five phthalate compounds in ToxRefDB are found in this cluster. Cluster 3 contains 63 
chemicals with limited toxicity for which parental and offspring body weight changes are 
driving the formation of the cluster. Cluster 4 formation is heavily weighted with 
cholinesterase inhibition effects and is comprised of 12 organophosphorus compounds. 
Clusters 5 and 6 contain 48 and 64 chemicals, respectively, and the formation of these 
clusters are heavily weighted with reproductive toxicity endpoints, including testicular and 
epididymal pathologies in cluster 5 and offspring viability in cluster 6.  
 The complete listing of chemical clusters and endpoint weights for each cluster is 
available for download from the ToxRefDB homepage (USEPA, 2009b). The unsupervised 
approach clearly segmented the chemicals into distinct classes based on their profile of 
phenotypic activity and these cluster assignments are available as endpoints for predictive 
modeling. This analysis also guides the manual endpoint selection process by highlighting 
groups of chemical-phenotype relationships. Many of these associative differences are 
expected, but others are not. For instance, reproductive performance, reproductive organ and 
offspring viability effects were segregated slightly from each other and to a greater extent 
from parental systemic effects and even delays in sexual maturation.  
Comparative Analysis with Chronic and Subchronic Systemic Toxicity 
 Parental, reproductive and offspring potencies (i.e., inverse log transformed LEL) 
from the multigeneration studies were compared to potency values for systemic toxicity from 
two-year chronic and 90-day subchronic studies in the rat (Figure 2.2). For this comparison, 
data were available in ToxRefDB for 254 chemicals tested in both multigeneration and 2-
year chronic studies, and 207 chemicals tested in both multigeneration and 90-day 
subchronic studies. The potency values compared rarely correspond to the same treatment-
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related effect across study type. For the majority of chemicals, potency values between the 
multigeneration, chronic and subchronic studies were comparable, with a general linear 
relationship falling within ten-fold of each other. However, for four chemicals (bisphenol A, 
deltamethrin, flucycloxuron, flufenpyr-ethyl) that caused parental or reproductive effects in 
the multigeneration study, there was no systemic toxicity observed in either the chronic or 
subchronic studies. For another five chemicals (cyprodinil, diethyltoluamide, difenoconazole, 
ethametsulfuron methyl, thiamethoxam) potencies for the most sensitive multigeneration 
endpoints were more than 10-fold greater than for the most sensitive effects in chronic 
studies. Of these five chemicals only thiamethoxam was more potent based solely on 
reproductive endpoints, i.e., testicular atrophy. Decreasing the threshold from 10-fold to a 
two-fold increase in potency resulted in 37, 7 and 20 chemicals more potent for parental, 
reproductive, or offspring endpoints, respectively. Of the seven chemicals identified as two-
fold more potent reproductive toxicants, no reproductive organ toxicity was observed in the 
rat chronic/cancer or subchronic studies for these chemicals- the multigeneration test 
detected reproductive toxicity that could have been missed in chronic or subchronic studies. 
Under the conditions of the 2-year chronic studies, the vast majority of chemicals observed 
effects at lower doses than in the multigeneration reproductive study. However, even in these 
cases, the multigeneration test often identified selective reproductive toxicants and endpoints 
not detected in the chronic study.  
Comparative Analysis of Parental, Reproductive and Offspring Endpoints 
 Chemicals with increased potency in the second generation were identified by 
comparing P1 and F1, or F1 and F2 LEL across parental, reproductive and offspring endpoint 
categories for 316 chemicals (Figure 2.3). Specific second generation effects (i.e., F1 
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parental or reproductive, F2 offspring) not observed in the first generation (i.e., P1 parental 
or reproductive, F1 offspring), or sensitive effects occurring at a lower LEL in the second 
generation are provided for all 316 chemicals on the ToxRefDB homepage (USEPA, 2009b). 
For parental effects, 15 chemicals had specific effects in the F1 versus P1, and another 48 
were more sensitive in the F1 versus P1 based upon at least a two-fold difference in LEL. For 
reproductive toxicity endpoints, 52 chemicals had specific effects in the F1 versus P1, and 
another 14 were more sensitive in the F1 versus P1 based upon at least a two-fold difference 
in LEL. For offspring toxicity endpoints, 14 chemicals had specific effects in the F2 versus 
F1, and another 28 were more sensitive in the F2 versus F1 based upon at least a two-fold 
difference in LEL. Across all the effect categories, this came to a total of 137 chemicals that 
displayed specificity or sensitivity for one of the endpoint categories (i.e., parental, 
reproductive, or offspring) in the second generation. However, the F1 reproductive or F2 
offspring LEL was the most sensitive LEL across all endpoint categories for only 16 of these 
137 chemicals. This analysis in ToxRefDB has identified a subset of chemicals for ToxCast 
predictive modeling that may be more specific or potent reproductive toxicants. It is 
important to note that these values are LEL for all treatment related effects, and are not 
necessarily critical effects being used for determination of NOAEL/LOAEL. 
Selected Multigeneration Study Endpoints for Predictive Modeling 
 Figure 2.4 presents the incidence and distribution by generation of effects on 
reproductive performance, reproductive organs, offspring viability, and parental systemic 
toxicities selected for ToxCast predictive modeling. Toxicity profiles from multigeneration 
studies on 316 chemicals were based on a diverse set of 19 selected effects or effect 
aggregations distributed in various combinations across the P1, F1 and F2 generations. A 
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detailed table listing all 19 of these endpoints for the 316 chemicals, including endpoint 
descriptions and various transformations of LEL values, is available for download from the 
ToxRefDB homepage (USEPA, 2009b). Treatment-related changes to reproductive 
performance including fertility, mating, gestational interval, implantations, litter size, and 
live birth index demonstrated effects at different stages of the reproductive cycle. Besides 
effects of many chemicals on offspring viability at PND4 and PND21 (viability and lactation 
indices, respectively), pubertal delays were also recorded for some chemicals. Pubertal 
delays were not part of the ToxCast modeling dataset because only a small subset of 
chemicals and studies assessed these endpoints. Effects on reproductive performance and 
offspring viability were observed in 110 (35%) and 108 (34%) of the 316 tested chemicals, 
respectively. Effects on reproductive organs, both organ weight and pathology, were 
observed in 98 (31%) of the chemicals with roughly 50% of those chemicals causing the 
effect only in the second generation (F1 adult). Of the 98 chemicals, 31 caused both male and 
female reproductive organ effects, 43 male only, and 24 female only. Systemic target organ 
weight and pathology endpoints were also selected, including the liver, kidney and spleen, 
along with the endocrine related adrenal, pituitary and thyroid glands.  
Discussion 
 The objective of the ToxCast research program is to develop a cost-effective rapid 
approach for screening and prioritizing a large number of chemicals for toxicological testing 
(Dix, et al., 2007). Using data from high throughput screening (HTS) bioassays developed in 
the pharmaceutical industry, ToxCast is building computational models to forecast the 
potential human toxicity of chemicals. These hazard predictions should provide EPA 
regulatory programs, including OPP, with science based information helpful in prioritizing 
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chemicals for more detailed toxicological evaluations, and therefore lead to using fewer 
animal tests. ToxCast is currently in the proof-of concept phase, wherein over 300 chemicals 
have been assayed in over 600 different HTS bioassays, creating bioactivity profiles being 
used to derive signatures predicting the known toxicity for these chemicals. The Phase I 
chemicals are primarily conventional pesticide actives that have been extensively evaluated 
using traditional mammalian toxicity testing, and hence have known properties representative 
of a number of toxicity outcomes (e.g., carcinogenicity; and developmental, reproductive and 
neural toxicity). Thus a critical component of ToxCast is ToxRefDB, which is being 
populated with data from OPP for pesticide active chemicals and being extracted from the 
evaluations on these studies conducted by OPP scientists. Comparable toxicity data from 
other toxicity sources (e.g., National Toxicology Program) are also being captured in 
ToxRefDB. A broader and more diverse set of complementary data on thousands of 
chemicals is being captured in EPA’s Aggregated Computational Toxicology Resource 
(Judson et al., 2008).  
 The underlying data represented in ToxRefDB has been evaluated by EPA in prior 
pesticide registration decisions, and the presence of effects in high-dose animal studies do not 
translate directly into significant human risk stemming from registered uses of the pesticide. 
It should be noted that the EPA uses animal toxicology studies, like those entered into 
ToxRefDB, as well as other sources of information such as effects on wildlife populations, 
mechanisms of action, use patterns, environmental fate and persistence, food residue levels, 
and human exposure potential in its determinations to register pesticides, and to establish 
acceptable levels of pesticide residues for uses in the United States. While pesticide toxicity 
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data currently predominates in ToxRefDB, the database is being expanded to a broader range 
of chemicals, both by category and use. 
 The toxicity data in ToxRefDB and the HTS data generated in ToxCast will be made 
publicly available through EPA websites. The first component of ToxRefDB was recently 
published (Martin, et al., 2009), presenting toxicity profiles from two-year rodent bioassays 
on 310 chemicals. Multigeneration reproduction study data for 316 chemicals was entered 
into ToxRefDB in order to uniformly assess the reproductive toxicity potential of the 
chemical set and to profile chemical toxicity across generation, life-stage, and different 
classes of endpoints. The unsupervised two-way hierarchical clustering by chemical and 
effect identified chemical-phenotype relationships for which to characterize the chemical set. 
In the current analysis six chemical clusters were identified along with the relative endpoint 
weights for each cluster providing an indication of the composition of each cluster with 
respect to chemicals and effects. For predictive modeling, the phenotypic profile of these 
chemicals and resulting cluster sets could be used to match up with HTS bioactivity profiles 
in much the same manner. In the meantime, the resulting cluster sets guided the organization 
of the manual analysis and corroborated the distinction between parental, offspring and 
reproductive effects in subsequent analyses. 
All 12,230 effects in the multigeneration study dataset were placed into three major 
classes of effects; parental, reproductive and offspring. The LEL for each class or category of 
effects were used to identify sensitive or specific reproductive toxicants based on 
comparisons to chronic and subchronic study data and cross-generational comparisons within 
the multigeneration reproductive test. In general, chemical exposures under conditions of the 
multigeneration reproduction study were less sensitive than under the conditions of the two-
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year chronic study and comparable to the 90-day subchronic study. The analysis did, 
however, identify a subset of chemicals with sensitive or specific reproductive or offspring 
toxicities when compared to systemic effects under longer continuous exposure periods. 
Similar insight can be gleamed from comparing endpoints occurring at a lower dose or only 
in the second generation, i.e., second generation sensitive or specific effects, respectively. 
Effects that occur in the first generation and are not corroborated in the second generation 
can be questioned as to its toxicological relevance. Conversely, effects with consistent 
increases in second generation sensitivity or specificity might reflect the need for 
reproductive or developmental exposure to occur. Comparisons across these broad classes of 
endpoints honed in on specific effects for which to characterize the chemical set. The 
primary set of effects selected as anchoring endpoints for ToxCast predictive modeling were 
reproductive indices, offspring viability, and male and female reproductive organ effects, 
along with a set of parental systemic organ toxicities. 
 The ToxRefDB multigeneration study dataset has also played a key role in 
retrospective analyses by providing uniformly captured legacy reproductive toxicity data and 
by expanding the scope of questions that can be asked of the data. Multigeneration 
reproductive toxicity studies traditionally involve assessment through two generations and 
the value of the second generation is now being assessed for its regulatory impact. The 
analysis may also influence study design changes in subsequent guideline studies (Janer et 
al., 2007). The current study focused on providing endpoints for predictive modeling as part 
of the ToxCast research program (Dix, et al., 2007), but also began to address the importance 
of specific study design parameters, including differences across generation, life-stage and 
various classes of endpoints. Additional analysis will be performed on this dataset in 
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collaboration with OPP and other international chemical regulatory agencies to expound 
upon the role of these and other study design parameters with respect to chemical regulation 
and potential guideline study design changes. This includes the potential to assess the ability 
of the current and previous multigeneration study guidelines to identify reproductive effects 
related to endocrine disruption. Fifty-three of the 73 chemicals proposed for screening in the 
Endocrine Disruptor Screening Program (EDSP; 
http://www.epa.gov/endo/pubs/prioritysetting/draftlist.htm) have multigeneration studies 
entered into ToxRefDB and are part of the ToxCast Phase I chemical set. Where available, 
multigeneration study data for the remaining chemicals are now being entered into 
ToxRefDB. A focused analysis of the EDSP chemical set would be just one example of the 
utility of ToxRefDB and the toxicity data stored within it. The use of ToxRefDB to address 
many research and regulatory science questions regarding in vivo mammalian toxicity not 
only provides transparency, but also assists in guiding the next set of questions.  
 The diverse utility of ToxRefDB as a reference database for research applications 
such as ToxCast demonstrates the power of curating toxicity information into a relational 
database. In the current analysis on the multigeneration reproductive toxicity test, six 
chemical clusters were derived using unsupervised methods, and subsequently nineteen 
specific endpoints were identified for anchoring endpoints in predictive modeling. These 
endpoints are further defined by life-stage or generation, and characterize the 316 chemicals 
with respect to their reproductive toxicity potential. Capturing this reproductive toxicity data 
in ToxRefDB supports ongoing retrospective analyses, test guideline revisions, and 
computational toxicology research. 
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Tables 
Table 2.1. Summary statistics for 329 multigeneration reproduction studies on 316 chemicals 
within ToxRefDB 
    
Treatment 
Groups 
Treatment 
Groups 
w/ Effects Effectsa 
Unique 
Effectsb 
Total 7,869 3,239 12,230 458 
G
en
er
at
io
n P1 2069 902 3331 322 
F1 2,775 1306 6,329 400 
F2 2,717 945 2,396 144 
F3 308 86 174 31 
(a) – Total No. of effects observed in any treatment group 
(b) - No. of distinct effects observed in at least one treatment group 
 
 
Table 2.2. Distribution of chemicals and effects across life-stage, endpoint category and 
generation for 316 chemicals in ToxRefDB with a multigeneration reproductive study 
 
Life-Stage Adult Adult Juvenile 
Endpoint 
Category Parental
c Reproductived Offspringe 
G
en
er
at
io
n 
P1 275
a 
(2935)b 
100 
(376)   
F1 275 (3265) 
129 
(648) 
255 
(2274) 
F2     247 (1979) 
a - No. of chemicals with at least one effect observed at specified life-stage, 
endpoint category and generation 
b - No. of effects observed at specified life-stage, endpoint category and 
generation 
c - Parental endpoints include adult body weight, mortality, clinical signs and 
target-organ weight and pathology effects 
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d - Reproductive endpoints include reproductive organ weight and pathology 
and reproductive indices (e.g., fertility, mating, live birth index, etc.) 
e - Offspring endpoints include pup weight, offspring survival (e.g., viability 
and lactation index), and juvenile target-organ weight and pathology, and 
pubertal delay (e.g., PPS and VO) effects 
  
Figures 
Figure 2.1. Unsupervised two-way hierarchical clustering of 75 treatment-related effects 
from multigeneration reproduction tests on 316 chemicals in ToxRefDB. Six chemical 
clusters were identified based on a distance height cutoff of five. Each cluster description is 
derived from the mostly heavily weighted endpoints (see Results and 
http://www.epa.gov/ncct/toxrefdb/ for details) forming the respective chemical cluster and 
does not mean that every chemical in the cluster causes the endpoint. 
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Figure 2.2. Parental, reproductive and offspring lowest effect levels (LEL; inverse log 
transformed) from multigeneration rat studies were compared to systemic LEL from 
chronic/cancer and subchronic rat studies for 254 and 207 chemicals, respectively. Points 
within gold lines indicate less than 2-fold difference between multigeneration and chronic 
studies. Points within orange lines indicate less than 10-fold difference between 
multigeneration and chronic studies. ‘NE’ stands for not established. 
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Figure 2.3. Comparing lowest effect levels (LEL) across generation and endpoint category. 
Points within dark orange lines indicate less than 2-fold difference between generations. 
Points within light orange lines indicate less than 10-fold difference between generations. 
‘NE’ stands for not established. 
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Figure 2.4. Incidence and distribution, by generation, of the 19 endpoints selected for 
predictive modeling, including reproductive, offspring and systemic toxicity endpoints from 
the rat multigeneration reproduction study (see Results and 
http://www.epa.gov/ncct/toxrefdb/ for details). The light gray bar indicates chemicals 
observing the endpoint only in the first generation, either P1 adult or F1 juvenile. The 
medium gray bar indicates chemicals observing the endpoint in both first and second 
generation treatment groups. The dark gray bar indicates chemicals observing the endpoint 
only in the second generation, either F1 adult or F2 juvenile. 
 
 59 
References 
Collins, F. S., Gray, G. M. and Bucher, J. R. (2008). Toxicology - Transforming 
environmental health protection. Science 319, 906-907, DOI 10.1126/science.1154619. 
 
Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W. and Kavlock, R. J. 
(2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. 
Toxicol Sci 95, 5-12, kfl103 [pii] 
10.1093/toxsci/kfl103. 
 
Gentleman, R. and Hornik, K. (2002). R 1.5 and the Bioconductor 1.0 releases. Comput Stat 
Data An 39, 558-559. 
 
Gibson, J. E. (2010). An Integrated Summary of Commentary on The National Academy of 
Sciences Report on "Toxicity Testing in the 21st Century: A Vision and a Strategy". Hum 
Exp Toxicol 29, 33-35, Doi 10.1177/0960327109354659. 
 
Houck, K. A. and Kavlock, R. J. (2008). Understanding mechanisms of toxicity: Insights 
from drug discovery research. Toxicol Appl Pharm 227, 163-178, DOI 
10.1016/j.taap.2007.10.022. 
 
Janer, G., Hakkert, B. C., Slob, W., Vermeire, T. and Piersma, A. H. (2007). A retrospective 
analysis of the two-generation study: What is the added value of the second generation? 
Reprod Toxicol 24, 97-102, DOI 10.1016/j.reprotox.2007.04.068. 
 
Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., Cathey, T., Transue, T. 
R., Spencer, R. and Wolf, M. (2008). ACTOR - Aggregated Computational Toxicology 
Resource. Toxicol Appl Pharm 233, 7-13, DOI 10.1016/j.taap.2007.12.037. 
 
Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. 
M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M. and Dix, D. J. (2010). In Vitro 
Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast 
Project. Environ Health Persp 118, 485-492, Doi 10.1289/Ehp.0901392. 
 
Martin, M. T., Judson, R. S., Reif, D. M., Kavlock, R. J. and Dix, D. J. (2009). Profiling 
Chemicals Based on Chronic Toxicity Results from the US EPA ToxRef Database. Environ 
Health Persp 117, 392-399, Doi 10.1289/Ehp.0800074. 
 
USEPA (1982). OPP Guideline 83–4: Reproductive and Fertility Effects. Pesticide 
Assessment Guidelines, Subdivision F, Hazard Evaluation: Human and Domestic Animals. 
Office of Pesticides and Toxic Substances, Washington, DC.EPA–540/9–82–025 
 
USEPA (1996). Reproductive Toxicity Risk Assessment Guidelines. Fed. Regist 61, 56274–
56322. 
 
USEPA (1998). Health Effects Test Guidelines  
 60 
OPPTS 870.3800 Reproduction and Fertility Effects. Office of Pesticides and Toxic 
Substances, Washington, DC.EPA 712–C–98–208 
 
USEPA (2009a). ToxCast Homepage.http://www.epa.gov/ncct/toxcast 
 
USEPA (2009b). ToxRefDB: Toxicity Reference Database.http://actor.epa.gov/toxrefdb 
 
 
 
 61 
 
 
 
 
CHAPTER 3 
IMPACT OF ENVIRONMENTAL CHEMICALS ON KEY TRANSCRIPTION 
REGULATORS AND CORRELATION TO TOXICITY ENDPOINTS WITHIN EPA’S 
TOXCASTTM PROGRAM2
 
 
Abstract 
Exposure to environmental chemicals adds to the burden of disease in humans and 
wildlife to a degree that is difficult to estimate and, thus, mitigate. The ability to assess the 
impact of existing chemicals for which little to no toxicity data are available, or to foresee 
such effects during early stages of chemical development and use, and before potential 
exposure occurs, is a pressing need. However, the capacity of the current toxicity evaluation 
approaches to meet this demand is limited by low throughput and high costs. In the context 
of EPA’s ToxCast™ project, we have evaluated a novel cellular biosensor system 
(Factorial™) that enables rapid, high-content assessment of a compound’s impact on gene 
regulatory networks. The Factorial biosensors combined libraries of cis- and trans-regulated 
transcription factor reporter constructs with a highly homogeneous method of detection 
enabling simultaneous evaluation of multiplexed transcription factor activities. Here we 
demonstrate application of the technology towards determining bioactivity profiles by 
quantitatively evaluating the effects of 309 environmental chemicals on twenty-five nuclear 
receptors and forty-eight transcription factor response elements. We demonstrate coherent 
                                               
2 Previously published as Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M., Richard, A. M., 
Rotroff, D. M., Romanov, S., Medvedev, A., Poltoratskaya, N., Gambarian, M., Moeser, M., Makarov, S. S. and 
Houck, K. A. (2010). Impact of environmental chemicals on key transcription regulators and correlation to 
toxicity end points within EPA's ToxCast program. Chem Res Toxicol 23, 578-90, 10.1021/tx900325g. 
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transcription factor activity across nuclear receptors and their response elements and that 
Nrf2 activity, a marker of oxidative stress, is highly correlated to the overall promiscuity of a 
chemical. Additionally, as part of the ToxCast program, we identify molecular targets that 
associate with in vivo endpoints and represent modes of action that can serve as potential 
toxicity pathway biomarkers, and inputs for predictive modeling of in vivo toxicity. 
Introduction 
Estimating the toxicity of environmental chemicals is impeded by the sheer number 
of potential contaminants, the high costs of animal testing, and the poor prognostic power of 
traditional toxicity testing for assessing risks to humans. Relatively few predictive in vitro 
assays have been routinely used for screening, outside of those for genetic toxicology or 
specific molecular targets such as the steroid hormone receptors and the sodium channel 
hERG (Houck and Kavlock, 2008;  Wilson et al., 2004). The paradigm of traditional 
toxicology has been challenged to shift towards using predictive or pathway-based 
toxicology approaches to more efficiently and systematically evaluate large numbers of 
chemicals for a diversity of toxicity endpoints (NRC, 2007). The U.S. Environmental 
Protection Agency (EPA) and National Institutes of Health (NIH) have responded to this 
challenge with major new computational toxicology testing and research initiatives. EPA’s 
ToxCastTM program (USEPA, 2009b), and the affiliated Tox21 program (Collins et al., 
2008), the latter a collaboration between three U.S. government entities – EPA, NIH’s 
National Toxicology Program, and the NIH Chemical Genomics Center (NCGC) – are 
generating broad spectra of high-throughput/high-content biochemical and cell-based in vitro 
assays for a relatively large number of environmental chemicals (Collins, et al., 2008;  Dix et 
al., 2007). These data are being used to derive biological and chemical profiles predictive of 
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in vivo biological endpoints and to serve as the basis for new toxicity screening and 
prioritization approaches.  
One source of high-content, cellular data was obtained using a recently developed 
biological profiling technology, Factorial™ (Romanov et al., 2008), that enabled high-
content, functional assessment of core components of cellular gene regulatory networks. 
Assessment was accomplished by measuring activity of transcription factors (TFs), i.e., the 
specialized classes of DNA-binding proteins that recognize regulatory elements in gene 
promoters and control transcription. Originally designed for multiplexed detection of specific 
cis-regulatory response element constructs (CIS), the technology has been further developed 
to provide assessment of trans-activating potential of multiple nuclear hormone receptors, a 
super-family of ligand-activated TFs (TRANS). The current technology was utilized in Phase 
I of EPA’s ToxCast program to screen 320 environmental substances, the large majority of 
which are pesticide actives. We report here the results of that screening using forty-eight CIS 
and twenty-five TRANS assays chosen to place particular emphasis on factors and receptors 
that control toxicologically relevant cellular responses to xenobiotics, genotoxic stress, 
hypoxia, oxidative damage, immuno-modulation and endocrine disruption. Furthermore, we 
use these biological profiling results to identify perturbed gene regulatory networks and 
possible modes of action for the ToxCast 320 environmental substances. By introducing the 
plurality of CIS and TRANS assays into a human liver cell line, the biosensors enabled 
characterization of chemicals in the context of the cell’s gene regulatory networks. We show 
that HepG2 cells responded to many chemical compounds through changes at the level of 
transcription factor and nuclear receptor activities. The changes elicited by the chemicals 
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reflect well-understood interactions in some instances, whereas in others they provide new 
insights into possible modes of action for chemical specific toxicities. 
Methods 
Chemical Library 
The ToxCast 320 chemical library consists of 309 unique chemical structures meeting 
physicochemical property requirements for high-throughput screening (8,9). Five substances 
were tested in duplicate (separately sourced) and three chemicals were tested in triplicate 
(sample replicates) for internal quality control purposes. Most of the compounds are pesticide 
active ingredients associated with extensive in vivo toxicity data generated in support of their 
registration process with the EPA. These data were extracted from documents, standardized, 
and compiled in the EPA ToxRefDB relational database (Knudsen et al., 2009;  Martin et al., 
2009a;  Martin et al., 2009b). The derivation of the mammalian in vivo toxicity endpoints 
was focused on chronic/cancer, multigenerational reproductive, and prenatal developmental 
toxicity studies. For any given study type, roughly 250 of the 309 unique chemicals tested in 
this study have toxicity endpoint data in ToxRefDB. The full list of chemicals is available 
with quality reviewed structure-annotation from the EPA DSSTox website (USEPA, 2008). 
Chemicals samples were procured and plated by BioFocus DPI (San Diego, CA). Supplier-
provided certificates of analysis indicated purity >97% for the large majority of chemicals 
(87%), and >90% purity for all but a few instances of technical grade or known mixtures. 
Follow-up analysis of an original solution plate by BioFocus DPI using LC and GC/MS 
(liquid and gas chromatography mass spectrometry), subsequent to assay screening, has 
confirmed mass identification, stability, and purity in excess of 90% for over 87% of the 
chemical library, with follow-up analysis underway for the remaining compounds. Summary 
 65 
QC information mapped to chemical sample and solution IDs will be provided on the 
ToxCast website as an auxiliary chemical file (USEPA, 2009b). Compounds were dissolved 
in dimethyl sulfoxide (DMSO) to a final target concentration of 20 mM, in almost all cases. 
For testing in concentration-response format, serial dilutions were performed in DMSO 
followed by aqueous dilution in cell culture medium. 
Assay Design and Implementation 
Attagene Inc. (RTP, NC), under contract to the U.S. EPA (Contract Number EP-W-
07-049), provided multiplexed reporter transcription unit (RTU) assays (Factorial™) 
consisting of forty-eight human transcription factor DNA binding sites transfected into the 
HepG2 human liver hepatoma cell line as previously described (Romanov, et al., 2008). In 
addition to the cis-acting reporter genes (CIS), a modification of the approach was used to 
generate a trans-system (TRANS) with a mammalian one-hybrid assay consisting of an 
additional twenty-five RTU library reporting the activity of nuclear receptor (NR) super-
family members (Martin et al., 2010). A schematic representation of both systems is 
illustrated (Figure 3.1). The human ligand-binding domain of each nuclear receptor was 
expressed as a chimera with the yeast GAL4 DNA-binding domain that activated in trans a 
5X-UAS-TATA promoter, which regulated transcription of a reporter sequence unique to 
each NR RTU. To ensure specificity of detection, each individual trans-RTU system 
including both receptor and reporter gene was separately transfected into suspended cells 
followed by pooling and plating of the transfected cells prior to screening. A major 
difference between the CIS and TRANS system is that in CIS activities of endogenous TFs 
are measured, whereas the TRANS assay evaluates changes in activities of exogenous, 
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chimeric NR-Gal4 proteins. Since the HepG2 cell line does not express some nuclear 
receptors the CIS assay cannot be used to evaluate these targets. 
Concentration Selection 
An initial cytotoxicity screen was performed to establish the maximum tolerated 
concentration (MTC) of the chemical library. The chemicals were tested for cytotoxicity 
against HepG2 cells in the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) tetrazolium assay (Mosmann, 1983) following 24 hour chemical exposure to five 
concentrations with an upper concentration of 50µM and 10-fold dilutions. All 
concentrations were run in triplicate. IC50 were determined based on fifty percent cell death, 
as measured by decreasing MTT conversion to formazan. The MTC was derived based on 
the one-third the calculated IC50 or, if no IC50 was determined, the MTC was set to 100µM. 
Results of cytotoxicity assessment are shown below. 
Chemicals were then tested in the CIS and TRANS assays at seven concentrations 
starting at the MTC and followed by three-fold serial dilutions. Following exposure to 
chemical for a twenty-four hour period, cells were harvested and RNA was isolated and 
reverse transcribed into cDNA using fluorescent-tagged primers. Digestion with HpaI 
resulted in unique reporter gene fragments that were resolved and quantitated by capillary 
electrophoresis as previously described (Romanov, et al., 2008). 
Statistical Analysis 
Changes in transcription factor activity were expressed as fold-change over DMSO 
control by dividing expression levels of treated by the average of control (DMSO) treatments 
from the same assay plate. Both induction and suppression can occur. However, only 16 out 
of >20,000 possible chemical-assay combinations had marked suppression and were 
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observed at no more than two chemicals per assay. Therefore, suppression values were 
filtered out and only induction levels were considered in subsequent analyses. An initial 
maximum fold-change value (Emax) was used to compare across assays. Hierarchal 
clustering was performed using log 2-transformed Emax and subjected to clustering by 
Pearson’s Dissimilarity using Ward’s Method. Analyses were carried out using R version 
2.8.1 (Gentleman et al., 2002). Emax values were also used to determine an optimal global 
cutoff as one criterion in establishing a hit, based on the agreement between replicates and 
stabilization of the overall hit rate as the Emax filter increases (Figure 3.2). Specifically, 
overall and hit concordances were calculated as is done in the final replicate analysis shown 
below, except solely using an Emax filter to establish hit calls. For each pair in the triplicate 
sets (comparing A with B, B with C and A with C), we asked if the chemicals were both hits, 
both non-hits or if they disagreed. Total concordance was defined as all 3 were hits or all 3 
were non-hits, and non-concordance as either 1 or 2 were hits and the remainder were non-
hits. The total overall concordance is the number of comparisons where the pair was either 
hits or both non-hits, divided by the total number of comparisons. The hit concordance is the 
number of cases where each of the pair was a hit divided by all cases where one or each of 
the pair was a hit. 
The pairwise correlation of Emax values between any two assays was represented by 
R-squared. The distribution of correlations across all pairwise combinations of assays, a total 
of 2628, determined the ninety-fifth and ninety-ninth percentile; R-squared of 0.27 and 0.51, 
respectively. These values help determine the relative significance of the correlation between 
any two assays in this dataset.  
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A Hill function was fit to all fold-change data and an AC50 was derived, the 
concentration in which 50% of the maximal response, based on the fitted curve, is achieved. 
All assay-chemical combinations that did not achieve a fit with an R-squared >0.5 and an 
Emax greater than two were considered negative. A hit is considered anything that achieved 
an AC50 and met the criteria described above. A univariate analysis was conducted in order 
to test for associations, by way of relative risk (RR) values, between in vitro assays and 
mammalian in vivo toxicity endpoints. The mammalian in vivo toxicity endpoints, from 
chronic/cancer rat and mouse, multigeneration rat, and prenatal developmental rat and rabbit 
toxicity studies, were previously compiled and aggregated for use in predictive toxicology 
(Knudsen, et al., 2009;  Martin, et al., 2009a;  Martin, et al., 2009b). Each chemical-endpoint 
combination assessed in a toxicity study and captured in ToxRefDB were represented as the 
lowest effect level (LEL: mg/kg/day) if the endpoint was observed, thus defining a positive 
for an in vivo endpoint. RR values were calculated as:  
  RR = [TP / (TP+FP)] / [FN / (TN+FN)] 
TP and FP represent the numbers of true and false positive chemicals, respectively, and TN 
and FN represent the numbers of true and false negative chemicals, respectively. A 
permutation test was developed in order to identify significant RR values and was carried out 
for 10,000 permutations. If the RR fell within the upper 95th percentile (p<0.05) of the 
permuted data, then the corresponding association was regarded as statistically significant. 
The permuted RR percentile values for all in vitro assays by in vivo endpoints were subjected 
to clustering by Pearson’s Dissimilarity using Ward’s Method.  
Results 
Cytotoxicity Assessment 
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Prior to running the CIS and TRANS assays, cytotoxicity was assessed in an attempt 
to establish a MTC for each chemical for purposes of concentration selection. Of the 320 
total tested chemicals, 246 (77%) were not frankly cytotoxic under conditions of the assay 
and therefore a MTC of 100µM was used for subsequent testing. Sixty-four chemicals (20%) 
showed cytotoxicity at micromolar concentrations, whereas another ten chemicals (3%) 
displayed cytotoxicity at sub-micromolar concentrations.  
Summary Statistics 
In total, there were 23,360 chemical-assay observations with 1,923 (8.2%) showing 
significant responses. Of these hits, 78% of the AC50 were greater than 10μM with 4% being 
under 1µM. The median number of chemical hits across all assays was six, with a 
comparable hit rate across both CIS and TRANS formats. The pregnane X receptor response 
element (PXRE) was the most active of the assays with 234 significant chemical interactions 
(225 unique chemicals), consistent with the promiscuous nature of the receptor which is 
known to be activated by a wide range of pharmaceuticals, steroids, xenobiotics and natural 
products (Ekins et al., 2002). A complete listing of the assays with the number of hits per 
assay along with the maximal responder across the ToxCast 320 chemical library, and the 
Emax of the positive control, where available, is presented in Table 3.1. In the TRANS 
system, individual members of the TF family can be distinguished, for example PPARα, 
PPARγ and PPARδ, whereas the CIS system evaluates the integral activity of the entire 
PPAR family through use of the direct repeat (DR)-1 PPAR response element (PPRE) which 
does not show receptor isotype specificity (Lemay and Hwang, 2006). In total, 10 NR 
families across 16 TRANS assays were represented with their corresponding response 
elements. 
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Replicate Analysis 
Of the 320 chemicals tested for transcription factor modulation there are three 
triplicates and five duplicates imbedded into the blinded chemical set. The triplicates were 
from the same production lot and vendor, whereas the duplicates were sourced independently 
and therefore excluded from the replicate analysis. Pairwise assessments of the triplicates 
were performed for the 657 chemical-assay combinations with 58 total hits (Figure 3.3). 
Including both positive and negative combinations, the overall concordance was >99%. Of 
the 58 hits, there was 87% concordance between the triplicates with twenty-seven pairs 
agreeing and four disagreeing. This is equivalent to nine assay-triplicate combinations in 
complete agreement and two assay-triplicate combinations having only a single hit. It should 
be noted that any disagreement in the triplicates would be accounted for twice because every 
comparison is performed pairwise. Therefore, 87% hit concordance was considered high and 
permitted the aggregation of replicates for specific downstream analyses making the total 
number of chemicals 309. For each triplicate the average AC50 was used when all or the 
majority were in agreement, otherwise the results were considered negative. The overall 
concordance among the duplicates was >96%, but a conservative approach was used due to 
the independent sourcing of the chemicals requiring both to be a hit and the average AC50 
was then used, otherwise the results were considered negative. The complete data set is being 
made publicly available (USEPA, 2009b). 
In vitro Relationships 
Using Emax values, unsupervised hierarchal clustering of the 48 CIS and 25 TRANS 
assays demonstrated consistency across the chemical library (Figure 3.4). This was 
evidenced by co-clustering of the independently tested CIS and TRANS assays 
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corresponding to the same transcription factor function, including pregnane X receptor 
(PXR) with the PXR response element (PXRE), estrogen receptor alpha (ERα) with the 
estrogen response element (ERE), and peroxisome proliferator-activated receptor alpha and 
gamma (PPARα/γ) with the PPAR response element (PPRE). Such a response strongly 
suggests that the assay system is capable of detecting and reporting chemical perturbation of 
the cell, which is reflected in specific gene regulatory network alterations. Additional 
coherence in the dataset can be observed by the chemical-induced clustering of highly related 
nuclear receptors across their respective subtypes, including the retinoic acid receptors 
(RARα, RARβ, RARγ) and liver X receptor (LXRα and LXRβ). The corresponding 
response elements in the CIS assays, DR5 for RAR and DR4 for LXR co-clustered with the 
TRANS assays as expected. However, of the 10 NR families tested in both CIS and TRANS 
formats, 5 showed little evidence of co-clustering primarily due to a lack of significant 
activity in one of the assay systems, including farnesoid X receptor (FXR), glucocorticoid 
receptor (GR), vitamin D receptor (VDR), constitutive androstane receptor (CAR), and RAR-
related orphan receptor (ROR). A lack of activity was not unexpected for certain targets with 
few known ligands, including FXR, VDR, and GR. Whereas, CAR and ROR are 
constituitively active permitting the evaluation of antagonists, but not agonists. All 5 NR 
families with robust activity were specifically and significantly correlated across assays. 
PXR/PXRE 
The xenobiotic sensor, PXR, which regulates a diverse set of xenobiotic response 
genes including phase I, II and III metabolic enzymes (Gillam, 2002), responded to a large 
number of the chemicals in the library in both the CIS and TRANS format (Figure 3.5). 
While the TRANS assay used an exogenously expressed GAL4-PXR for activation of the 
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reporter gene, the CIS system used a 628 base-pair fragment (-7836 to -7208) of a PXR-
regulated gene, CYP3A4, previously identified as containing a PXRE (Goodwin et al., 1999) 
together with endogenous PXR. These assays showed a strong correlation with an R-squared 
of 0.67. As stated in the Methods section, the 95th and 99th R-squared percentile was 0.27 and 
0.51, respectively, thus demonstrating the significant correlation between the independently 
tested PXR_TRANS and PXRE_CIS assays. However, less robust responses were observed 
in the TRANS version across chemicals when compared to the CIS assay. Responses 
averaged approximately eight-fold lower in the TRANS assays, Sensitivity was thus lower in 
the TRANS version, resulting in the derived AC50 values of the TRANS assay being a 
nearly complete subset of the hits in the CIS assay. In addition, ~90% of the AC50s for 
TRANS hits fell within three-fold of the PXRE_CIS AC50 (R-squared of 0.56). This is 
evident among the top five most efficacious and most potent PXR agonists within the 
chemical library (Figures 3.5b and 3.5c). The qualitative and quantitative similarities 
between the PXRE_CIS and PXR_TRANS concentration response curves provide redundant 
and corroborating evidence of PXR agonism. The positive control and known human PXR 
ligand, rifampicin, was only run in the CIS format and showed comparable efficacy and 
potency with a number of the tested chemicals representative of diverse set of chemical 
classes, demonstrating the promiscuous nature of PXR and the suitability of the assay for 
detecting such agonists.  
RAR/DR5 
The endogenous ligands for the retinoid acid receptors, retinoids, control key 
components of development, differentiation and homeostasis (Chambon, 1996). The TRANS 
version of reporter for the retinoid receptor assays demonstrated increased sensitivity in 
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comparison to its response element, DR5, as shown with RARα in Figure 3.6a. While the 
reason for this is not apparent, it may be due to insufficient endogenous RAR levels in the 
HepG2 cells. Similar differences in sensitivity across other nuclear receptor families from 
CIS and TRANS versions may also be due to insufficient endogenous receptor in HepG2 
cells, which is required in the CIS assays. In general, RARα, RARβ and RARγ all showed 
activation by similar chemicals and were positively and significantly correlated to their 
response element, DR5, with R-squared values of 0.58, 0.36, 0.27, respectively. Trans-
retinoic acid, an endogenous RAR ligand, is teratogenic when developing animals are 
exposed experimentally. Hence, it is important to understand both the potency and efficacy 
of the chemicals identified as RAR activators. The top five most efficacious and potent RAR 
agonists, based on average RARα and DR5 results, were substantially less responsive than 
retinoic acid with respect to both potency and maximum efficacy (Figures 3.6b and 3.6c). 
The retinoic acid used as a positive control, tested only in the DR5_CIS assay, generated an 
Emax of 7.5 and an AC50 of 0.047μM compared to the highest Emax of 3.2 and the lowest 
AC50 of 0.76μM across the chemical library. 
ER/ERE 
Direct activation of the estrogen receptor (ER) is one mechanism for xenobiotic 
endocrine disruption through alteration of the physiological function of endogenous steroid 
hormone receptors (Witorsch, 2002). The TRANS ERα assay provides a measurement of 
receptor activation as does the ER response element (ERE) although the latter is less direct. 
The correlation between CIS and TRANS assays is above the 99th percentile with an R-
squared of 0.53 (Figure 3.7). Among the most potent and/or efficacious chemicals, several 
are well known estrogen receptor agonists including bisphenol A, methoxychlor and its 
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metabolite, HPTE (Gaido et al., 2000;  Gould et al., 1998;  Gray et al., 1989). HPTE was the 
most potent in the chemical library, but showed low efficacy most likely due to limitations on 
the highest concentration tested coming out of the cytotoxicity pre-screen. Other chemicals 
showing significant activity in either the TRANS or CIS format have not been reported to be 
ERα agonists. Additionally, the ER TRANS assay generated 90 hits, higher than would be 
expected, demonstrating sensitivity but potentially lacking specificity. However, where there 
is good agreement across all assay types for novel findings, e.g. fludioxonil and flumetralin, 
strong consideration should be given to additional testing in other assay formats to confirm 
the activity of these chemicals as ER ligands. It should be pointed out that many of these 
chemicals primarily behave as partial agonists relative to a strong endogenous ligand such as 
17-β-estradiol (ERE_CIS: AC50 of 0.035nM and Emax of 9.3; ERα_TRANS: AC50 of 
0.87nM and Emax of 23) and this may impact their biological effects both quantitatively and 
qualitatively. 
PPAR/PPRE 
The PPRE binds the PPAR subfamily (α, β/δ, γ) to regulate genes associated with 
lipid metabolism (PPARα), fatty acid oxidation (PPARβ/δ) and adipocyte differentiation 
(PPARγ). In Figure 3.4, PPRE_CIS clusters with PPARα_TRANS and PPARγ_TRANS 
assays but not with PPARβ/δ_TRANS. The lack of significant activators of 
PPAR β/δ explains why it failed to cluster with the PPRE. In Figure 3.8a, the correlation of 
the PPRE and PPARγ is shown (R-squared = 0.53) with a subset of the chemicals (n=7) also 
displaying PPARα activity. These apparent PPARα/γ co-agonists and their involvement in 
rodent liver tumor formation is further investigated below. Rosiglitazone, a selective ligand 
of PPARγ used as the positive control, had roughly 30% greater efficacy and was five-fold 
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more potent than the rest of the chemicals, with the single exception of fentin in the 
PPRE_CIS assay (Figures8b and 8c). However, fentin demonstrated substantially depressed 
induction in PPARγ_TRANS and no activity in PPARα_TRANS. The PPRE_CIS response 
may be indicative of activation of the PPAR/RXR heterodimer signal-transduction pathway 
through RXR agonist activity (le Maire et al., 2009). This is supported by fentin’s strong 
RXR responses in the RXRβ_TRANS assay with an AC50 of 83nM. This behavior, termed 
permissive heterodimeric activity (Aranda and Pascual, 2001;  Bettoun et al., 2003), has been 
reported for other receptor pairs in the mammalian one-hybrid assay (Bettoun, et al., 2003). 
Rosiglitazone showed moderate induction of the PPARα_TRANS assay with an Emax of 3.6 
and an AC50 of 6µM reflecting partial agonist behavior at much higher concentrations than 
for PPARγ, consistent with previously reported results (Reifel-Miller et al., 2005). Similar to 
the situation with ERα, the biological significance of the relatively lower efficacy and 
potency of these chemicals compared to the positive control may impact high-dose animal 
toxicity as well as create additional uncertainty for implications for human disease. 
NRF2/ARE 
The nuclear-factor-E2-related factor (NRF)-2, a member of the bZIP transcription 
factor family, regulates cytoprotective enzymes in response to oxidants and electrophilic 
compounds through binding to the antioxidant response element (ARE) (Nguyen et al., 
2009). Regulated genes include γ-glutamylcysteine synthetase, NADPH:quinone reductase, 
and glutathione-S-transferase (Lee and Johnson, 2004). Many of the chemicals evaluated 
here produced significant induction of the NRF2/ARE reporter gene (Figure 3.9). Among the 
top ten activators are many pesticides known to cause oxidative damage in a variety of 
species. These include metolachlor (Stajner D., 2001), diquat dibromide (Wolfgang et al., 
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1991), trichlorfon (Karademir et al., 2007), oxyfluorfen (Peixoto et al., 2006), alachlor 
(Burman et al., 2003), and dichlorvos (Yarsan and Cakir, 2006). Other significant activators 
of NRF2 were compounds capable of reaction with sulfhydryl groups, e.g. methyl isocyanate 
(Emax = 3.5), a breakdown product of metam sodium (Emax = 6.0), dazomet (Emax = 3.6) 
and metiram-zinc (Emax = 3.2). As this is an adaptive response, the toxicological relevance 
may be very dependent on specific in vivo exposure scenarios. However, using the 
NRF2_ARE_CIS assay results as an indicator of oxidative or electrophilic damage, we 
observed a relationship between NRF2 response and the non-specific and promiscuous 
behavior of various chemicals and assays. In comparing the NRF2 activity and the average 
activity across all other assays, a significant relationship emerged (R-squared = 0.5) (Figure 
3.9). It should be noted that these values were log2-transformed in order to mitigate the 
impacts of averaging across assays with significant differences in dynamic range. This 
relationship cannot be attributed to assay conditions, because the positive control chemicals 
demonstrated very specific activity for their respective target with no evidence of NRF2 
activity at comparable concentrations.  
The phenomena of oxidative stress leading to promiscuous transcription factor 
activity may help explain the large number of active compounds in assays with fairly specific 
ligand binding domains, including ERα and PPARγ. For example, bisphenol A, a known ERα 
agonist, achieved an AC50 in 13 of the 73 assays, but only the AC50s for ERα_TRANS and 
ERE_CIS were significantly (>3-fold) more potent than the NRF2_ARE_CIS. Specifically, 
bisphenol A had AC50s of 1.1 and 0.64 μM in the ERα_TRANS and ERE_CIS assays, 
respectively, compared to an AC50 of 27 μM in the NRF2_ARE_CIS assay. An additional 
26 chemicals hit the two ER assays and the Nrf2 assay, but their ERα_TRANS or ERE_CIS 
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AC50s were all comparable to their respective NRF2_ARE_CIS AC50. In general, these 26 
chemicals showed promiscuous activity across both CIS and TRANS systems, averaging 
double the number of hits compared to the rest of the chemical library (11 versus 5.5). Thus, 
oxidative/electrophilic stress appears to elevate transcription factor activity non-selectively, 
and comparing potencies to NRF2 activity is therefore useful for putting compound activity 
into perspective and aiding interpretation of results. 
In vitro to In vivo Associations 
In comparing the 73 in vitro assay data to 77 in vivo endpoints from rodent chronic 
bioassays, rat multi-generational reproductive toxicity studies and rat and rabbit prenatal 
developmental toxicity studies, 133 significant univariate associations were established based 
on the methods described above. Various non-steroidal nuclear receptors involved in 
xenobiotic metabolism and/or lipid metabolism are specifically associated with target-organ 
pathologies and tumorigenesis, whereas steroidal and other nuclear receptors are specifically 
associated with endocrine-related organ pathologies, offspring survival and the developing 
system (Figure 3.10). Examples of these associations are detailed below.  
PPAR & Rat Liver Tumors 
Of the 309 chemicals, 256 have two-year rat cancer bioassay recorded in ToxRefDB. 
Of these, 101 were found to cause tumors at one or more target sites. Of those 101 chemicals, 
23 were found to cause liver tumors, specifically hepatocellular adenomas or carcinomas. 
These 23 chemicals were evaluated for genotoxicity throughout the pesticide registration and 
re-registration process and generally found to be negative (USEPA, 2009a), which suggests 
that these chemicals predominantly act through non-genotoxic mechanisms of action. In 
comparing the in vitro assay data to in vivo endpoints, only PPARα and PPARγ were 
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significantly associated with rat liver tumors. The PPAR mode of action has been a focus of 
toxicological research with special emphasis on assessing relevance to humans (Lai, 2004). 
Additionally, the prevalence of rodent liver and other tumors in chronic toxicity studies of 
PPARα agonists and PPARα/γ co-agonists has resulted in the U.S. Food and Drug 
Administration (FDA) issuing guidance for development and use of PPAR agonists that 
requires special consideration be given to the carcinogenic potential of these agents (USFDA, 
2008). In total, 143 chemicals activated PPARγ with seven of those chemicals also activating 
PPARα (Figure 3.11). Five out of these seven chemicals (diethylhexyl phthalate (DEHP), 
perfluorooctanoic acid (PFOA), imazalil, lactofen, and diclofop-methyl) are positive for rat 
liver tumorigenicity; while only bromoxynil and fenthion are not. PPARα assay results 
demonstrated the ability to independently classify chemicals as potential liver tumorigens. If 
a chemical was considered a hit for PPARα the relative risk for rat liver tumor induction is 
9.9 (p<0.01) with very high specificity (99%) and lower sensitivity. Additionally, PPARγ 
agonist chemicals were significantly associated with rat liver tumorigens with a relative risk 
of 6.6 (p<0.01), but with high sensitivity (83%) and lower specificity. One could postulate 
that these chemicals act predominantly through a non-genotoxic peroxisome proliferation-
mediated mode of action, and for a few chemicals there is data in the literature to support 
this, including PFOA (Lau et al., 2004), DEHP (Melnick, 2001), Lactofen (Butler et al., 
1988;  Lai, 2004), and Diclofop-methyl (Lai, 2004). It should be noted that oxadiazon and 
perfluorooctane sulfonic acid (PFOS) are purported to cause liver tumors via a PPARα 
mode-of-action (DeWitt et al., 2009;  Richert et al., 1996;  USEPA, 2003), but were not 
positive under the conditions of this assay, although both of these chemicals were PPARγ 
agonists. PFOS was tested at a top concentration of 14 µM and oxadiazon at 24.5 µM 
 79 
because of cytotoxicity observed in the MTC determination. Two reports evaluating the in 
vitro activation of human PPARα by PFOS differed with one determining an AC50 of 13-15 
µM (Shipley et al., 2004) and the other reporting no significant activity up to 250 µM 
(Takacs and Abbott, 2007); therefore, the interpretation of the present results are difficult. 
For oxadiazon, direct activation of PPARα has not been reported in the literature although in 
vivo peroxisome proliferation was seen in rodents treated with high doses (≥ 100 mg/kg/day 
for 28 days) and significant peroxisomal enzyme induction measured in primary rat 
hepatocytes cultures required 50-100 µM (Richert, et al., 1996). 
Endocrine Pathology, Offspring Survival & the Developing System 
In total, 251 and 261 chemicals have rat multigenerational reproductive and prenatal 
developmental toxicity studies recorded into ToxRefDB, respectively, with 225 chemicals 
having both studies in ToxRefDB. Two groups of assays showed significant associations 
with specific reproductive and developmental processes or targets (Table 3.2). As shown 
above, RARα and DR5 were correlated to each other and RAR has direct biological links to 
the developing system (Chambon, 1996). Chemicals positive for RARα/DR5 have a 
significantly greater potential for effects in various developmental systems and at different 
stages of development, including orofacial defects (i.e., cleft lip/palate) and urogenital 
malformations (i.e., renal and ureteric). In contrast, the estrogen receptor alpha (ERα) and its 
response element (ERE), a known endrocrine disrupting target, were associated with 
reproductive effects, including reproductive performance (i.e., decreased fertility and 
implantation loss). In addition to their specific associations, RARα/DR5 and ERα/ERE 
appear to have similar impacts on early offspring survival as indicated by shared associations 
to litter size and live birth outcomes. Interestingly, RARα/DR5 and ERα/ERE activity is not 
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correlated with an R-squared of roughly zero, meaning there shared associations are 
independent and may reflect varying mechanisms leading to the same adverse outcome. In 
general, the predictive power of probing these molecular targets for tissue-specific 
observations such as testicular or adrenal effects is limited, whereas data on hormone or 
cholesterol levels would most likely provide direct links from molecular to phenotypic 
alterations, but are not available for sufficient numbers of compounds in this chemical 
library. 
Discussion 
Cells respond to changes in their environment through a variety of recognition 
systems and signaling pathways that are integrated at the level of transcription factors, which 
coordinate appropriate responses. The multiplexed reporter gene technology described here 
attempts to probe this biological response by generating profiles of individual chemicals 
acting against a large panel of transcription factors in two different assay systems. These 
profiles provide information on potential molecular interactions of the chemicals, as well as 
more generalized activity such as induction of oxidative and electrophilic stress. Quantitation 
of the effects of chemicals on specific transcription factor responses provides information 
that can be used to determine potential for toxicity. Characterizing the responses to known 
toxicants in these assays allows the magnitude and potency of responses for new chemicals to 
be put into an appropriate context for evaluation. Testing chemicals in both the CIS and 
TRANS systems revealed specific limitations of each system, as well as complementarity of 
the data from each system. Valuable insights for interpreting large screening datasets came 
from comparing CIS and TRANS data, especially when limitations of one system, e.g., lack 
of endogenous activity for a particular target, were attenuated by data from the other. In cases 
 81 
where both complementary assays demonstrated robust responses, greater confidence 
resulted from associating a given chemical with a specific molecular activity. 
Chemicals can both directly and indirectly affect transcription factor activities. The 
nuclear receptor superfamily and the Ah receptor are examples of TFs that can bind 
xenobiotic chemicals directly through their ligand-binding domains, resulting in modulation 
of target gene activity. In some cases, receptors such as PXR appear to have evolved to 
recognize such xenobiotics and to control expression of a large series of Phase I, Phase II, 
and Phase III metabolizing enzymes and transporters (Kliewer et al., 2002). Whereas such 
interactions generally serve to help eliminate or detoxify a xenobiotic, they may also lead to 
undesirable consequences, resulting in a variety of toxicities when exposure is sufficiently 
high. For example, induction of the Phase I, II, and III activities can also cause effects on 
endogenous compounds, e.g., steroid hormone metabolism, altering normal physiology. In 
addition, such enzyme induction can cause interference with the expected metabolism of 
pharmaceuticals leading to side effects resulting from either too high or too low a dose of the 
drug (Wilkinson, 2005). Endocrine disruption is another example, whereby xenobiotics 
mimic natural ligands such as steroid hormones in binding to nuclear receptors, resulting in 
disruption of normal receptor signaling and potentially leading to reproductive toxicities 
(WHO, 2002). Outside the endocrine system, chemicals activating PPARα cause peroxisome 
proliferation in rodents and subsequent hepatocarcinogenesis, a cancer mode of action that 
does not seem to occur in humans (Lai, 2004). Thus screening environmental chemicals for 
the ability to affect ligand-activated transcription factors can provide a means to recognize 
the potential for the chemical to cause endocrine disruption and other toxicities. 
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Chemical effects on cells may also be detected though effects on non-ligand-activated 
TFs. Such TFs include those that respond to a wide variety of cellular stressors, including 
oxidative, electrophilic, hyperosmolarity, DNA damage, hypoxia, etc. These stress-response 
effects enable a cell to survive environmental changes by adapting through increasing levels 
of target gene products involved in reducing or buffering the stress, e.g. increasing 
glutathione levels to handle oxidative stress or heat-shock proteins to provide protection to 
newly synthesized proteins during heat or UV light stress (Lee and Johnson, 2004). When 
stress is beyond the tolerance of the adaptive systems, cell death occurs through necrosis or 
apoptosis, the latter allowing selective removal of irreparably damaged cells from the tissue. 
Examples of effects seen in the current study included many chemicals inducing 
oxidative/electrophilic stress (Nrf-2/ARE CIS) but few inducing DNA damage as measured 
by activation of the p53 CIS assay. The latter finding is consistent with the majority of the 
chemicals tested being food-use pesticides that would not be expected to have significant 
genotoxic effects. Because transcription factors of this general functional class are involved 
in adaptive responses, changes in their activation do not necessarily equate directly to 
toxicity. Rather, they suggest that the chemical inducing the response possesses a mode of 
action that may, under sufficient exposure conditions, lead to effects that can overwhelm the 
capacity of the adaptive response, resulting in toxicity. Evaluating the potential for toxicity of 
chemicals with such activity will require careful consideration of potency and exposure to 
properly inform estimations of risk. 
In contrast to the receptors involved in nuclear receptor signaling and stress response, 
many of the other transcription factors screened in this study are known to be involved with 
specific signaling pathways controlling growth and differentiation. For example, E2F, MYC, 
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and SMAD regulate growth in virtually all cells (Grandori et al., 2000), whereas OCT, PAX, 
SOX, GLI, and TCF are among the factors involved in specific aspects of cellular 
differentiation (Maeda et al., 2007). In general, the reporter genes for these response 
elements showed only marginal response to the chemical library. The reasons for this are not 
clear. One possibility is that the signaling pathway controlling the specific reporter gene 
response is not functional under the conditions used for the assay. Not every reporter gene 
response was evaluated with suitable positive controls and, thus, activity could only be 
inferred from the fact that some basal level of reporter gene product was present in the cell. 
Use of a different cell line may be one way to expand functional pathway coverage. In 
addition, by prescreening for cytotoxicity, we ensured that frankly cytotoxic concentrations 
of chemicals would not be used in the screen. It is possible that interference with many of the 
transcription factors required for growth and differentiation results in cytotoxicity and, thus, 
the screening strategy employed to avoid this biased the results against finding effects on 
these pathways. Future screening efforts will take both of these points into consideration. 
Relating effects observed with in vitro assays using transformed cell lines to in vivo 
toxicity remains a significant challenge. Here we evaluated statistical correlations between 
chemical effects on transcription factors and toxicity endpoints, the latter collated in a 
relational database derived from extensive animal testing in support of the U.S. pesticide 
registration process. The relatively few significant associations detected were plausible 
associations between peroxisome proliferator-activated receptors and liver toxicity, estrogen 
receptor activity correlating to reproductive toxicities and retinoic acid receptor toxicities 
associated with developmental defects. These results were confirmed by the co-clustering of 
specific targets across the CIS and TRANS systems, thus increasing confidence in the in vivo 
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associations. The application of in vitro screening to chemical prioritization is enhanced by 
multiple, complementary assays such as these for the same target. There are many possible 
explanations for the inability to discern more correlations. The associations between these 
selected groups of molecular targets and apical endpoints do not encompass all possible 
routes by which a chemical can induce an adverse effect or toxic outcome. Likewise, it may 
be that there are insufficient chemicals within the current library representing each possible 
route to enable detection of significant associations. It is also understood that there are 
significant uncertainties in drawing associations between high-dose laboratory animal 
toxicity studies and in vitro animal target activities, much less the further extrapolation from 
in vitro human molecular target activities, despite the greater relevance of the latter to 
potential human risk. Chemical in vivo effects in relation to in vitro effects also may be 
greatly affected by chemical ADME properties (adsorption, distribution, metabolism and 
elimination), with metabolic biotransformation, in particular, resulting in either much greater 
or reduced toxicity than might otherwise be predicted. Whereas the HepG2 cell line used 
here is derived from liver and maintains some metabolic capacity, it is much less than in the 
intact liver (Donato et al., 2008). Finally, many of the responses seen were statistically 
significant; however, the magnitude of the response was frequently much less than that seen 
with a positive control compound. Again, relating the level of efficacy observed in the in 
vitro assay to biological meaningful results in vivo poses significant challenges.  
The multiplexed RTU assay results evaluated in the present study encompass only a 
fraction of the full range of biological targets and assays, both cell-free and cell-based, being 
run against the ToxCast Phase I chemical library (USEPA, 2009b). However, the present 
assays are based on human transcription factors and, thus, are believed to have particular 
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potential relevance to humans and to informing in vivo extrapolations. The associations 
reported in this study, many of which are corroborated by results reported in the literature, 
demonstrate the biological relevance of several of the presently studied molecular targets for 
monitoring and probing toxicity pathways and for understanding mechanisms of action 
leading to specific chemical toxicities. Along with chemical properties and ADME 
considerations, combining these activity profiles with additional in vitro assay profiles 
having the potential to probe a broader range of biological responses in animals and humans, 
will offer greater opportunities to discern meaningful associations of in vitro profiles with in 
vivo effects. Ongoing efforts to enlarge the test chemical library will additionally enrich the 
chemical and biological information dimensions in relation to toxicity endpoints of 
regulatory interest and, in so doing, provide greater coverage of toxicity mechanisms and 
facilitate the development of robust methods suitable for prioritizing chemicals based on 
potential for toxicity.  
Tables 
Table 3.1.  The 73 CIS and TRANS assays listed with the number of hits per assay, the 
maximal responder out of the ToxCast_320 chemical library, and positive control (where 
available). Maximal efficacy values (Emax) are provided in parenthesis for each listed test or 
positive control chemical. 
Assay Name 
No Hits 
(n=320) 
ToxCast_320 
Max Responder 
(Emax) 
Positive Control 
(Emax) 
CIS/TRANS Related Assays 
ERE_CIS 39 Pyridaben (8.7) Estradiol (9.3) 
ERa_TRANS 90 Pendimethalin (27) Estradiol (23) 6-Fluor-Test (23) 
IR1_CIS 3 Tebupirimfos (3.5)   
FXR_TRANS 1 Butachlor (2.3) CDCA (6.5) 
GRE_CIS 0 Spiroxamine (1.6) Dexamethazone (5.0) 
GR_TRANS 0 Butachlor (1.9)   
DR4_LXR_CIS 7 Tebupirimfos (3.8)   
LXRa_TRANS 23 Tebupirimfos (23) T9 (55) 
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LXRb_TRANS 21 Tebupirimfos (13) T9 (81) 
PPRE_CIS 125 Resmethrin (5.7) Rosiglitazone (6.7) 
PPARa_TRANS 9 Lactofen (11) GW7647 (11) 
PPARd_TRANS 1 Flusilazole (2) GW7647 (13) 
PPARg_TRANS 146 Resmethrin (22) GW7647 (39) Rosiglitazone (31) 
PXRE_CIS 234 Flufenacet (31) Rifampicin (29) 
PXR_TRANS 102 Fipronil (7.9)   
DR5_CIS 27 Imazalil (3.2) 9-cis-Retinoic Acid (7.5) 
RARa_TRANS 49 Lindane (5.9)   
RARb_TRANS 5 Oxadiazon (2.6)   
RARg_TRANS 4 Imazalil (2.2)   
RORE_CIS 35 Tetraconazole (3.3)   
RORb_TRANS 1 Tebufenozide (2.2)   
RORg_TRANS 1 Azoxystrobin (2.9)   
VDRE_CIS 134 Pyridaben (5.5)   
VDR_TRANS 0 Rotenone (1.9)   
PBREM_CIS 24 Prodiamine (2.8)   
CAR_TRANS 4 Phosalone (2.4)   
        
        
Remaining TRANS Assays 
ERRa_TRANS 3 Cyazofamid (2.1)   
ERRg_TRANS 13 Fenthion (2.5)   
RXRa_TRANS 0 Esfenvalerate (2.3)   
RXRb_TRANS 8 Fludioxonil (17)   
AR_TRANS 0 Butachlor (2.1) 6-Fluor-Test (6.3) 
Hpa5_TRANS 0 Rotenone (1.9)   
HNF4a_TRANS 16 Trichlorfon (3)   
NURR1_TRANS 9 Pirimiphos-methyl (5.6)   
THRa1_TRANS 18 (Z,E)-Fenpyroximate (3.2) T3 (11) 
Assay Name No Hits (n=320) 
ToxCast_320 
Max Responder 
(Emax) 
Positive Control 
(Emax) 
Remaining CIS Assays 
Ahr_CIS 54 Tetraconazole (72) FICZ (100) 
AP_1_CIS 52 Prochloraz (4.6)   
AP_2_CIS 0 Hexaconazole (1.7)   
NRF2_ARE_CIS 165 Dichlorvos (16)   
BRE_CIS 93 Fipronil (12)   
C_EBP_CIS 5 Cyazofamid (2.4)   
CMV_CIS 37 Tebupirimfos (3.4)   
CRE_CIS 52 Prallethrin (4.4) Forskolin (2.5) 
E2F_CIS 0 Triclosan (1.5)   
E_Box_CIS 1 Prallethrin (2.5)   
EGR_CIS 40 Prallethrin (8.1)   
Ets_CIS 0 Fluazinam (1.3)   
FoxA2_CIS 0 d-cis,trans-Allethrin (1.8)   
FoxO_CIS 0 Simazine (1.5)   
GATA_CIS 0 Rotenone (1.4)   
GLI_CIS 2 d-cis,trans-Allethrin (3)   
HIF1a_CIS 25 Tetraconazole (3.7)   
HNF6_CIS 0 Spiroxamine (1.5)   
HSE_CIS 22 Prallethrin (33) Geldanamycin (5.7) 
ISRE_CIS 0 Oxasulfuron (1.6)   
MRE_CIS 62 d-cis,trans-Allethrin (28)   
Myb_CIS 0 Hexaconazole (1.6)   
Myc_CIS 4 d-cis,trans-Allethrin (3.6)   
NFI_CIS 4 Prallethrin (2.6)   
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NF_kB_CIS 10 Dichloran (3.4)   
NRF1_CIS 0 Prohexadione-calcium (1.4)   
Oct_MLP_CIS 86 Prallethrin (12)   
p53_CIS 2 Dichlorvos (2.4)   
Pax6_CIS 14 Prallethrin (5.2)   
Sox_CIS 2 Cacodylic acid (2)   
Sp1_CIS 8 d-cis,trans-Allethrin (2.9)   
SREBP_CIS 6 d-cis,trans-Allethrin (2.5)   
STAT3_CIS 0 Dichloran (1.8)   
TA_CIS 4 Tribufos (2.5)   
TAL_CIS 1 Prallethrin (2.3)   
TCF_b_cat_CIS 0 Diphenylamine (1.7)   
TGFb_CIS 8 Oxamyl (9.6)   
Xbp1_CIS 12 Prallethrin (9.7)   
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Table 3.2. Two distinct molecular targets with known links to developmental and 
reproductive toxicities, retinoic acid receptor and estrogen receptor, demonstrate coherent 
associations to in vivo developmental and reproductive endpoints from ToxRefDB and are 
shown with their respective significant relative risk (RR) values (p<0.05).  
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Figures 
Figure 3.1. Evaluation of ToxCast compounds by using libraries of cis- and trans-reporter 
transcription units. Schematic representation. (a.) Detection of cis-RTUs. A mix of 51 
individual plasmids encoding cis-RTUs was co-transfected into suspension of HepG2 cells, 
cells were plated and stimulated with evaluated compound. At the end of incubation period, 
total RNA was isolated and detected as described previously (Romanov, et al., 2008). (b.) 
Detection of trans-RTUs. Twenty four trans-RTU plasmids were separately transfected into 
HepG2 cells, the transfected cells pooled, plated, and stimulated with evaluated compound. 
At the end of incubation, total RNA was isolated and detected as described previously 
(Romanov, et al., 2008). 
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Figure 3.2. Overall and hit concordances across technical replicates determine optimal cutoff 
as a primary summary call criteria. 
 
Figure 3.3. Replicate analysis performed on the technical replicates. For each pair in the 
triplicate sets (comparing A with B, B with C and A with C), we asked if the chemicals were 
both hits, both non-hits or if they disagreed. Total concordance was defined as all 3 were hits 
or all 3 were non-hits, and non-concordance as either 1 or 2 were hits and the remainder were 
non-hits. The total overall concordance is the number of comparisons where the pair was 
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either hits or both non-hits, divided by the total number of comparisons. The hit concordance 
is the number of cases where each of the pair was a hit divided by all cases where one or each 
of the pair was a hit. 
 
Figure 3.4. Two-way hierarchical clustering of the 48 CIS and 25 TRANS assays 
demonstrating the relationship between families of nuclear receptors and their response 
elements, independently tested in either the CIS or TRANS format. 
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Figure 3.5. Comparison of pregnane X receptor (PXR) activity in the CIS (PXRE) and 
TRANS format characterizes both relative efficacy and potency across the chemical library. 
Maximum efficacy (Emax) plotted for both the CIS and TRANS assays across the chemical 
library (a). The colored circles represent the chemicals positive (AC50 derived) or negative 
for the assays on the x- and y-axis. (b. and c.) The top 5 most efficacious and top 5 most 
potent chemicals averaged across both assays demonstrate the relative response compared to 
the positive control and the representative chemicals. 
 
 
Figure 3.6. Comparison of retinoic acid receptor (RAR) activity in the CIS (DR5) and 
TRANS (RARα) format characterizes both relative efficacy and potency across the chemical 
library. Maximum efficacy (Emax) plotted for both the CIS and TRANS assays across the 
chemical library (a). The colored circles represent the chemicals positive (AC50 derived) or 
negative for the assays on the x- and y-axis. (b. and c.) The top 5 most efficacious and top 5 
most potent averaged across both assays demonstrate the relative response compared to the 
positive control and the representative chemicals. 
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Figure 3.7. Comparison of estrogen receptor (ER) activity in the CIS (ERE) and TRANS 
(ERα) format characterizes both relative efficacy and potency across the chemical library. 
Maximum efficacy (Emax) plotted for both the CIS and TRANS assays across the chemical 
library (a). The colored circles represent the chemicals positive (AC50 derived) or negative 
for the assays on the x- and y-axis. (b. and c.) The top 5 most efficacious and top 5 most 
potent averaged across both assays demonstrate the relative response compared to the 
positive control and the representative chemicals. 
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Figure 3.8. Comparison of peroxisome proliferator-activated receptor (PPAR) activity in the 
CIS (PPRE) and TRANS (PPARγ) format characterizes both relative efficacy and potency 
across the chemical library. Maximum efficacy (Emax) plotted for both the CIS and TRANS 
assays across the chemical library (a). The colored circles represent the chemicals positive 
(AC50 derived) or negative for the assays on the x- and y-axis. (b. and c.) The top 5 most 
efficacious and top 5 most potent averaged across both assays demonstrate the relative 
response compared to the positive control and the representative chemicals. 
 
Figure 3.9. Oxidative stress is a plausible explanation for non-specific activity of some 
chemicals. (a.) Nrf2, a marker of oxidative stress, explains fifty percent of the variability in 
the overall activity across the remaining 72 targets probed in this study, both CIS and 
TRANS, based on the log-transformed maximal efficacy values (Emax). Emax values were 
log-transformed to minimize the effect of varying dynamic ranges across the assays. (b.) 
Representative dose response curves of the 10 most efficacious chemicals demonstrate the 
relative dose-response across selected chemicals.   
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Figure 3.10. Two-way hierarchical clustering of the relative risk percentiles from the 
permutation test exhibits clustering of developmental and reproductive endpoints across 
species and study types and grouping of systemic endpoints across chronic and 
multigeneration studies. Of the 73 in vitro and 77 in vivo endpoints, 133 significant (p<0.05) 
assay/endpoint associations were established. 
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Figure 3.11. Associations were derived between PPAR activity, both alpha (a) and gamma 
(g), and rat liver tumorigenesis. In total, 5 of the 7 chemicals that significantly affected 
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PPARa and PPARg caused rat liver tumors in the chronic/cancer bioassay. Individual relative 
risks of 9.9 and 6.6 were established based on significant PPARa and PPARg activity, 
respectively. 
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CHAPTER 4 
PREDICTIVE MODEL OF RAT REPRODUCTIVE TOXICITY FROM TOXCAST HIGH 
THROUGHPUT SCREENING3
 
 
Abstract 
 The EPA ToxCast research program uses high throughput screening for bioactivity 
profiling and predicting the toxicity of large numbers of chemicals. ToxCast Phase I tested 
309 well-characterized chemicals in over 500 assays for a wide range of molecular targets 
and cellular responses. Of the 309 environmental chemicals in Phase I of ToxCast, 256 were 
linked to high quality rat multigeneration reproductive toxicity studies in the relational 
Toxicity Reference Database. Reproductive toxicants were defined here as having achieved a 
reproductive lowest observed adverse effect level less than 500 milligram per kilogram of 
body weight per day. 86 chemicals were identified as reproductive toxicants in rat; 68 of 
those with sufficient in vitro bioactivity to model. Each assay was assessed for univariate 
association with the identified reproductive toxicants. Significantly associated assays were 
linked to gene sets and used for the subsequent predictive modeling. Using linear 
discriminant analysis and five-fold cross-validation, a robust and stable predictive model was 
produced capable of identifying rodent reproductive toxicants with 77±2% and 74±5% 
training and test cross-validation balanced accuracies, respectively. With a 21 chemical 
external validation set the model was 76% accurate, further indicating the model’s potential 
                                               
3 Martin, M. T., Knudsen, T. B., Reif, D. M., Houck, K. A., Judson, R. S., Kavlock, R. J. and Dix, D. J. (2011). 
Predictive Model of Rat Reproductive Toxicity from ToxCast High Throughput Screening. Biol Reprod, 
biolreprod.111.090977 [pii] 10.1095/biolreprod.111.090977. 
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for prioritizing the many thousands of environmental chemicals with little to no hazard 
information. The biological features of the model include steroidal and non-steroidal nuclear 
receptors, cytochrome P450 enzyme inhibition, G protein-coupled receptors, and cell 
signaling pathway readouts- mechanistic information suggesting additional targeted, 
integrated testing strategies and potential applications of in vitro HTS to risk assessment. 
Introduction 
 Current chemical evaluations in the U.S. range from either little to no evidence of 
safety for most industrial chemicals, or an expensive battery of animal tests for food-use 
pesticides that offers little mechanistic insights. No in vivo toxicology test uses more animals 
than the rat multigeneration reproductive test. It has been estimated that 70% of the total cost 
and 90% of the animal use for compliance with REACH will be due to reproductive toxicity 
testing (Hartung and Rovida, 2009). Addressing the existing chemical evaluation bottleneck 
can only be achieved through progressive changes to the current animal testing paradigm. A 
promising resource for addressing this bottleneck is computational toxicology, a field that 
integrates tools from computer science, bio- and chemi-informatics, molecular biology, and 
high throughput screening. Currently prescribed in vivo tests for chemical toxicity are 
resource-intensive, particularly for multigenerational reproductive and prenatal 
developmental assessment. Policy directives such as the European Union’s (EU) Cosmetics 
Directive call for the elimination of animals for evaluating reproductive toxicity in 2013 for 
cosmetic products and development of alternative methods for safety evaluation. In the past, 
significantly less attention has been spent modeling or predicting chemical-induced 
reproductive toxicity, relative to efforts modeling cancer and other endpoints. Reasons for the 
meager effort in this area include a lack of reference animal toxicity data to model, as well as 
 106 
the molecular and physiological complexity of maternal-fetal interactions, life-stages, and 
generational sensitivities (Cronin and Worth, 2008). Recent efforts capturing in vivo 
reproductive toxicity studies into databases, and in vitro bioactivity profiling have enabled 
the development of predictive, mechanistic and pathway-based models for these complex 
reproductive outcomes. 
 ToxRefDB, the Toxicity Reference Database, has been the primary tool for storing 
and accessing high quality toxicology studies and is available online for searching and 
download (USEPA, 2009). ToxRefDB has characterized thousands of studies using a 
standardized vocabulary, a uniform structure across study types, and a high level of internal 
and external quality control for the extraction of endpoints useful in developing predictive 
models (Martin et al., 2009a). The primary study for assessing reproductive effects of 
chemicals is the multigenerational reproductive test (OPPTS 870.3800 and OECD 416), and 
is typically conducted under continuous exposure to male and female rats from 10-weeks 
pre-mating through lactation in the second generation. From multigeneration reproductive 
studies in ToxRefDB we have the capacity to identify individual or aggregated endpoints for 
predictive modeling across hundreds of chemicals and have made comparisons across 
generations to identify adverse impacts on developmentally sensitive reproductive endpoints, 
based on the prevalence of specific endpoints at later generations compared to the first 
generation (Martin et al., 2009b). Generational comparisons using ToxRefDB have also been 
part of the OECD evaluation of the proposed Extended One-Generation Reproductive 
Toxicity Study (EOGRTS). ToxRefDB was the primary database used in the large scale 
retrospective analysis aimed at evaluating the impact of the second generation on risk 
assessments, and classification & labeling (C&L) in Europe (Piersma et al., 2010). However, 
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the acceptance of the EOGRTS in lieu of the existing two generation test will not alleviate 
the chemical testing bottleneck for the many thousands of chemicals in commerce. One set of 
solutions to this testing bottleneck are alternative methods for chemical prioritization and 
intelligent, targeted testing decisions. 
 The use of alternative methods as part of an integrated reproductive and 
developmental toxicity testing strategy is currently being developed as a battery of in silico, 
in vitro, and in vivo tests (Hareng et al., 2005;  Spielmann, 2009). One component of this 
toolbox is the large-scale bioactivity profiling of chemicals in high throughput screening 
(HTS) and high-content assays. EPA’s ToxCast™ research project has produced a substantial 
amount of HTS data on environmental chemicals for developing predictive models of 
toxicity (Dix et al., 2007). Phase I of ToxCast profiled 309 toxicologically well-characterized 
chemicals in over 500 assays using nine technologies, including cell-free HTS assays and 
cell-based assays. ToxCast HTS data and multigenerational reproductive toxicity data from 
ToxRefDB provides an effective dataset for developing predictive toxicology models. In this 
study, we present a robust and stable predictive model of chemically-induced reproductive 
toxicity that demonstrates external predictivity useful for targeted testing prioritizations and 
significantly advancing predictive and computational toxicology. 
Methods 
Chemical 
Phase I of the EPA ToxCast™ program employs a chemical library containing 320 
samples consisting of 309 unique structures, 5 duplicates that were differently sourced and 3 
triplicates as technical repeats for internal quality control. The rationale for chemical 
selection was based on several criteria: extensive chronic, cancer, multigenerational 
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reproductive, and developmental assay data available (95% of compounds meet this criteria); 
soluble in DMSO (-1 < logP < 6, i.e., log of the octanol/water partition coefficient; 97.5% 
meet this criteria); molecular weight range 250-1000 (90% meet this criteria); and 
commercially available with purity >90% (98% meet this criteria). These criteria were 
largely satisfied with a diverse set of pesticide active ingredients that have had guideline in 
vivo toxicology studies conducted as part of their registration process with the EPA. Several 
other miscellaneous chemicals of environmental concern meeting these criteria were also 
included in the library. Despite its large representation of pesticidal actives, the Phase I 
chemical library spans a wide range of property values and is quite structurally diverse, 
representing over 40 chemical functional classes (e.g., pyrazole, sulfonamide, 
organochlorine, pyrethroid, etc.) and over 24 known pesticidal mode-of-action classes (e.g., 
phenylurea herbicides, organophosphate insecticides, dinitroaniline herbicides, etc.). A 
complete listing of the quality reviewed and structure-annotated chemical library is available 
for download as a Structure Data Format (SDF) file at the DSSTox website (USEPA, 2008). 
Chemicals comprising the ToxCast™ Phase I library were commercially procured 
and plated by BioFocus DPI (South San Francisco, CA). Supplier-provided certificates of 
analysis indicated purity >97% for the large majority of chemicals (87%), and >90% purity 
for all but a few instances of technical grade or known mixtures. Follow-up analysis of an 
original solution plate by BioFocus DPI using LC/MS (liquid chromatography mass 
spectrometry), subsequent to assay screening, has confirmed mass identification, stability, 
and purity for over 83% of the chemical library. For the majority of the remaining chemicals, 
currently employed analysis methods are known or suspected to be inadequate for confirming 
sample purity and, for the remaining 8% of the chemicals, follow-up studies have provided 
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some evidence of sample decomposition in DMSO over time. A QC summary result mapped 
to chemical solution sample is provided on the ToxCast™ website in association with assay 
results (U.S. EPA, 2008). All chemicals were included in the analysis regardless of analytics 
results, but were accounted for throughout the analysis process. 
In Vivo (Class Data) 
Multigenerational reproductive toxicity testing study design and treatment group 
information along with all treatment-related effects were manually collected into EPA’s 
Toxicity Reference Database (ToxRefDB). The database structure, standardized vocabulary 
and ontology, and quality control procedures have been described previously (Martin, et al., 
2009a). To date, ToxRefDB has captured 393 acceptable reproductive studies across 353 
chemicals equating to 14, 347, 32 one-, two- and three- generation studies, respectively. An 
acceptable study can be defined as any study that adequately followed the multigeneration 
testing guideline, primarily determined by regulatory toxicologists from EPA’s Office of 
Pesticide Programs, and that the review of the study contains sufficient information for 
complete entry into ToxRefDB. Of the 309 ToxCast chemicals, 256 chemicals have been 
linked to an acceptable reproductive study entered in ToxRefDB with 242 exact structural 
matches, 4 close structural matches presumed to be toxicological equivalents (e.g., parent-to-
salt, salt-to-parent, different isomeric forms) not already linked to a ToxCast chemical, 4 
close structural matches already linked to a ToxCast chemical (e.g., Fluazifop-butyl and 
Fluazifop-P-butyl), and 6 parent-to-metabolite pairs (e.g., Diethylhexyl phthalate and 
Phthalic acid, mono-2-ethylhexyl ester). An additional 39 chemicals have unacceptable 
reproductive studies while 14 chemicals have no data available in ToxRefDB.  
 110 
In ToxRefDB, 650 unique effects were observed across the entire multigenerational 
reproductive toxicity study dataset, ranging from body weight decreases to organ weight 
changes to litter survival to fertility decrements. Each unique effect was mapped to one of 
three multigeneration study categories; parental (e.g., body weight, liver weight, and other 
systemic toxicities), reproductive (e.g., primarily fertility and early offspring survival), and 
offspring (e.g., offspring weight, longer-term offspring survival, and other systemic offspring 
toxicities during their juvenile period). Specifically, 120 effects were directly related to 
reproductive outcomes and another 175 effects indicated adverse offspring outcomes, with 
the remainder being systemic parental effects (Martin, et al., 2009b). Based on the review of 
each study, primarily by regulatory toxicologists from EPA’s Office of Pesticide Programs, 
parental, offspring, and reproductive lowest observed adverse effect levels (LOAEL) were 
established based on the weight of evidence and expert judgment of the reviewer. The 
reproductive LOAEL (rLOAEL) was used to delineate a positive and negative set for 
reproductive toxicity, based on a 500 mg/kg/day cutoff. This cutoff value approximates the 
testing limit of 1000 mg/kg/day in the reproductive test guideline and accounts for the large 
uncertainty around the dose intake measurements and standard conversions used in capturing 
the dosing information across hundreds of chemicals and over 30 years of toxicity testing. 
Any chemical with a rLOAEL less than or equal to the cutoff was considered a positive and 
any chemical with a rLOAEL greater than the cutoff or that was not assigned a rLOAEL by 
the study reviewer was considered to be negative for reproductive toxicity. Specific effects 
within this endpoint category include reproductive performance measures (e.g., fertility, 
mating, gestational interval), male and female reproductive tract effects (e.g., testis, 
epididymis, ovary, uterus pathology and weight along with sperm measures and 
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morphology), and sexual developmental landmarks (e.g., preputial separation, vaginal 
opening and anogenital distance). Teratogenic endpoints from prenatal toxicity testing were 
not included as part of the definition of a reproductive toxicant for the purposes of this 
modeling effort. Additional information regarding the treatment groups including the life-
stage and generation of the animals and the administered dose were captured in ToxRefDB to 
provide additional context for each chemical’s reproductive toxicity potential. 
In Vitro (Features) 
As part of the ToxCast research program, the chemical library was tested in over 500 
assays across 9 technologies, including high throughput cell-free assays and cell-based assays 
in multiple human and rodent primary and derived cell lines. A complete overview of the 
assays, assay selection, analysis methods, quality measures, and assay annotation have been 
previously published (Judson et al., 2010). In general, AC50 (concentration at half maximal 
efficacy) values or LEC (lowest effective concentrations) were derived for each assay and 
time-point, where applicable. The complete data set, including AC50/LEC values and 
corresponding concentration response data for all chemical-assay measurement pairs is 
available from the EPA ToxCast website (U.S. EPA, 2008). For the purpose of predictive 
modeling, assays form the input features and can be thought of as the right side of the 
equation where some linear combination of these assays or sets of assays is equal to the class 
data; the reference in vivo endpoint. 
AC50/LEC values were -log3 transformed (-log3 [AC50/1000]), and a value of 0 was 
given to all negative assay results. A log3 transformation and setting negatives to 1000µM 
was used over a log10 transformation and setting negatives to one molar, as has been done in 
previous publications of ToxCast results(Judson, et al., 2010), to enhance the scoring range 
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between high and low potency active chemicals and to decrease the distance between active 
and inactive chemicals. Therefore, the “assay score” where the AC50 was 100µM would 
have a value of roughly 2 while a 100nM AC50 would have a value of roughly 8. A “gene 
score” or “gene-set score” was derived based on the average assay score across a set of 
closely related assays, e.g., assays mapped to a single gene or gene family. Any chemical 
active in fewer than or equal to 10 assays (≤2% aggregate active) was removed from the 
initial model development due to the lack of information provided by the chemical’s 
bioactivity fingerprint to discern active and inactive for any toxicity. The rationale for 
excluding the chemicals with little or no in vitro activity is based on the following logic. 
Specific chemicals may lack activity in in vitro assays for a number of reasons including 
chemical degradation, aqueous insolubility, lack of metabolic activation, or volatility. Such 
chemicals would be characterized by little to no activity across a broad range of in vitro 
assays. Since this behavior is, at least to some extent, relevant only to the in vitro systems, 
they are not good candidates for including in a model predicting in vivo activity. They were 
thus excluded from the training set and their exclusion is making no statement of a 
chemical’s true reproductive toxicity potential. 
Model (Class ~ Features) 
The first step in the development of a predictive model was univariate feature 
selection. Each assay was compared to the training set of chemicals, positive and negative for 
reproductive toxicity, using continuous and dichotomous statistical methodology, including 
linear (Pearson’s) correlation test, chi-square test, and t-test with the level of significance 
returned as p-values. Each assay with a p-value of less than 0.1 from any method passed the 
initial feature selection filter. The resulting assays were then grouped by gene or assay 
 113 
family, as described above, to form the input features for subsequent modeling. In some 
instances, assays that were not statistically significantly associated but provided orthogonal 
or complimentary readouts for the same target were included in model development. This 
was performed for various nuclear receptor targets in which cell-based transcription factor 
assays were significantly associated with reproductive toxicity, whereas the more specific 
cell-free binding assays were not due to the low number of active chemicals. The highly 
specific assays provide increased evidence that a chemical interacts with a particular target. 
Significantly associated assays that were part of a large assay family or that were highly 
correlated to other higher prioritized assays, based on relative p-value and correlation, were 
excluded to minimize the total number of assays moving into the model development phase. 
For example, as part of ToxCast, 54 GPCR (G protein-coupled receptor) binding assays were 
evaluated, with 18 being significantly associated with reproductive toxicity. Of those 18 
GPCR assays, 5 were selected based on having the greatest correlation collectively; adding 
further GPCR assays only lowered the overall association to reproductive toxicity.  
Based on the selection of a small and balanced feature set, the prediction of 
reproductive toxicity potential was performed using linear discriminant analysis (LDA). 
Five-fold cross-validation was used to explore the stability of the resultant model, a process 
of developing the model using 80% of the chemical set and testing the model accuracy with 
the remaining 20% and repeating five times until all data has been used as both training and 
test datasets. The resulting cross-validation statistics are presented as the average and 
standard deviation of the training and test set balanced accuracies across the five runs. In 
addition, a subset of chemicals with positive findings in unacceptable studies within 
ToxRefDB and chemicals with clear literature evidence of reproductive toxicity or not were 
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used to assess the forward predictivity of the resultant model and to serve as an initial 
external validation set. 
Results 
The quality and forward predictivity of any model is limited by the quality of the 
feature and class data being used in the model development process. Therefore, strict and 
transparent methods were used for identifying the training set used in the initial modeling 
effort from both in vivo (i.e., class) data and in vitro (i.e., feature) data perspectives. Of the 
256 chemicals linked to an acceptable reproductive study, 86 reported a reproductive 
LOAEL (rLOAEL) less than 500 mg/kg/day (Table 4.1). The additional 12 chemicals that 
reported an rLOAEL from an unacceptable reproductive study were not incorporated into the 
initial model development process, but were used for model assessment and external 
validation of the model. Six chemicals had rLOAEL above the 500 mg/kg/day cutoff and 
were considered negative for modeling purposes, including Fluoxastrobin (862 mg/kg/day), 
Trifloxysulfuron-sodium (631 mg/kg/day), Propoxycarbazone-sodium (1314 mg/kg/day), 
Oxasulfuron (1115 mg/kg/day), Isoxaben (1000 mg/kg/day), and Propamocarb hydrochloride 
(1000 mg/kg/day). The toxicity profile for these chemicals primarily consisted of high-dose 
systemic parental and offspring toxicities leading to confounding sexual developmental 
landmark findings and early offspring survival decrements. Of the total 98 chemicals 
identified as reproductive toxicants (i.e., 86 from acceptable and 12 from unacceptable 
studies), 49 chemicals observed treatment-related effects to the male and/or female 
reproductive tract, 51 chemicals caused decrements in reproductive performance, 67 
chemicals affected early offspring survival, and 18 chemicals altered sexual development. A 
combined model of reproductive toxicity is presented, as opposed to individual models of 
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each endpoint class, due to the large overlap in chemicals across these endpoint classes, the 
lack of gender-specific phenotypes, and no mechanistic information in the guideline 
multigeneration reproductive studies.   
A significant number of ToxCast chemicals had little to no in vitro activity across 
hundreds of assays. Aggregate activity for each chemical was calculated as the number of 
actives (i.e., achieving an AC50 and defined as a hit in the assay) divided by the total number 
of assays used in this analysis (n=512). A 2% activity cutoff was established based on the 
minimal impact of aggregate in vitro activity on the sensitivity and, to limited degree, 
specificity of resulting models. In total, 62 chemicals were identified as falling below the 2% 
cutoff and not used in the initial model development process. Table 4.2 summarizes the 
chemical counts for each chemical group based on in vivo reproductive study 
acceptability/availability and aggregate in vitro activity. The entire chemical library was split 
into these groups to identify a chemical set with the capacity to develop a stable and robust 
model without the negative impacts of low in vivo multigeneration study quality or potential 
limited amenability to in vitro screening. Thus, chemical group A was selected for the initial 
development of the predictive reproductive toxicity model, including internal cross-
validation. Groups B, C, and D were used to evaluate the stability and to identify current 
weaknesses, limitations and gaps of the model. Groups E and F have also provided insight 
into the forward predictivity of the model, based on available open-literature reproductive 
toxicity studies. In conjunction with Table 4.2, a schematic of the full decision process, 
including chemical groupings, class definitions (i.e., positive or negative for reproductive 
toxicity), and final summary model statistics is provided as an overview and guidepost to the 
remaining more detailed results (Figure 4.1). 
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 Of the 206 chemicals used in the initial development of the predictive reproductive 
toxicity model (i.e., chemical group A), 68 were identified as reproductive toxicants, roughly 
one third of the total. In relating the in vitro bioactivity to these reproductive toxicants, a set 
of assays and genes were identified as significant indicators of reproductive toxicity, based 
on their univariate association. In total, 36 out of over 500 assays were selected for model 
development and subsequently mapped to genes or gene sets (Table 4.3). The primary genes 
identified were nuclear receptors, both steroidal and non-steroidal, and included the androgen 
receptor (AR), estrogen receptor alpha (ERα; ESR1), peroxisome proliferator-activated 
receptors, alpha (PPARα) and gamma (PPARγ). These molecular targets have extensive 
literature detailing their role in normal reproductive function as well as reproductive and 
endocrine toxicity. A number of cytochrome P450 enzyme inhibition (CYP) assays, 
including aromatase (Cyp19a1), were also significantly associated with the reproductive 
toxicants. Interestingly, besides the human aromatase assay, rat CYP assays had increased 
association to the endpoint as compared to the human CYP assays. For the purposes of the 
model and based on the increase in overall statistical correlation, all associated rodent CYP 
assay scores, as well as aromatase, were averaged and used as a single feature, called ‘CYP’. 
In addition to these genes and assay sets, individual assays representing cell-based markers of 
growth factor stimulation and cell signaling, including epidermal growth factor 1 (EGFR1) , 
transforming growth factor beta 1 (TGF-β1), vesicular monoamine transporter 2 (VMAT2), 
and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) were other 
positive indicators of reproductive toxicity potential. These assays were also averaged 
together as a miscellaneous set of assays and called ‘OTHER’. As part of ToxCast, 54 GPCR 
(G protein-coupled receptor) binding assays were evaluated, with 18 being significantly 
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associated with reproductive toxicity. Of those 18 GPCR assays, 5 were selected based on 
having the greatest correlation collectively; adding further GPCR assays only lowered the 
overall association to reproductive toxicity. Assays targeting the pregnane X receptor (PXR) 
were negatively correlated with reproductive toxicity potential and used in the model 
development process with the expectation of providing some indication of the metabolic 
clearance of the chemical or representing general nuclear receptor promiscuity. 
Using the combination of the selected gene/gene-set scores, a multivariate linear 
classifier was developed using linear discriminant analysis (LDA) and five-fold cross 
validation. The feature set included PPARα (average -log3(AC50/1000) across 3 assays), AR 
(average -log3(AC50/1000) across 3 assays), ERα (average -log3(AC50/1000) across 7 
assays), PPARγ (average -log3(AC50/1000) across 4 assays), CYP (average -
log3(AC50/1000) across 7 assays), GPCR (average -log3(AC50/1000) across 5 assays), 
OTHER (average -log3(AC50/1000) across 4 assays), and PXR (average -log3(AC50/1000) 
across 3 assays) for a total of eight features. Figure 4.2 demonstrates the relative impact on 
classification rates between individual assays, genes/gene-sets and the final model. In 
general, we find that aggregating multiple related assays into a single feature increased the 
classification rate and yielded a more balanced and stable model. Grouping the assays by 
gene and gene-sets also allows for assays with low hit prevalence that would otherwise not 
be included in the model to contribute to the overall assessment of whether or not a chemical 
interacts with a specific molecular target.  
Using the eight gene and gene-set features a robust (i.e., high predictivity with high 
balanced accuracy; >70%) and stable (i.e., high test cross-validation and external validation 
accuracies; >70%) classifier or predictive model was generated as shown by resulting model 
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statistics (Table 4.4). The cross-validation balanced accuracy (BA, equal to the average of 
sensitivity and specificity) for the training and test sets, averaged across all 5 runs, were 77% 
and 74% for both training and test sets with a standard deviation of 2% and 5%, respectively. 
Conversely, using the single most significantly associated assay per gene or gene-set resulted 
in training and test balanced accuracies of 71% and 64%, respectively, illustrating the loss in 
predictivity and model stability when relying on a single assay to represent a molecular target 
or pathway. After demonstrating stability across the cross-validation runs, a model generated 
using all 206 Group A chemicals was optimized resulting in a balanced accuracy of 80% (p-
value = 4.2E-17), indicating a highly predictive model for reproductive hazard. 
Chemical group B was not included in the initial model development due to the lack 
of in vitro bioactivity across hundreds of assays. Interestingly, a comparable prevalence of 
reproductive toxicants was observed in chemical group B with 18 of the 50 chemicals 
characterized as actives (36% active versus 64% inactive). Only 20 chemicals in group B 
were active across any of the 33 assays or 7 input features that positively indicated 
reproductive toxicity. If the model is applied to chemical group B only, the balanced 
accuracy is 54% with a very low sensitivity of 11%. If the model is applied to chemical 
groups A and B, balanced accuracy and sensitivity drop to 75% and 66%, respectively. The 
diminished model performance, especially in terms of sensitivity when including low in vitro 
activity chemicals provides justification for considering these chemicals outside the domain 
of in vitro biological applicability, akin to the domain analysis performed in structure activity 
studies, and provide no evidence as to the safety or toxicity of the chemical. In real-world 
applications of this reproductive toxicity model, chemicals could be identified for follow-up 
analysis ranging from traditional animal toxicity testing, to additional in vitro screening 
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attempting to address confounding issues such as chemical decomposition, aqueous 
insolubility, or volatility, to the application of purely in silico models. 
Chemical groups C and D are comprised of 39 chemicals that have been tested in 
guideline reproductive studies that were deemed unacceptable for a variety of reasons, 
including quality of the review, dose selection, and guideline adherence. It would not be 
expected that these studies were deemed unacceptable due to false positive findings; 
therefore, the 12 chemicals designated as reproductive toxicants were used to demonstrate 
external predictivity of the model. Examples of such chemicals include the putative anti-
androgen Prochloraz (Laier et al., 2006) and the possible endocrine disrupting chemical 
Fenitrothion (Okahashi et al., 2005), both of which were predicted to be positive for 
reproductive toxicity. In total, 7 of the 12 reproductive toxicants in chemicals groups C or D 
were predicted to be positive. The same presumption for the positive findings cannot be 
extended to the negative findings across studies flagged as unacceptable. For example, the 
male reproductive toxicant boric acid (Chapin and Ku, 1994) caused only limited 
reproductive effects in the unacceptable guideline multigeneration reproductive study and 
showed little in vitro activity (chemical group D), possibly due to limited amenability to 
HTS.  
Chemical groups E and F have no guideline-based multigeneration reproductive 
toxicity study entered into ToxRefDB and in most cases have never had such a study 
performed. However, of the 14 chemicals in groups E and F, 9 were linked to reproductive 
toxicity tests available in the open literature. Varying sources and degrees of evidence can be 
found for reproductive toxicity; Methoxychlor and its metabolite HPTE based on positive 
findings in numerous pubertal and other in vivo assays (Akingbemi et al., 2000;  Armenti et 
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al., 2008;  Chapin et al., 1997;  Uzumcu et al., 2006), Bromoxynil based on EU labeling as a 
reproductive toxicant (R62), and Methyl Cellusolve (2-Methoxyethanol) based on 
reproductive findings in multiple systemic repeat-dose and multigenerational studies 
(Canada, 1999), and Monocrotophos based on male and female reproductive toxicity across 
multiple studies (Rao and Kaliwal, 2002;  Ratnasooriya et al., 1996). Equivocal evidence of 
reproductive toxicity could be found for Alachlor (USEPA, 1998a), based on non-dose 
dependent effects on ovarian weight and pregnancy index effects, which did not result in a 
reproductive LOAEL being determined. Dimethyl phthalate (DMP) and its metabolite 
Methyl hydrogen phthalate (MHP) (Gray et al., 2000;  Kwack et al., 2009) as well as 
Butralin (USEPA, 1998b) were considered to be negative for reproductive toxicity based on 
the available studies. The model correctly divided this subset of chemicals as reproductive 
toxicants or not with the exception of Monocrotophos, which was in the low in vitro activity 
group (chemical group F). Interestingly, Alachlor, which showed limited evidence of 
reproductive toxicity, was predicted to be positive and was just above the cutoff or model 
intercept, which could readily be interpreted as an equivocal prediction. In summary, 5 of 6 
chemicals with literature evidence of reproductive or endocrine toxicity were accurately 
predicted while all 3 negative chemicals were accurately predicted. 
The remaining 5 chemicals have no reproductive toxicity information available in the 
literature and were candidates for forward predictions. Based on the model, Symclosene and 
Phenoxyethanol were predicted to be negative, but it should be noted that the chemicals had 
low confidence in their purity from the analytical QC and/or low in vitro activity. Three 
chemicals with no reproductive toxicity data were predicted to be positives, including 
Diniconazole, Niclosamide, and Clorophene. Diniconazole, similar to many of the other 
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conazoles, demonstrated CYP inhibition, which was highly associated with decrements in 
early offspring survival. Niclosamide displayed fairly potent PPARγ agonist activity in 
multiple assays (top 5 of 309 chemicals for aggregate PPARγ activity), which was associated 
most with male and female reproductive tract effects. Androgen receptor binding was 
observed for Clorophene at similar potencies to CYP inhibition findings, which were both 
associated with delays in sexual development and decrements in reproductive performance. 
These results provide examples of how in vitro screening leading to targeted testing could be 
used to identify chemicals as potential reproductive toxicants based on model predictions. 
Additionally, the components of the predictive model have increased associations with 
specific endpoints and can help make recommendations about study design, including 
incorporating more sensitive or mechanistic endpoints into the study. A summary of the 
external validation (i.e., chemicals not used in training or testing the model and that have 
sufficient ToxRefDB or literature data to confidently classify the chemical as a reproductive 
toxicant or not) and forward validation (i.e., chemicals in which a prediction has been made 
but have no available evidence of whether or not the chemical is a reproductive toxicant or 
not) chemical sets demonstrates the forward predictivity of the model and provides examples 
of predictions made on chemicals with no reproductive toxicity information available (Table 
4.5). Of the 21 external validation chemicals, 12 were accurately predicted as reproductive 
toxicants, 5 chemicals were incorrectly predicted as negative, and 4 were accurately 
predicted to be negative resulting in an external validation accuracy of 76% and a balanced 
accuracy of 85%.  
In practice, the use of a predictive reproductive toxicity model can assist in 
prioritizing further targeted testing. Using chemical group A, we demonstrate the utility of 
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this model in decision making and how it could assist in alleviating the current chemical 
testing bottleneck. Depending on prioritization goals, increasing or decreasing the optimal 
balanced cutoff would alter the specificity, sensitivity and predictivity of the applied model 
(Figure 4.3). Using a high cutoff, testing the top 30 scoring chemicals would yield 26 
reproductive toxicants. On the other hand, to identify the vast majority of reproductive 
toxicants (57 of the 66 total reproductive toxicants), one would have to test the top 136 of 
206 scoring chemicals. If the prioritization task was to follow-up with an expensive and time-
consuming multigeneration reproductive study in a short period of time, then a more specific 
approach (i.e., higher cutoff) may be more appropriate. If the prioritization task was to 
follow-up with a medium-throughput assay capable of testing many chemicals, then a more 
sensitive approach (i.e., lower cutoff) could be used, ensuring the testing strategy catches as 
many potential reproductive toxicants as possible. A maximum sensitivity of 86% and a 
maximum specificity of 97% are achieved dependent on the cutoff, which can be adjusted to 
the prioritization task. 
Beyond the accurate prediction of reproductive toxicants identified solely from 
animal studies, we have compiled the available European Union (EU) C&L for reproductive 
toxicity (R60&62 for fertility and R61&63 for developmental toxicity) in Table 4.6. Of the 
206 group A chemicals, 19 have been reviewed for EU classification with 7 being classified 
for fertility (R60&62), 8 classified for developmental toxicity (R61&63), and 4 classified for 
neither. In all, 14 of the 15 R60-63 classified chemicals were predicted by the current model 
to be positive. Only the metabolically activated Benomyl was a false negative using the 
predictive model (Lim and Miller, 1997). All 4 non-classified chemicals were predicted to be 
negative, but it should be noted that these chemicals could have been unclassified due to 
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insufficient data to assess C&L. As opposed to the risk assessment process where 
quantitative dose response information is needed, the C&L process evaluates the intrinsic 
hazard of a substance. The output of the predictive reproductive toxicity model appears well 
suited to C&L.  
Discussion 
The results of this analysis demonstrate that in vitro HTS data can be used to predict 
developmentally sensitive reproductive toxicity in the rat. The capacity to use ToxCast HTS 
data, costing roughly $20,000-$30,000 per chemical for over 500 assays, in predicting the 
reproductive toxicity of 100s to 1000s of chemicals could transform the way in which 
chemicals are prioritized and selected for targeted reproductive toxicity testing. Reproductive 
toxicity testing is animal intensive, time-consuming, and costly. Current testing requirements 
are expanding internationally beyond conventional pesticides to industrial chemicals and 
other chemical domains. Past, present and future multigenerational reproductive studies 
characterize reproductive toxicity through the integrated assessment of over 100 potential 
endpoints across varying life-stages and generations. Even with these large numbers of 
measured endpoints, the imprecise nature of many of the endpoints limits the ability to 
identify gender and life-stage specificity, let alone mechanisms of action. The complexity of 
the biology, physiology, and study design are primary reasons for using molecular and 
cellular markers to model reproductive toxicity, but these complexities are also the reasons 
previous modeling efforts have not shown dramatic success. Therefore, we have focused not 
only on the model development, but also on the detailed capture and uniform assessment of 
the reference in vivo reproductive toxicity information leading to a predictive and 
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biologically relevant model that can be applied not just to testing prioritization but also 
testing refinement or even replacement.  
The overall accuracy and predictivity of the current model based on the cross-
validation statistics and examples of forward predictivity demonstrates its potential for use in 
an integrated evaluation strategy for environmental chemicals. Additionally, the model has 
shown to be specific to reproductive toxicity and is not modeling general systemic toxicity as 
is evident with the lack of concordance with the systemic parental and offspring LOAEL. It 
should be noted that the ToxCast assay data is concurrently being used to develop 
independent predictive models of cancer, systemic and developmental toxicities. Once 
further model performance assessment has been performed on models developed using 
ToxCast data, the models could be combined into an integrated testing strategy. As a starting 
point in this process, the current reproductive toxicity model underwent performance-based 
assessment demonstrating its strengths and limitations. For example, chemicals that require 
metabolic activation such as Benomyl or Molinate will not be predicted as a reproductive 
toxicant by this model, at least not until HTS data using metabolically competent systems are 
available (Jewell et al., 1998;  Lim and Miller, 1997). Additionally, chemicals such as Boric 
Acid that likely causes its male reproductive toxicity through non-molecular interactions 
demonstrate limitations of the current model (Chapin and Ku, 1994;  Jewell, et al., 1998) and 
points to the larger issue of chemical domain of applicability. The ToxCast Phase I chemical 
set contains a large number of conventional pesticides. The ToxCast Phase II chemical 
library contains about 700 chemicals with more diverse structural and use characteristics, 
including on-the-market and failed pharmaceuticals, food additives, antimicrobials, and other 
industrial chemicals. ToxCast Phase II will provide a robust external validation set testing the 
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forward predictivity of the current model, and evaluating the model’s chemical domain of 
applicability. An advantage of developing predictive models using quantative HTS data 
linked to genes, proteins and pathways is the ability to identify gaps in the mechanisms 
covered by the model. There are also instances of chemicals predicted to be reproductive 
toxicants that caused minimal reproductive toxicity in the multigenerational study but have 
been shown to cause reproductive related effects in either chronic, developmental or other 
types of studies. Examples of reproductive related effects for Triclosan and Bensulide (Foran 
et al., 2000;  Zorrilla et al., 2009) from other study types demonstrate the difficulty in 
definitively calling training set chemicals ‘positive’ or ‘negative’ for reproductive toxicity. 
Among the chemicals selected for external validation, the model provided accurate 
predictions for 16 of the 21 chemicals. The five chemicals with inaccurate predictions 
provide valuable insight into potential limitations or gaps of the model. Interestingly, the 5 
chemicals had a common phenotypic profile with respect to reproductive toxicity. Tribufos, 
Spiroxamine, Tefluthris, Disulfoton, and Esfenvalerate all caused reduced early offspring 
survival, particularly litter size decrease with little to no accompanying effects on 
reproductive performance or reproductive tract pathology. The rLOAEL for all 5 chemicals 
was set at the high dose tested based on the early offspring survival effects and the parental 
and offspring LOAEL were set at the lower dose levels. Based on the inclusive definition 
used for defining a positive for reproductive toxicity for model development all 5 were 
considered positive, but lack evidence of specific fertility-related or developmentally 
sensitive reproductive outcomes. Nonetheless, a gap in model predictivity has been identified 
and could potentially be filled using additional assay technologies, physical chemical 
properties and structural descriptors, or acute or short-term in vivo studies. 
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The model development process identified biologically plausible features and 
pathways from over 500 assays mapped to 100s of genes and spanning many reproductive 
relevant modes-of-action. PPARα activity was clearly associated with reproductive toxicity, 
with all 10 PPARα agonists in the training set (chemical group A) causing reproductive 
toxicity. Putative PPARα agonists (Lactofen (Butler et al., 1988), Imazalil (Takeuchi et al., 
2006), Diclofop-methyl (Takeuchi, et al., 2006), DEHP (Klaunig et al., 2003), MEHP 
(Klaunig, et al., 2003), and PFOA (Klaunig, et al., 2003)) and environmental chemicals 
identified as potential PPARα agonists through the ToxCast research program (Fluazinam, 
Emamectin benzoate, Vinclozolin, and Fenthion) span many chemical classes yet share a 
relatively common reproductive toxicity profile; a decrease in reproductive performance (i.e., 
decreased fertility) in 8 out of the 10 chemicals. Although a mechanistic link between PPAR 
activity and fertility or other reproductive impairments remains unclear (Peraza et al., 2006), 
the role of PPAR in steroid metabolism and its activity in reproductive tissues infers that it is 
a plausible target for disruption of endocrine signaling and altered gametogenesis.  
AR and ERα activity was also associated with reproductive toxicity. The ToxCast 
receptor profiling identified most if not all the known anti-androgenic and estrogenic 
chemicals in the current dataset, including well studied chemicals such as Vinclozolin, 
Bisphenol A, Methoxychlor, HPTE and Clorophene. The role of potency in determining a 
chemical’s relative reproductive toxicity potential needs to be explored further, considering 5 
of the top 7 scoring ERα activators (i.e., active across multiple ERα assays and at relatively 
low concentrations) did not cause substantial reproductive toxicity in vivo, including 
Flumetralin, Fenhexamid, Fludioxonil, Pyridaben, and Endosulfan. Additionally, the impact 
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of weak or partial nuclear receptor agonists and antagonists on reproductive toxicity potential 
and other toxicities needs to be explored further.  
CYP enzyme inhibition, as compared to gene induction, was significantly more 
associated with reproductive toxicity. Alterations in steroid metabolism through CYP 
induction have been previously associated with reproductive impairment (Goetz et al., 2007), 
however the non-specific inhibition of CYPs may be a surrogate for a chemical’s capacity to 
disturb steroid metabolism including inhibition of key CYPs involved in steroidogenesis 
(e.g., Cyp19 and Cyp17). Related to CYP activity, PXR interestingly displayed a negative 
correlation/association with reproductive toxicity. In general, PXR lowered the false positive 
rate of the model by lowering the model score of chemicals with non-specific and low 
potency nuclear receptor activity. Robust PXR activity is an indication of potent xeno-
sensing and potentially rapid metabolism.  
The pyrethroid class of pesticides has shown limited reproductive toxicity in 
guideline toxicity studies, although there is limited evidence linking pyrethroid exposure to 
decreased human sperm quality (Meeker et al., 2008). Of the 10 pyrethroids in chemical 
group A, only Resmethrin was considered a reproductive toxicant based on the criteria 
described in this manuscript. All 10 pyrethroids displayed low potency activity across one or 
more of the selected features, including AR, ERα, and PPARγ, but not CYP. Without the 
down-weighting based on each of their PXR activities the pyrethroids would have all been 
predicted to be reproductive toxicants.  
A major component of the model not directly related to nuclear receptor biology and 
xenobiotic/steroid metabolism was GPCR binding. Numerous GPCR binding assays were 
significantly associated with reproductive toxicity. Those chosen to represent the GPCR 
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family were selected for statistical, and not biological, reasons as there is limited literature 
information on their role in reproduction in contrast to their well characterized role in 
nervous system function. 
Platforms measuring EGFR, TGF-β1 and NF-κB activity were also associated with 
reproductive toxicity and make up the “OTHER” feature. All three gene products have been 
shown to modulate the relative sensitivity of developmental toxicants, especially aryl-
hydrocarbon receptor signaling (Abbott et al., 2003;  Tian et al., 1999) and may be indicative 
of altered xenobiotic metabolism, cellular proliferation, cell-cell signaling or potential 
epigenetic effects (Tian, 2009;  Tian et al., 2002). Overall the key targets in the model 
identify plausible modes of action leading to reproductive toxicity covering anti-androgenic, 
estrogenic, cholesterol/steroid metabolism, limited coverage of disruption of steroidogenesis, 
and altered xenobiotic metabolism modes of action. 
There have been limited efforts toward the development of models predictive of 
reproductive toxicity, due in part to the lack of reference data in which to model. One 
resource for predictive models have come from structure based methods (i.e., Quantitative 
Structure Activity Relationship (QSAR) models) and the accuracy and predictivity of the 
resultant models has been limited. A comprehensive effort toward the prediction of 
reproductive and developmental toxicity was undertaken by the FDA (Matthews et al., 
2007). The resultant QSAR models were developed for endpoints such as sperm effects, 
female reproductive toxicity and male reproductive toxicity and were generally highly 
specific models with an average specificity across all generated models being 88%. However, 
the average balanced accuracy across all models was 58%, with the maximum balanced 
accuracy for any single model being 68% for predictive trans-species female reproductive 
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toxicity. It is difficult to assess the true accuracy and forward predictivity of the models 
based solely on the summary statistics, but the balanced accuracy values provide the most 
direct and unbiased comparison to the current model. Most likely, the limitation lies in the 
physiological complexity of reproductive toxicity and structural diversity of reproductive 
toxicants. The current predictive model has improved accuracy over any published QSAR 
model of reproductive toxicity and provides additional mechanistic information and 
indications of specific reproductive effects. The model also can be extended to include new 
data either covering the gene targets in the current model or new gene targets of other 
potential reproductive toxicity modes-of-action. Additional international efforts are 
underway with the goal of using alternative testing approaches in the detection of 
reproductive toxicants and on limited chemical sets have shown promise (Schenk et al., 
2010). However, the current ToxCast-based approach utilizes hundreds of diverse biological-
chemical activities associated with many potential modes of action leading to reproductive 
toxicity. The output of the current model provides a binary classification. Applications 
beyond hazard identification and testing prioritization may require dose response and even 
mechanistic information. To accomplish this, research is underway incorporating 
toxicokinetic information into the modeling process using primary rodent and human 
hepatocytes, plasma protein binding, and pharmacokinetic modeling intended to reverse 
engineer expected oral dose required to achieve a particular in vitro bioactivity level (Rotroff 
et al., 2010). Experimentally and computationally deriving dosimetry relevant to in vivo 
exposures has the potential to provide quantitative dose response information that can be 
incorporated into the modeling process. For example, the in vitro constitutive androstane 
receptor (CAR) and PXR activity on a set of conazole fungicides in ToxCast Phase I 
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demonstrated the dose response relationship between the equivalent in vivo levels required to 
observe the CAR/PXR activity and the known dose levels causing rodent liver toxicity 
(Judson et al., 2011). Examples such as this provide a path toward incorporating in vitro 
assay data into the risk assessment process, but also demonstrate the amount of prior 
knowledge currently required to perform such an analysis. The vast majority of 
environmental chemicals have little to no prior toxicity data and those that do commonly lack 
information on potential modes-of-action or human relevance. The reality is that among the 
thousands of environmental chemicals few will ever have a multigeneration reproductive 
study run. Over the past 30 years, only, 500 chemicals have been run in multigeneration 
reproductive studies due to the high animal and financial burden for such large scale animal 
testing (Hartung and Rovida, 2009). A practical solution and pressing need, especially with 
regards to reproductive toxicity testing, is for prioritization tools such as the current model, to 
make more informed reproductive toxicity testing decisions. 
Cross-validation and external validation sets used to develop and assess the quality of 
the reproductive toxicity model helped identify strengths and weaknesses of the present 
model and will help focus future research. Using HTS assays as the input into the model 
provided mechanistic insights and helped further characterize the predicted chemicals beyond 
negative and positive prediction outcomes. However, a subset of chemicals were deemed 
outside the domain of applicability based on low in vitro activity due to physical chemical 
characteristics, biological gaps, chemical decomposition or volatility. Further research is 
needed to better characterize this chemical subset to expand the current model’s domain of 
applicability. A limited number of chemicals selected from the ToxCast Phase I chemical set 
were used for external validation and provided supporting evidence of the model quality. A 
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large set of chemicals from ToxCast Phase II will have a full complement of in vitro 
bioactivity data and rodent reproductive toxicity studies will be used to further evaluate, 
validate and expand the predictive model. Additionally, ToxCast Phase II contains a library 
of failed pharmaceuticals with pre-clinical and clinical toxicity outcomes as well as reference 
chemicals with known mechanisms of reproductive toxicity. In addition to diversifying the 
current chemical library these chemicals will aid in the expansion of predictive reproductive 
toxicity model development toward mechanistic and human reproductive toxicity models 
useful in risk assessment applications.   
The ability of this predictive reproductive toxicity model to externally predict 
numerous chemicals with biological and structural diversity demonstrates suitability for 
chemical testing prioritization. Although the model does not provide quantitative dose 
response information, it does provide accurate predictions of a chemical’s reproductive 
toxicity potential. Since the model is based on HTS data, it is amenable to screening and 
prioritizing thousands of chemicals. Additionally, the biological features of the model 
provide mechanistic insights into modes of action useful in developing an integrated testing 
strategy for reproductive toxicity. 
Tables 
Table 4.1. Ninety-eight chemicals, linked to 86 acceptable and 12 unacceptable studies in 
ToxRefDB, achieved a reproductive LOAEL (rLOAEL ≤ 500 mg/kg/day) and used as the 
positive class set for the training and testing of the predictive model. In enforcing the 
500/mg/day cutoff, rLOAEL were rounded to one significant figure due to the uncertainty of 
dose intake especially at high doses. 
CASRN Chemical Name 
rLOAEL 
(mg/kg 
/day) 
Acceptable 
Study? 
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71751-41-2 Abamectin 0.4 NO 
30560-19-1 Acephate 25 YES 
135410-20-7 Acetamiprid 51 YES 
33089-61-1 Amitraz 12 YES 
3337-71-1 Asulam 250 YES 
35575-96-3 Azamethiphos 50 YES 
1861-40-1 Benfluralin 401 YES 
17804-35-2 Benomyl 234 YES 
80-05-7 Bisphenol A 500 YES 
134605-64-4 Butafenacil 23.8 YES 
75-60-5 Cacodylic acid 17.9 YES 
63-25-2 Carbaryl 92.4 YES 
5234-68-4 Carboxin 20 YES 
101-21-3 Chlorpropham 150 YES 
64902-72-3 Chlorsulfuron 541 NO 
210880-92-5 Clothianidin 31.2 YES 
1134-23-2 Cycloate 50 YES 
94-75-7 2,4-D 80 YES 
94-82-6 2,4-DB 112 YES 
1596-84-5 Daminozide 500 YES 
117-81-7 DEHP 391 YES 
333-41-5 Diazinon 35.2 YES 
962-58-3 Diazoxon 35.2 YES 
84-74-2 Dibutyl phthalate 531 YES 
1918-00-9 Dicamba 419 YES 
99-30-9 Dichloran 102 YES 
120-36-5 Dichlorprop 220 YES 
62-73-7 Dichlorvos 7.2 YES 
51338-27-3 Diclofop-methyl 7.3 YES 
115-32-2 Dicofol 2.4 YES 
141-66-2 Dicrotophos 0.56 YES 
60-51-5 Dimethoate 6.5 YES 
122-39-4 Diphenylamine 399 YES 
298-04-4 Disulfoton 0.12 NO 
155569-91-8 Emamectin benzoate 1.8 YES 
66230-04-4 Esfenvalerate 6.7 NO 
60168-88-9 Fenarimol 1.2 YES 
114369-43-6 Fenbuconazole 40 YES 
122-14-5 Fenitrothion 0.68 NO 
55-38-9 Fenthion 0.7 YES 
76-87-9 Fentin 1.4 YES 
120068-37-3 Fipronil 26.3 YES 
69806-50-4 Fluazifop-butyl 5.8 YES 
79241-46-6 Fluazifop-P- 5.8 YES 
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butyl 
79622-59-6 Fluazinam 47.3 YES 
103361-09-7 Flumioxazin 12.7 YES 
85509-19-9 Flusilazole 17.5 YES 
133-07-3 Folpet 180 YES 
68157-60-8 Forchlorfenuron 544 YES 
79983-71-4 Hexaconazole 50 YES 
35554-44-0 Imazalil 80 YES 
144550-36-7 Iodosulfuron-methyl-na 346 YES 
55406-53-6 IPBC 37.5 YES 
77501-63-4 Lactofen 26.2 YES 
330-55-2 Linuron 54 YES 
12427-38-2 Maneb 106 YES 
94-74-6 MCPA 22.5 YES 
4376-20-9 MEHP 391 YES 
104206-82-8 Mesotrione 1.1 YES 
950-37-8 Methidathion 1.25 YES 
9006-42-2 Metiram-zinc 16 NO 
7786-34-7 Mevinphos 0.5 YES 
51596-11-3 Milbemectin 65.6 NO 
2212-67-1 Molinate 0.8 YES 
131-70-4 Monobutyl phthalate 531 YES 
88671-89-0 Myclobutanil 50 YES 
300-76-5 Naled 18 YES 
27314-13-2 Norflurazon 103 YES 
116714-46-6 Novaluron 298 YES 
42874-03-3 Oxyfluorfen 146 YES 
40487-42-1 Pendimethalin 215 YES 
335-67-1 PFOA 30 YES 
1763-23-1 PFOS 3.2 YES 
2310-17-0 Phosalone 29.4 YES 
86209-51-0 Primisulfuron-methyl 250 YES 
67747-09-5 Prochloraz 31.3 NO 
709-98-8 Propanil 53 YES 
31218-83-4 Propetamphos 5.5 YES 
60207-90-1 Propiconazole 238 YES 
23950-58-5 Propyzamide 123 YES 
10453-86-8 Resmethrin 70.8 YES 
83-79-4 Rotenone 7 YES 
148477-71-8 Spirodiclofen 178 YES 
118134-30-8 Spiroxamine 44.8 NO 
122836-35-5 Sulfentrazone 33 YES 
119168-77-3 Tebufenpyrad 19.3 YES 
96182-53-5 Tebupirimfos 1.25 NO 
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79538-32-2 Tefluthrin 12.5 NO 
112281-77-3 Tetraconazole 6 YES 
153719-23-4 Thiamethoxam 1.84 YES 
43121-43-3 Triadimefon 90 YES 
55219-65-3 Triadimenol 25 YES 
2303-17-5 Tri-allate 30 YES 
78-48-8 Tribufos 15 NO 
52-68-6 Trichlorfon 175 YES 
68694-11-1 Triflumizole 1.5 YES 
131983-72-7 Triticonazole 250 YES 
50471-44-8 Vinclozolin 4.9 YES 
 
Table 4.2. Chemical groupings based on aggregate in vitro activity across the over 500 
ToxCast assays, and in vivo reproductive study acceptability/availability within ToxRefDB. 
  
In vitro 
Activity 
Little to No 
In vitro 
Activity 
(<2% 
Active) 
Total In vivo 
Chemical 
Counts 
Acceptable Reproductive Study 206 (A) 50 (B) 256 
Unacceptable Reproductive 
Study 31 (C) 8 (D) 39 
No Reproductive Study 
Available 10 (E) 4 (F) 14 
Total In vitro Chemical Counts 247 62 309 
 Parenthesis: Each chemical group identified by letter 
 
Table 4.3. Feature selection statistics based on univariate correlations and associations 
between individual assays or genes/gene-sets and reproductive toxicants in chemical group 
A, dichotomously represented (i.e., 1 for positive and 0 for negative). 
Individual Assay Correlation (p-value) 
Gene / 
Gene 
Set 
Correlation (p-
value) 
ATG_PPARα_TRANS 0.24 (6.6E-4) 
PPARα 0.30 (9.6E-6) NCGC_PPARα_Agonist 0.17 (1.7E-2) 
NVS_NR_hPPARα 0.17 (1.6E-2) 
NCGC_AR_Antagonist 0.18 (3.6E-3) 
AR 0.31 (4.8E-6) NVS_NR_hAR 0.28 (3.7E-5) 
NVS_NR_rAR 0.04 (NS) 
ATG_ERα_TRANS 0.17 (1.5E-2) ERα 0.15 (2.3E-2) 
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ATG_ERE_CIS 0.04 (NS) 
NCGC_ERalpha_Agonist 0.05 (NS) 
NCGC_ERalpha_Antagonist 0.11 (9.3E-2) 
NVS_NR_hER 0.10 (NS) 
NVS_NR_mERα 0.10 (NS) 
NVS_NR_bER 0.10 (NS) 
ATG_PPRE_CIS 0.10 (NS) 
PPARγ 0.14 (4.1E-2) ATG_PPARγ_TRANS 0.09 (NS) 
NCGC_PPARγ_Agonist 0.06 (NS) 
NVS_NR_hPPARγ 0.14 (4.1E-2) 
NVS_ADME_rCYP2A2 0.30 (1.5E-5) 
CYP 0.27 (1.1E-4) 
NVS_ADME_rCYP2B1 0.23 (7.2E-4) 
NVS_ADME_rCYP2C12 0.14 (4.9E-2) 
NVS_ADME_rCYP2C11 0.17 (1.5E-2) 
NVS_ADME_rCYP2A1 0.21 (2.4E-3) 
NVS_ADME_rCYP2C13 0.21 (2.3E-3) 
NVS_ADME_hCYP19A1 0.17 (1.3E-2) 
NVS_GPCR_hOpiate_mu 0.26 (1.8E-4) 
GPCR 0.34 (8.6E-7) 
NVS_GPCR_h5HT6 0.22 (1.3E-3) 
NVS_GPCR_hAdra2C 0.21 (2.0E-3) 
NVS_GPCR_hPY2 0.20 (3.3E-3) 
NVS_GPCR_gOpiateK 0.19 (7.3E-3) 
BSK_hDFCGF_EGFR_up 0.14 (4.5E-2) 
OTHER 0.28 (4.5E-5) BSK_BE3C_TGFb1_up 0.08 (NS) 
NVS_TR_rVMAT2 0.21 (2.7E-3) 
ATG_NF_kB_CIS 0.14 (4.9E-2) 
ATG_PXR_TRANS -0.14 (4.2E-2) 
PXR -0.14 (4.5E-2) ATG_PXRE_CIS -0.11 (NS) 
NCGC_PXR_Agonist_human -0.09 (NS) 
 (NS) – Not statistically significant (p-value>0.1) 
 
Table 4.4. Performance metrics for the predictive model of reproductive toxicity, including 
cross-validation and optimized model statistics and weighting of model input features. 
Cross-Validation 
Statistics Full Model Statistics 
Parameter 
Coefficients 
Learner LDA TP 55 F1 73% PPARα 1.37 
CV 5-fold FP 28 RR 6.3 AR 0.98 
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No. F 8 FN 13 OR 17 ERα 0.45 
Assays 36 TN 110 PPV 66% PPARγ 0.23 
BA 
Train 77% SENS 81% NPV 90% CYP 0.28 
SD 
Train 2% SPEC 80% Pred 78% GPCR 0.5 
BA Test 74% BA 80% P-Value 4.2E-17 OTHER 0.45 
SD Test 5% A 80% Cutoff 0.6 PXR -0.21 
CV = Cross Validation; No. F = Number of selected features; Assays=Number of assays comprising the selected features; BA = Balanced 
accuracy (Average of sensitivity and specificity); SD= Standard deviation of the Balanced Accuracy for each Fold; TP= True Positive 
Count; FP= False Positive Count; FN=False Negative Count; TN= True negative count; SENS= Sensitivity; SPEC= Specificity; A = 
Accuracy; P-Value = Chi-Square P-Value; Cutoff = LDA Model Intercept; F1=F-measure (harmonic mean of precision and recall); OR= 
Odds ratio; PPV=Positive predictive value; NPV=Negative predictive value; Pred=Predictivity (Average of PPV and NPV) 
 
Table 4.5. External validation chemical set used to test the forward predictivity of the model. 
Each chemical is associated with a chemical group based on reproductive study 
acceptability/availability and aggregate in vitro activity. Chemical group C showed evidence 
of reproductive toxicity based on positive findings in an unacceptable multigeneration study, 
while chemical groups E and F showed literature evidence of reproductive toxicity. 
Chemical 
Group CASRN Chemical Name 
Evidence of 
Reproductive 
Toxicity 
Predicted 
Reproductive 
Toxicant 
Model 
Score 
E 2971-36-0 HPTE Yes Yes 11.9 
C 122-14-5 Fenitrothion Yes Yes 5.5 
C 67747-09-5 Prochloraz Yes Yes 3.4 
E 1689-84-5 Bromoxynil Yes Yes 3.4 
E 72-43-5 Methoxychlor Yes Yes 2.7 
C 51596-11-3 Milbemectin Yes Yes 2.4 
C 9006-42-2 Metiram-zinc Yes Yes 1.6 
C 64902-72-3 Chlorsulfuron Yes Yes 0.8 
F 109-86-4 Methyl cellusolve Yes Yes 0.8 
C 71751-41-2 Abamectin Yes Yes 0.7 
C 96182-53-5 Tebupirimfos Yes Yes 0.7 
E 15972-60-8 Alachlor Yes Yes 0.7 
C 78-48-8 Tribufos Yes No 0.0 
C 118134-30-8 Spiroxamine Yes No -0.1 
C 79538-32-2 Tefluthrin Yes No -0.1 
C 298-04-4 Disulfoton Yes No -0.2 
C 66230-04-4 Esfenvalerate Yes No -0.5 
E 4376-18-5 Methyl hydrogen No No 0.0 
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phthalate 
F 6923-22-4 Monocrotophos No No 0.0 
F 131-11-3 
Dimethyl 
phthalate No No -0.2 
E 33629-47-9 Butralin No No -0.2 
E 120-32-1 Clorophene Unknown Yes 4.4 
E 83657-24-3 Diniconazole Unknown Yes 2.4 
E 50-65-7 Niclosamide Unknown Yes 1.6 
F 122-99-6 Phenoxyethanol Unknown No 0.0 
E 87-90-1 Symclosene Unknown No -0.2 
 
Table 4.6. Comparison of predictive model results to classification and labeling for 
reproductive toxicity. Repro C&L is the European Union classification and labeling for 
reproductive toxicity, with R60 and 62 referring to fertility impairment, and R61 and 63 to 
developmental toxicity. 
Chemical Name 
Predicted 
Positive 
Repro 
C&L 
Model 
Score 
Bisphenol A Yes R62 6.1 
Vinclozolin Yes R60&61 4.7 
Flusilazole Yes R61 4.6 
Linuron Yes R62&61 2.9 
Myclobutanil Yes R63 2.4 
Fenarimol Yes R62 2.5 
Fentin Yes R63 3.5 
Fluazifop-P-butyl Yes R63 1.7 
Flumioxazin Yes R61 0.9 
Cyproconazole Yes R63 1.2 
Diethylhexyl phthalate 
(DEHP) Yes R60&61 0.9 
Isoxaflutole Yes R63 0.6 
Fluazifop-butyl Yes R61 1.0 
Dibutyl phthalate Yes R62&61 0.8 
Benomyl No R60&61 0.0 
Diuron No --- 0.4 
Lindane No --- 0.0 
Propazine No --- -0.3 
Propargite No --- -0.5 
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Figures 
Figure 4.1. Decision tree diagram representing the process by which the 309 ToxCast 
chemicals were grouped, based on in vivo study acceptability/availability and in vitro 
aggregate bioactivity, and subsequently defined as positive or negative for reproductive 
toxicity based on having achieved a reproductive lowest observed adverse effect level 
(rLOAEL) less than 500 mg/kg/day. Applying the model developed using chemical group A 
to all other chemical groups, individual and combined balanced accuracy values (average of 
sensitivity and specificity) are summarizing the results across the entire chemical library and 
provides context and summary information as each chemical group is discussed in greater 
detail throughout the results and discussion sections. 
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Figure 4.2. Classification or predictivity rates increase from individual HTS assays, to 
aggregated genes or gene-sets, while misclassification rates proportionately decrease, 
demonstrating the advantage of combining assays for same genes in model development. 
Classification rate (blue line) was calculated as the proportion of true positives (greater than 
the mean assay/gene/gene-set/model and positive for in vivo reproductive toxicity) over the 
total number positives (n=68). The misclassification rate (red line) was calculated as the 
proportion of false positives (greater than the mean assay/gene/gene-set/model score but 
negative for reproductive toxicity) over the total number of chemicals negative for 
reproductive toxicity (n=138).  
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Figure 4.3. Chemicals ordered by their reproductive toxicity model score with the positive 
training set on the left and the negative training set on the right. The optimal cutoff was 
determined to be 0.6 (black line) and achieved a balanced accuracy of 80%. Depending on 
the prioritization goals, an increased or decreased cutoff could greatly alter your confidence 
in detecting a reproductive toxicant. Using an increased cutoff, one could test the top 32 
scoring chemicals and expect to have 27 be reproductive toxicants (cutoff of 1.8 in blue). On 
the other hand, to accurately predict 59 of the 68 total reproductive toxicants one would have 
to test the top scoring 137 of 206 chemicals (cutoff of >0 in red). 
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CHAPTER 5 
A PREDICTIVE MODEL OF REPRODUCTIVE TOXICITY: FORWARD VALIDATION 
AND APPLICATION 
 
Abstract 
 A predictive model of reproductive toxicity, as observed in rat multigeneration 
reproductive (MGR) studies, was previously developed using high throughput screening 
(HTS) data from 36 assays mapped to 8 gene or gene-sets from Phase I of the USEPA 
ToxCast research program. The model was capable of predicting rodent reproductive toxicity 
with over 75% balanced accuracy. In a forward validation study, the predictive model was 
applied to 77 chemicals from ToxCast Phase II with the full battery of HTS and rodent 
reproductive toxicity data. The model sustained accuracy levels above 70% and demonstrated 
the ability to maintain predictivity in light of real-world constraints. These constraints 
included a more diverse chemical library, a new and independent round of HTS testing, 
increased prevalence of positives in the forward validation chemical set, single point versus 
concentration response data in a subset of assays, as well as assay attrition and replacement. 
A second study was performed on 381 chemicals from all phases of model development and 
validation to test the flexibility and applicability of the model as a tool in chemical testing 
decision-making. Three case studies were derived representing different statutory contexts 
that represent real-world regulatory actions, including waiving study requirements, 
requesting studies, and classifying chemicals. For each case study, the predictive model was 
optimized to maximally increase testing efficiency in terms of accuracy and cost. In all three 
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case studies, total cost savings were roughly 15% with false classification rates below 15%. 
For example, applying the model under case study 1 resulted in the waiving of the MGR 
study requirement for 67 chemicals based on negative predictions with 8 chemicals being 
positive, a misclassification rate of 12%. However, the costs savings of not testing 67of 381 
chemicals when assessed purely from a testing efficiency viewpoint, i.e., cost of 
misclassification not accounted, would save close to $40 million dollars. The forward 
validated predictive model of reproductive toxicity will continue to evolve as new assays 
become available to fill recognized biological gaps and will be combined with other 
predictive models, particularly models of developmental toxicity, to form an initial tier to an 
overarching integrated testing strategy.   
Introduction 
 Predicting toxicity using high-throughput screening and computational approaches 
will inevitably alter the current toxicity testing paradigms, but the degree and pace to which 
these technologies and approaches affect toxicity testing will play out over time. Current 
efforts by the U.S. Environmental Protection Agency’s (EPA) National Center for 
Computational Toxicology in the ToxCast research program and the Tox21 interagency 
project between National Institutes of Health (NIH), Food and Drug Administration (FDA), 
and EPA are generating a wealth of biological pathway data on thousands of chemicals 
across hundreds of biological assays (Collins et al., 2008). To make incoming high 
throughput screening (HTS) data useful in terms of chemical toxicity evaluation, we have 
attempted to link in vitro screening data with increased risk of causing specific adverse 
outcomes (Judson et al., 2010). ToxCast Phase I produced and evaluated the largest 
publically available collection of HTS data on a chemical library. The Phase I chemical 
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library, of 309 chemicals, spanned many chemical classes but was over-enriched for food-use 
pesticides that were all designed to be bioactive. Moving into Phase II of ToxCast, the 
chemical library was ever increasing in diversity in terms of physical chemical property, 
structural, use, and class diversity. In order to fully evaluate predictive toxicity models from 
ToxCast Phase I, applying the model to chemicals with independently generated data is 
required. 
Historically, predicting toxicity relied largely on structure and inherent chemical 
property-based toxicity alerts or on single assay readouts that attempted to mimic whole 
animal toxicities. Many lessons have been learned from these approaches concerning their 
limited success either in terms of predictivity or increasing testing efficiency. One such 
lesson is the need for appropriate modeling best practices, including external and forward 
validation (Tropsha and Golbraikh, 2007). Any model can be developed given enough data, 
but the ability to blindly predict a structurally diverse set of chemicals is difficult but 
necessary to validate any model (Golbraikh et al., 2003;  Golbraikh and Tropsha, 2002;  Shen 
et al., 2004;  Tropsha and Golbraikh, 2007). Another lesson is that end-stage toxicity (e.g., 
cancer, malformations, infertility) is a complex manifestation of many events that cannot 
usually be modeled or predicted using a single property, feature, or assay. With the large 
amount of bioactivity data now available on hundreds of toxicologically well-characterized 
chemicals it is easy to ignore these lessons and throw hundreds of assays at a single endpoint 
and to expect robust models to emerge. This, not surprisingly, is not the case. Developing a 
predictive model of toxicity requires careful consideration in the methods used to analyze the 
screening data, annotate assays, identify training and test set chemicals, and model the data 
without over-fitting. 
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Developing a model for reproductive toxicity introduces additional considerations 
including life-stage and generational sensitivities, molecular versus physiological modes of 
action, and confounding systemic toxicities (Cronin and Worth, 2008;  Perreault, 2008). 
Using a suite of HTS bioactivity assays we were able to produce a stable (i.e., test set 
accuracy commensurate with training set accuracy) and robust (i.e., able to accurately predict 
a limited external validation set) model of rat reproductive toxicity (Martin et al., 2011). The 
model accurately predicts effects on adult reproductive performance, male and female 
reproductive tract effects, early offspring survival, and sexual developmental landmarks. The 
model does not cover developmental malformations or systemic parental or offspring 
toxicities. Providing mechanistic insight may be one of the biggest advantages of HTS-
derived models. In particular, this model of reproductive toxicity hones in on 8 genes or 
gene-sets that begin to characterize a chemical’s potential mode of action. A chemical with 
strong estrogen or androgen receptor activity may be leading to reproductive impairment 
through endocrine disrupting pathways (Witorsch and Thomas, 2010), whereas a chemical 
with strong cytochrome P450 inhibition or peroxisome proliferator-activated receptor activity 
may cause reproductive impairment through xenobiotic or steroid metabolism alterations 
(Toda et al., 2003). Identifying mechanisms of action also enables an evaluation of which 
mechanisms were not covered and for which new assays need to be developed. For example, 
steroidogenesis is recognized as a mode of reproductive toxicity for which we have only a 
single assay, a CYP19A1 inhibition assay, so clearly other assays need to be added to test for 
activity against this pathway in a high throughput manner (Hecker and Giesy, 2008). In 
summary, the model features were PPARA, PPARG, ESR1, AR, GPCR (collection of GPCR 
binding assays), CYP (collection of cytochrome P450 inhibition assays), PXR and OTHER 
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(collection of significantly associated assays not with limited to no redundant gene 
coverage). The weight of each feature was determined in the modeling process using linear 
discriminant analysis (LDA) and a model cutoff was derived to separate the positive and 
negatives based on an optimal balanced accuracy.  
 The current study aims to forward validate the HTS-derived predictive model of 
reproductive toxicity by applying the model to a new set of chemicals. Independently, 297 
chemicals were tested in the same or comparable HTS assays as the original 309 chemicals in 
Phase I of ToxCast (i.e., the chemical set used in model development). A subset of the 297 
chemicals has high quality reproductive toxicity study data and served as the forward 
validation chemical set. The predictive model of reproductive toxicity was applied to the 
forward validation chemical set to assess the model’s performance against this increasingly 
diverse set of chemicals, which included pharmaceuticals, industrial chemicals, 
antimicrobials, additional pesticides, and inert (i.e., other) ingredients. Case studies were then 
developed to assess the ability of the model to adapt to different regulatory conditions, e.g., 
waiving a testing requirement, requesting a study, or classifying chemicals in a data poor 
regulatory environment. Each case study was modeled after current regulations, but the 
model was assessed in isolation. Even though real-world testing decisions would be made 
using all available information, the goal of the case studies was to measure the impact of the 
current model on chemical testing decision-making. Testing the model across the various 
case studies ultimately demonstrated the acceptability and flexibility of the model as a tool 
for chemical testing decision-making. 
Methods 
Forward Validation Study 
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The EPA ToxCast™ program employs a chemical library containing 1011 samples 
consisting of 960 unique structures with 9 triplicates as technical repeats for internal quality 
control that are now incorporated into every phase of ToxCast. A summary of all in vitro and 
in vivo chemical libraries is graphically represented as well as the overlap between ToxCast, 
Tox21, and ToxRefDB, and the relationship between these testing efforts and the different 
phases of the predictive modeling effort (Figure 5.1). A large subset of the original Phase I 
library of 309 unique structures has now been re-procured for testing in new assays and 
currently consists of 293 unique structures, as 16 chemicals were removed from the initial 
library due to evidence of decomposition or sustained insolubility. The combined ToxCast 
chemical library of 960 chemicals contains 111 pharmaceuticals that failed in human clinical 
trials primarily due to toxicity, a large set of drug-like compounds, industrial chemicals, food 
additives, antimicrobials, additional ingredients in pesticide formulations, and pesticide 
active ingredients.  
Additionally, a library of 1462 samples equating to 1421 unique structures was 
previously run at the NIH Chemical Genomics Center (NCGC) across numerous nuclear 
receptor and oxidative stress pathway assays in quantitative high-throughput screening 
format. Of the 1421 chemicals, 583 chemicals are included in the ToxCast library. In total, 
297 chemicals have been tested as part of ToxCast Phase II, which were not tested in 
ToxCast Phase I (i.e., not included in the model development process), and tested at NCGC. 
Therefore, the 297chemical set has been tested across all assays used in the original 
predictive model of reproductive toxicity and can therefore be wholly evaluated by the 
model. 
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As the chemical library expanded beyond conventional pesticide actives the 
availability of guideline multigenerational reproductive toxicity (MGR) studies diminishes 
quickly. For the forward validation exercise, the available MGR studies were entered into 
EPA’s Toxicity Reference Database (ToxRefDB) as described previously (Martin et al., 
2009). Open literature studies were used to characterize the reproductive toxicity potential of 
drug or drug-like compounds and industrial chemicals. These studies included continuous 
breeding protocols and fertility and pre-/post-natal studies performed by the National 
Toxicology Program (NTP), academic and contract laboratories or pharmaceutical 
companies. In general, these studies were able to be successfully entered into ToxRefDB and 
a number were identified, for modeling purposes, as reproductive toxicants based on 
achieving a reproductive lowest observed adverse effect level (rLOAEL) less than or equal to 
500 mg/kg/day as previously described (Martin, et al., 2011). In some instances, clear 
evidence of reproductive toxicity, or not, was available in the literature, but the study design 
was not conducive for entry into ToxRefDB. In total, 77 chemicals were characterized as 
being reproductive toxicants or not for purposes of applying the predictive model to the 
chemical set to test the forward predictivity of the model. 
A complete overview of the ToxCast and NCGC assays including assay selection, 
analysis methods, quality measures, and assay annotation has been previously published 
(Huang et al., 2011;  Judson, et al., 2010). Due to the prospective nature of the forward 
validation effort, data tested as part of ToxCast Phase II have been analyzed in a manner as 
similar as possible to ToxCast Phase I. The transcription factor activation assays generated 
by Attagene™ Inc. and  indicated by “ATG” were analyzed across all ToxCast Phase II 
chemicals using the same procedure as previously described (Martin et al., 2010). The 
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ToxCast Phase II cell-free bioactivity profiling from Novascreen Biosciences was run in a 
single concentration screening mode in duplicate using the same protocol as ToxCast Phase I 
to select chemicals for concentration response testing. An analysis was performed using the 
single point screening and concentration response data from ToxCast Phase I to assess 
whether hit calling and active concentration estimations (e.g., AC50) could accurately be 
derived from single point data, which has been demonstrated before (Moody et al., 1999). 
Therefore, Novascreen assays, beginning with “NVS”, had AC50 values estimated based on 
single concentration screening values run in duplicate. Nuclear receptor data generated at the 
NCGC and cell-based cell signaling assays from BioSeek LLC, referred to as “BSK”, were 
generated and analyzed in the same manner as ToxCast Phase I.  
AC50/LEC values were -log3 transformed (-log3 [AC50/1000]), and a value of 0 was 
given to all negative assay results. A log3 transformation and setting negatives to 1000µM 
was used over a log10 transformation and setting negatives to one molar, as has been done in 
previous publications of ToxCast results (Judson, et al., 2010), to enhance the scoring range 
between high and low potency active chemicals and to decrease the distance between active 
and inactive chemicals. Therefore, the “assay score” where the AC50 was 100µM would 
have a value of roughly 2 while a 100nM AC50 would have a value of roughly 8. A “gene 
score” or “gene-set score” was derived based on the average assay score across a set of 
closely related assays, e.g., assays mapped to a single gene or gene family. The forward 
validation chemical set includes the 77 chemicals tested in a high quality reproductive study 
and tested across all assays in the mode. As previously described (Martin, et al., 2011), an in 
vitro activity filter of 2% (i.e., active in less than 2 out of every 100 assays) was applied to 
filter out those chemicals potentially confounded by insolubility, degradation or other issues 
 154 
leading to a lack of HTS testing amenability. Of these 77 chemicals, 62 chemicals had 
greater than 2% in vitro activity and were used as the primary forward validation chemical 
set. The model was then applied to the full 77 chemical forward validation set and to the in 
vitro activity filtered 62 chemical forward validation set resulting in model predictions based 
on the parameters and model cutoffs (i.e., linear discriminant analysis (LDA) intercept) 
previously established (Martin, et al., 2011). The predicted outcomes were then compared to 
the known outcomes and performance metrics were reported, including balanced accuracy 
and predictivity. 
Model Application Case Studies 
Using the totality of chemicals with available reproductive toxicity studies used in all 
phases of model development (N=381), the model was applied in three case studies that test 
the models ability to be used under different statutory contexts. The three case studies 
involve applying the model to chemicals with:   
1. Statutory requirement to run MGR and ability to waive requirement  
2. Statutory authority to request MGR 
3. Limited to no statutory authority to request MGR 
To customize model outputs, the predictive model was tuned to optimize specific summary 
statistics, including sensitivity, specificity, balanced accuracy, positive and negative 
predictivity, and overall predictivity. Optimization was done by adjusting the percent in vitro 
activity filter and the model cutoff. The original filter and cutoff were chosen based on 
optimizing the balanced accuracy alone, whereas the case studies may weight certain output 
statistics higher than others. To assess the impact that incorporating the model into testing 
and decision-making, cost savings estimates were also calculated based on the increased 
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evaluation or testing efficiency. In the case of waiving study requirements, cost savings per 
chemical (N=381 chemicals) were calculated as the cost of the HTS battery and the cost of 
the MGR study times the percent of un-waived studies minus the total cost of a MGR study. 
In the cases of requesting studies, the cost savings per chemical were calculated assuming 
current reproductive testing prioritization schemes are equal to random chance. For example, 
if 40% of chemicals are positive (i.e., prevalence) then on average it would take 10 studies to 
identify 4 positive chemicals chosen at random. Therefore, cost estimates per chemical were 
calculated as the difference between percent of studies requested when chosen randomly and 
chosen based on the model predictions multiplied by the cost of a MGR study. 
Results 
 Forward Validation Study 
 The predictive model of reproductive toxicity was internally trained and tested using 
206 chemicals, primarily pesticide active ingredients. The model was preliminarily externally 
validated using a set of 26 chemicals with well-characterized reproductive toxicity 
information, but generally lacked chemical diversity from the training dataset and the HTS 
tested was performed at the same time (Martin, et al., 2011). The sustained model accuracy 
with the internal test and external validation chemical sets successfully evaluated the model 
as not being over-fit and having the potential to be applied to a more diverse chemical 
library. To fully assess the external predictivity of the model and the reproducibility and 
stability of the model inputs, the model was applied to a forward validation chemical set. The 
forward validation chemical set was generally tested in the same HTS assays, but roughly a 
year later, and is a diverse set of chemicals spanning pesticides, industrial chemicals, drug-
like compounds, antimicrobials, food-additives, and other formulation ingredients. To date, 
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297 chemicals out of 676 ToxCast Phase II chemicals have been tested in all assays required 
to apply the model. Of those 297 chemicals, reproductive toxicity information in ToxRefDB 
or from quality public (e.g. National Toxicology Program Continuous Breeding Studies) or 
open literature sources was obtained for 77 chemicals (Table 5.1). Based on observed 
reproductive LOAEL less than or equal to 500 mg/kg/day, 51 chemicals were considered 
positive and 26 negative. The high prevalence of positive chemicals in the forward validation 
set was expected due to the fact that the majority of the chemicals did not require a MGR 
study, but came from the open literature which may be biased towards positive findings. The 
77 chemicals were further filtered to 62 chemicals, 43 positive and 19 negative, using the in 
vitro activity cutoff filter, which removed 15 chemicals that were active in less than 2% of all 
tested assays. The model was applied to the filtered and unfiltered forward validation 
chemical sets to assess the overall accuracy of the model with or without the in vitro activity 
filter applied and to assess the relative impact of filtering on interpretation of model 
prediction results.  
 Before the model could be applied, large-scale data analysis was performed on all 
available ToxCast HTS assays, to date. Highly comparable or identical methods were applied 
to the ATG, NCGC, and BSK datasets (Huang, et al., 2011;  Judson, et al., 2010). The NVS 
dataset was only tested at a single concentration (10 micromolar for cytochrome P450 
inhibition assays and 25 micromolar for all others) in duplicate. In Phase I of ToxCast a 
single concentration screen was performed and a subset of chemical-assay combinations was 
selected to be run in concentration response format. Using the single point data from NVS 
Phase I, AC50 values were estimated and compared to the published AC50 values derived 
from concentration-response analysis (Knudsen et al., 2011) to evaluate the accuracy of the 
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alternative approach as was previously published (Moody, et al., 1999). Using only the 16 
NVS assays in the model and the 963 chemical-assay combinations run in concentration 
response format, the hit calls and negative-log10of the AC50 were compared (Figure 5.2). 
The sensitivity and specificity in comparing hit calls were 85% and 88% respectively, 
resulting in a balanced accuracy of 87%. The correlation of the 305 true positives was 76% 
with only 31 single-point AC50 estimations having greater than an order of magnitude 
difference. The high accuracy level and relatively good correlation between single point and 
concentration response AC50 values support the preliminary use of the NVS ToxCast Phase 
II single point data in lieu of the concentration response data. Additionally, the ToxCast 
Phase II chemical library was only run against the human NVS cytochrome P450 inhibition 
(CYP) assays as opposed to rat and human in ToxCast Phase I, which when comparing the 
ToxCast Phase I human CYP profile to the rat CYP profile was highly correlated at 80%. 
The final forward validation assay set had the same number of assays as the published model, 
36 assays, covering the same 8 features. 
 The published predictive model of reproductive toxicity was applied to the forward 
validation chemical set, both in vitro activity filtered and not. The observed accuracy and 
balanced accuracy of the filtered forward validation chemical set was 77% and 72%, 
respectively, a value highly comparable with the published model accuracy values (Table 
5.2).  A 3% drop in balanced accuracy, to 69%, was observed when the unfiltered chemical 
set was tested, which was comparable to the drop in accuracy seen during the model 
development process. The model’s ability to maintain predictivity in light real-world 
constraints, including a more diverse chemical library, HTS data generation independent of 
the original dataset, increased prevalence of positives in the forward validation chemical set, 
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single point versus concentration response data, and assay attrition and replacement, has 
made application of the model for testing decision-making a possibility.  
Case Studies 
Using the totality of chemicals with available reproductive toxicity studies used in all 
phases of model development (N=381), the model was applied in three case studies that test 
the models ability to be used under different statutory contexts. The three case studies 
involve applying the model to chemicals with:   
1. Statutory requirement to run MGR and ability to waive requirement  
2. Statutory authority to request MGR 
3. Limited to no statutory authority to request MGR 
Of the 381 chemicals, 151 chemicals are considered positive for the purposes of the 
following case studies and 230 are considered to be negative. Two model parameters, the in 
vitro activity filter and the model cutoff, were used to customize the model performance 
based on the requirements on each case study. The in vitro activity for each chemical was 
calculated as the number of active calls (i.e., AC50 determined) over the total number of 
assays. The model was not applied to the chemicals that fell below the in vitro activity filter. 
As the model was developed using linear discriminant analysis (LDA), a model cutoff or 
intercept was established that best separated the positive training set from the negative 
training set. Using the published model in vitro activity filter, 2%, and model cutoff, 0.6, the 
predictive model of reproductive toxicity performs with a balanced accuracy of 78% and 
applies to 305 chemicals, while 76 chemicals fell below the in vitro activity filter. By 
removing the in vitro activity filter, the model’s balanced accuracy fell slightly to 74% but 
allowed the model to be applied to all 381 chemicals. It should be noted that the intention of 
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the case studies is not to provide a definitive mechanism for waiving or requesting studies 
but to demonstrate the customizability of the model as a tool in chemical testing decision-
making. However, each case study was devised with specific regulations in mind, including 
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), Food Quality Protection Act 
(FQPA), and Toxics Substances Control Act (TSCA), to ensure the practicality and 
applicability of each case study. 
 Case study 1 involves applying the model to chemicals with the statutory requirement 
to run a MGR study but where the MGR testing requirement could be waived by the 
regulatory body to reduce the overall testing requirements for a given chemical. The overall 
goal of this case study is to maximally reduce the number of studies required by waiving 
MGR testing while maintaining the highest confidence that the chemicals waived would have 
little to no reproductive toxicity potential (Figure 5.3). Therefore, the applied model was 
tuned to have a high sensitivity and a high negative predictive rate. To reduce the false 
negative rate, an 8% in vitro activity cutoff filter was applied, meaning the chemical had to 
be positive in roughly 40 out of 500 assays. The model was then applied to the remaining 161 
chemicals using the optimal model cutoff of 0.6, as adjusting the cutoff did not improve the 
model sensitivity. This resulted in a balanced accuracy of 79% with high sensitivity and 
negative predictivity of 89% and 88%, respectively. The summary statistics translate into 67 
waivers being granted across all 381 chemicals, leading to a 17.6% reduction in required 
MGR studies. The 8 chemicals of the 67 total waived that showed any reproductive toxicity 
were Benfluralin, Pendimethalin, Tri-allate, Butafenacil, Dichlorvos, Dicofol, Spiroxamine 
and Tribufos, but all 8 had accompanying systemic parental toxicities at doses at or below the 
rLOAEL, which were predominantly driven by high dose litter size and reproductive organ 
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weight effects. A two-generation reproductive study in rats costs upwards of $750,000 
(Scialli, 2008), while the full battery of HTS data costs roughly $30,000. The average cost 
savings under conditions of case study 1 would be roughly $102,000 per chemical or $39 
million in total savings when 67 of 381 MGR studies were waived, a 14% reduction. Cost 
savings was calculated as the difference between the total cost of a MGR study and the cost 
of the HTS assay battery and the fractional cost of the MGR based on the percent of un-
waived studies. The cost savings estimate assumes that the HTS bioactivity profiling is only 
being used for reproductive testing decision-making, which is unlikely, but cost sharing 
estimates cannot be made at this time. Additionally, the cost savings estimates solely 
demonstrate the savings of increased testing efficiency and does not quantify the cost of 
misclassification. 
 Case study 2 involves applying the model to chemicals with the statutory authority to 
request a MGR study, but for which justification needs to be provided. The overall goal of 
this case study is to balance the time, animal, and financial costs of requesting a MGR study 
with the potential impact that a MGR study could have on regulating the chemical. 
Therefore, the applied model was tuned to have a high specificity and a high positive 
predictive rate (Figure 5.4). No in vitro activity cutoff filter was applied as this would not 
increase either the specificity or positive predictivity. The model was therefore applied to all 
381 chemicals using an adjusted model cutoff of 2.35 resulting in a specificity of 97% and 
positive predictivity of 88%. Under the conditions of case study 2, 52 chemicals would have 
MGR studies requested. Of the 52 chemicals with MGR study requests, 46 chemicals would 
cause reproductive toxicity in the MGR study and potentially impact the regulation of the 
chemical. For the cost savings estimation based solely on increased testing efficiency, we 
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calculated the number of studies that would need to be requested if selected by chance to 
identify 46 positive chemicals.  The positive prevalence in the reference dataset was roughly 
40%, which is expected to be high based on the positive reporting bias in the open literature 
but was used as a conservative estimate.  Therefore, 113 studies would have to be conducted 
to identify 46 positive chemicals if selected randomly, as opposed to 52 studies when 
selected based on the model prediction. The total cost savings would be over $34 million in 
comparing 113 MGR study requests versus 52 MGR study requests and accounting for the 
cost of the full HTS assay battery. The average costs savings per chemical would be roughly 
$90,000 across the entire chemical set.   
 Case study 3 involves applying the model to chemicals with limited to no statutory 
authority to request a MGR study, but where hazard assessments still need to be performed. 
As most chemicals currently fall under this statutory context, assessment and testing 
prioritization is needed. An assessment, in theory, can be performed on those chemicals most 
and least likely to cause reproductive toxicity based on the applied model. The remaining 
chemicals can then be prioritized based on their likelihood of being a reproductive toxicant, 
based on their model score. To identify chemicals most likely to be reproductive toxicants, a 
strict cutoff of 3 was used resulting in the identification of 28 chemicals, 27 of which 
demonstrated clear reproductive toxicity (Figure 5.5). Using the same model filters from 
Case Study 1, 67 chemicals were identified as being negative for reproductive toxicity.  In 
total, an initial assessment could be performed on 95 chemicals, a 25% reduction in the 
number of chemicals requiring an assessment. To produce similar reductions in the number 
of chemicals accurately assessed with chemicals selected randomly, 66 and 99 MGR studies 
would have to be performed to accurately identify 27 positive and 59 negative chemicals, 
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respectively. The average cost savings per chemical would be $80,000 if these chemicals 
were all being selected for follow-up MGR studies as calculated in case study 2. The need for 
safety assessment without long-term testing, the lack of statutory power to request studies, 
and the limited public resources to run MGR or similar studies would cost the $30,000 to run 
the entire battery of HTS assays and provide an initial assessment for 25% of the chemical 
library. The three case studies provide perspective on the capacity of the predictive model to 
assess a large library of chemicals and estimates on the increased cost efficiency of 
incorporating the predictive model into the chemical testing decision making process. 
Discussion 
 We have developed a forward validated classification model of general reproductive 
toxicity capable of being optimized for a diverse set of applications regarding chemical 
testing decision-making. The published model of reproductive toxicity demonstrated a high 
level of accuracy and external predictivity, but was primarily trained and tested using 
conventional pesticide active ingredients (Martin, et al., 2011). The question remained 
whether a model trained and tested using such a narrow window of chemical space could be 
forward predictive across the broader chemical landscape. Using the available ToxCast Phase 
II chemical library and corresponding HTS data, a forward validation study was conducted 
using pharmaceuticals, other drug-like compounds, antimicrobials, food additives, pesticide 
formulation/inert ingredients, and additional pesticide active ingredients. The available in 
vivo reproductive toxicity study data quickly diminishes outside of the pesticide registration 
studies, yet 77 chemicals were characterized for the purposes of the forward validation study. 
The prevalence of positive chemicals within this set was inversely related to that of the 
original training and test dataset with roughly two-thirds being positive. We attribute this to 
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the number of chemicals for which only open literature studies were available, which has a 
recognized bias towards positive reporting. The published model’s cutoff parameter was 
established based on optimized balanced accuracy with the prevalence being roughly one-
third positive. Surprisingly, the cutoff of 0.6 remained optimal as did the in vitro activity 
filter of 2% or roughly 10 out of 500 assay actives. The in vitro activity filter removed 15 
chemicals which is comparable to the roughly 20% removed in the training dataset. The 77% 
(72% balanced accuracy) and 70% (69% balanced accuracy) accuracy levels with the model 
applied to the filter and unfiltered forward validation chemical set, respectively, quickly 
demonstrated the forward predictivity and stability of the model. 
 The ability of the model to be forward predictive and to maintain predictivity in light 
of replacing NVS rat CYP inhibition assays with human CYP assays and the use of the 
single-point AC50 estimates as opposed to full concentration response data, characterizes the 
model as highly practical, extensible, and flexible. Over time the model inputs, the individual 
HTS assays, will inevitably be modified due to changes in availability and advancements in 
assay technology. In addition to replacing assays over time, new assays will be developed 
with improved ability to assess perturbations of pathways and gene targets currently in the 
model and to fill data gaps. The data gaps that were previously discussed include 
steroidogenesis and metabolic activation across the targets (Martin, et al., 2011). A further 
recognized data gap identified from the forward validation chemical set is germ cell 
mutagenicity or clastogenicity. For example, acrylamide and a related chemical, N,N'-
methylenebisacrylamide, both cause dominant lethal effects on spermatids and other 
mutagenic/clastogenic effects to the spermatazoa (Sakamoto and Hashimoto, 1986;  
Sakamoto and Hashimoto, 1988) , but were false negatives in the forward validation study. 
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Chemicals acting through increased reactivity or mutagenicity such as the acrylamide 
compounds or benzene containing chemicals like nitrobenzene have a limited in vitro 
bioactivity profile as many of these chemicals are confounded by cytotoxicity and the current 
assay set does not sufficiently address chemical reactivity or mutagenicity. Currently, efforts 
are underway to develop methods to fill this data gap, including ReProComet, and could be 
combined with models measuring receptor- and enzyme-based mechanisms of action 
(Cordelli et al., 2007). Additionally, QSAR models have shown limited success in the area of 
genotoxicity and mutagenicity. Models relevant to germ-cell mutagenicity have been 
developed and could be applied as part of an integrated reproductive testing strategy (Jensen 
et al., 2008;  Novic and Vracko, 2010).  
In addition to testing the forward predictivity and reproducibility of the model, the 
forward validation study also identified features that may have been over predictive in the 
original model. The only two features not maintaining a significant association with 
reproductive toxicity was PPARA and PPARG.  The features, AR, ESR1, CYP, GPCR, 
OTHER and PXR, showed similar or even increased correlation with the forward validation 
chemical set. The highly sensitive ATG_PPARa_TRANS and ATG_PPARg_TRANS drove 
the decrease in correlation as the PPARA and PPARG gene-sets with these assays removed 
remain significantly associated. Although a mechanistic link between PPAR activity and 
fertility or other reproductive impairments remains unclear (Peraza et al., 2006), the role of 
PPAR in steroid metabolism and its activity in reproductive tissues infers that it is a plausible 
target for disruption of endocrine signaling and altered gametogenesis. The addition of 
pharmaceutical compounds targeting PPAR, e.g., glitizars and glitazones, could provide 
evidence concerning whether or not potent and efficacious activators of PPAR cause effects 
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on reproduction. However, very limited information is publically available on these 
compounds in terms of reproductive toxicity. One hypothesis to test in the future is the 
relationship between the relative potency between PPAR activity and specific off-target 
activities with the reproductive toxicity profile of those chemicals. In general, the interactions 
between the gene targets and pathways incorporated into the current forward validated 
model, as well as other pathways, will be explored in a systems biology context, which will 
lead to a better understanding of concentration, dose and time relationships. 
 Rather than diving into the systems biological perspective, practical case studies were 
derived to explore the flexibility of the predictive reproductive toxicity model.  The large 
dataset spanning all phases of model development provided a substantial chemical library 
with which to test the different statutory scenarios. Each case study explored different 
statutory situations or contexts which exist today for the vast majority of environmental 
chemicals. However, the purpose of these case studies was not to provide the full statutory 
context or make definitive testing decisions as the real-world implementation of the existing 
and future regulations would take into account all available information, scientific and 
policy. For instance, case study 1 relates to chemicals with the statutory requirement to run a 
MGR study, but can be waived at the discretion of the regulatory authority. For 
environmental chemicals, this case study is most closely related to the regulation of 
pesticides active ingredients under FIFRA and FQPA, where MGR studies are generally 
required, yet study waiver requests are submitted by the registrants for various reasons. The 
application of the model would differ between food-use and non-food-use pesticides and 
would most likely take into account, at minimum, the available toxicity (e.g., sub-chronic or 
developmental studies) and exposure potential information. The application of the predictive 
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model may be just one piece of information used in the overall waiver or study request 
process. The evaluation of the case studies performed in this study focused on the 
optimization and customization of the model assuming the model was the only tool or 
information available.    
The requesting of study waivers in Case study 1 aimed to test the models ability to 
identify likely negative compounds through optimizing the model for negative predictivity 
and sensitivity. The in vitro activity filter was raised to 8% (i.e., at minimum 8 out of every 
100 assays were active for that particular chemical) increasing the probability that the 
chemical’s bioactivity fingerprint was adequately captured and that the chemical is not acting 
through a mechanism not covered in the current assay battery or that the chemical is not 
amenable to HTS. The outputs of case study 1 are not static as regulators could tune the 
model to further optimize based on different criteria as shown in the mock-up of the decision 
dashboard display (Figure 5.3). Case study 1 captured the application of the model for waiver 
requests which could substantially lower the testing burden of chemical companies and also 
lower the study evaluation process that the regulatory bodies must perform. A better 
understanding of the model’s uncertainties is needed to ensure studies are not waived that 
would have played a major role in the regulation of the chemical, i.e., identifying critical 
effects and dose levels of concern. The cost of even missing a single chemical that would 
have otherwise been identified through traditional testing is difficult to quantify. However, 
the cost of not increasing testing efficiency and maintaining the status quo inherently keeps 
thousands of chemicals on the market and in our environment with no understanding of their 
toxicity potential. 
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Case study 2 explored the situation where costly MGR studies or alternative studies 
could be requested given some prior relevant information. This case study relates to 
antimicrobials regulated under FIFRA and FQPA, loosely to new industrial chemicals under 
TSCA, and is akin to the decision processes in place for tier two testing in EDSP. However, 
the case study exclusively demonstrates the ability of the model to be customized for the 
purposes of efficiently requesting MGR studies based solely on model predictions. Ideally, 
the study request would yield detailed hazard information including mechanistic information 
as well as dose response characterization. This is as opposed to numerous negative findings 
that do not contribute to the risk assessment process. The increased efficiency over randomly 
selecting chemicals for further testing or for choosing chemicals based on use patterns or 
estimated exposure yields a greater return on the investment. In contrast to case study 1, case 
study 2 required optimizing the model to have high specificity and positive predictivity. The 
model cutoff was therefore increased from the original 0.6 level to 2.35 limiting the number 
of requests made to less than 15% of the total number of chemicals, which is a reasonable 
rate of request and would be expected to produce roughly 9 positive findings out of every 10 
tested chemicals. Depending on the statutory authority a greater or lesser percentage of 
chemicals could be requested.  
Case study 3 challenges the model in that there is little to no data or statutory 
authority to request data on the set of chemicals, and therefore any assessment or 
classification would have to be almost entirely based on the outputs of the model. Therefore, 
the model was optimized for nearly every performance metric. The in vitro activity filter and 
model cutoffs were constrained to the point that model predictions were made on only 25% 
of the chemicals. However, for these chemicals, one would currently have little to no 
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capacity to obtain reproductive toxicity assessments. The remaining 75% of chemicals could 
be prioritized for assessment based on their model scores. The 25% of chemicals the model 
was applied to has roughly 90% accuracy and predictivity approaching a level of confidence, 
especially when other characteristics are taken into consideration (e.g., use, exposure 
potential, and physical/chemical properties), that assessments or classifications could be 
based. The three cases studies presented cover the statutory context of the vast majority of 
chemicals, especially environmental chemicals. Application of the model to chemicals within 
each case study showed clear increases in testing efficiency, animal use efficiency, cost 
reduction, and the characterization of previously untested chemicals.  
Further developing the classification model predictive of reproductive toxicity toward 
quantitative predictions of dose, life-stage, and mechanistic relevancy will require a broader 
spectrum of assays and integration of the information into a systems modeling context. 
Progression of the model toward quantitative predictions may enable the complete 
replacement of the multigeneration reproductive study. In the meantime, the forward 
validated predictive model of reproductive toxicity requires a minimal investment per 
chemical to produce a signature of bioactivity capable of accurately identifying candidates 
for further reproductive testing. The predictive tool can immediately impact chemical testing 
decision making and set a course for ultimate replacement of high dose animal testing. 
Tables 
Table 5.1. Forward validation chemical set with associated reproductive LOAEL (rLOAEL) 
values in mg/kg/day and ‘NE” for chemicals that no rLOAEL was established based up to the 
highest dose tested. Percent active shows the number of assay for a given chemical that were 
 169 
considered active over the total number of assays. A two percent in vitro activity filter was 
used to subset the chemicals for forward validation. 
CASRN Chemical Name rLOAEL (mg/kg/day) 
rLOAEL 
≤ 500 
mg/kg/day 
>2% 
In Vitro  
Active 
% 
In Vitro 
Active 
54965-24-1 Tamoxifen citrate 0.003 Yes Yes 18.8 
51-52-5 6-Propyl-2-thiouracil 0.1 Yes Yes 4.0 
57-74-9 Chlordane 0.125 Yes Yes 11.0 
50-28-2 17beta-Estradiol 0.17 Yes Yes 7.6 
1461-22-9 Tributyltin chloride 0.25 Yes Yes 32.9 
13311-84-7 Flutamide 0.4 Yes Yes 12.5 
79-94-7 3,3',5,5'-Tetrabromobisphenol 
A 
0.5 Yes Yes 9.1 
100-00-5 1-Chloro-4-nitrobenzene 0.7 Yes Yes 3.0 
131-18-0 Dipentyl phthalate 0.76 Yes Yes 7.0 
143-50-0 Kepone <1 Yes Yes 12.5 
50-55-5 Reserpine <1 Yes Yes 8.5 
59-05-2 Methotrexate <1 Yes Yes 11.2 
77-09-8 Phenolphthalein <1 Yes Yes 11.2 
4151-50-2 Sulfluramid 1.34 Yes Yes 25.6 
88-85-7 Dinoseb 2.33 Yes Yes 4.9 
5915-41-3 Terbuthylazin 2.5 Yes Yes 3.1 
79-06-1 Acrylamide 3.19 Yes Yes 3.0 
2795-39-3 Potassium 
perfluorooctanesulfonate 
3.2 Yes Yes 10.1 
732-11-6 Phosmet 6.1 Yes Yes 4.9 
119-61-9 Benzophenone 8.8 Yes Yes 2.7 
534-52-1 2-Methyl-4,6-dinitrophenol 10 Yes Yes 11.6 
84852-15-3 4-Nonylphenol, branched 10 Yes Yes 22.3 
69-09-0 Chlorpromazine hydrochloride 12.5 Yes Yes 19.5 
72178-02-0 Fomesafen 12.5 Yes Yes 2.1 
2921-88-2 Chlorpyrifos 15 Yes Yes 5.2 
59-87-0 5-Nitro-2-furaldehyde 
semicarbazone 
15 Yes Yes 2.1 
298-46-4 Carbamazepine 20 Yes Yes 2.7 
3825-26-1 Ammonium 
perfluorooctanoate 
30 Yes Yes 3.4 
10222-01-2 2,2-Dibromo-3-
nitrilopropionamide 
30 Yes Yes 5.2 
107534-96-3 Tebuconazole 30 Yes Yes 8.2 
120-83-2 2,4-Dichlorophenol 49.1 Yes Yes 3.0 
121-14-2 2,4-Dinitrotoluene 50 Yes Yes 4.0 
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446-72-0 Genistein 50 Yes Yes 9.5 
87-86-5 Pentachlorophenol 60 Yes Yes 12.2 
2634-33-5 1,2-Benzisothiazolin-3-one 75.1 Yes Yes 7.6 
140-66-9 4-(1,1,3,3-
Tetramethylbutyl)phenol 
100 Yes Yes 10.9 
85-68-7 Benzyl-butyl-phthalate 100 Yes Yes 5.2 
119-36-8 Methyl salicylate 150 Yes Yes 4.3 
52-51-7 Bronopol 200 Yes Yes 13.1 
65277-42-1 Ketoconazole 200 Yes Yes 8.2 
577-11-7 Docusate sodium 250 Yes Yes 16.8 
1806-26-4 4-Octylphenol 400 Yes Yes 5.5 
99-66-1 Valproic Acid 500 Yes Yes 15.2 
97-54-1 Isoeugenol 700 No Yes 4.9 
102-06-7 1,3-Diphenylguanidine NE No Yes 10.7 
1024-57-3 Heptachlor epoxide NE No Yes 3.7 
126-73-8 Tributyl phosphate NE No Yes 5.5 
137-30-4 Ziram NE No Yes 2.4 
149-30-4 2-Mercaptobenzothiazole NE No Yes 7.3 
151-21-3 Sodium dodecyl sulfate NE No Yes 22.9 
2058-46-0 Oxytetracycline hydrochloride NE No Yes 2.4 
2783-94-0 FD&C Yellow 6 NE No Yes 5.8 
29420-49-3 Perfluorobutane sulfonate, 
potassium 
NE No Yes 6.4 
298-02-2 Phorate NE No Yes 3.4 
307-24-4 Perfluorohexanoic acid NE No Yes 4.9 
319-85-7 beta-1,2,3,4,5,6-
Hexachlorocyclohexane 
NE No Yes 2.7 
34590-94-8 Propanol, 1(or 2)-(2-
methoxymethylethoxy)- 
NE No Yes 9.1 
50-29-3 p,p'-DDT NE No Yes 4.3 
59756-60-4 Fluridone NE No Yes 2.4 
6422-86-2 1,4-Benzenedicarboxylic acid, 
bis(2-ethylhexyl) ester 
NE No Yes 2.4 
88-06-2 2,4,6-Trichlorophenol NE No Yes 4.0 
91-53-2 Ethoxyquin NE No Yes 13.4 
98-95-3 Nitrobenzene 2 Yes No 1.5 
110-26-9 N,N'-methylenebisacrylamide 10 Yes No 0.6 
58-08-2 Caffeine 30 Yes No 1.5 
106-87-6 4-Vinyl-1-cyclohexene 
dioxide 
80 Yes No 0.6 
10605-21-7 Carbendazim 100 Yes No 1.5 
84-66-2 Diethyl phthalate 100 Yes No 0.6 
108-95-2 Phenol 318 Yes No 1.2 
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62-23-7 4-Nitrobenzoic acid 500 Yes No 0.9 
103-90-2 Acetaminophen 1430 No No 0.3 
117-84-0 Dioctyl phthalate NE No No 1.2 
1861-32-1 Chlorthal-dimethyl NE No No 1.8 
57-50-1 Sucrose NE No No 0.9 
80844-07-1 Etofenprox NE No No 1.8 
822-06-0 1,6-Diisocyanatohexane NE No No 1.2 
95-48-7 2-Methylphenol NE No No 0.3 
 
Table 5.2. Performance metrics for the predictive model of reproductive toxicity applied to 
the 77 or 62 chemical in vitro activity un-filtered or filtered forward validation set using the 
same model parameters as previously published (Martin, et al., 2011). The forward validation 
summary statistics were highly comparable to the internal and external validation summary 
statistics. 
Previously 
Published 
Model 
Statistics 
Previously 
Published 
Parameter 
Coefficients 
Forward Validation 
Model Statistics 
Activity Cutoff 
Filter Not 
Applied 
Activity Cutoff 
Filter Applied 
TP 55 PPARa 1.37 TP 37 TP 37 
FP 28 AR 0.98 FP 9 FP 8 
FN 13 ERa 0.45 FN 14 FN 6 
TN 110 PPARg 0.23 TN 17 TN 11 
BA 
Train 77±2% CYP 0.28 SENS 73% SENS 86% 
BA 
Test 74±5% GPCR 0.5 SPEC 65% SPEC 58% 
O-BA 80% OTHER 0.45 BA 69% BA 72% 
O-A 80% PXR -0.21 A 70% A 77% 
EV-A 76% Cutoff 0.6 OR 5 OR 8.5 
BA = Balanced accuracy (Average of sensitivity and specificity); Train=Five-fold cross-validation training set (average and standard 
deviation); Test=Five-fold cross-validation test set (average and standard deviation); O=Optimized or Full Model; EV-A=External 
Validation Accuracy; TP= True Positive Count; FP= False Positive Count; FN=False Negative Count; TN= True negative count; SENS= 
Sensitivity; SPEC= Specificity; A = Accuracy; Cutoff = LDA Model Intercept; OR= Odds ratio 
 
Figures 
Figure 5.1. Schematic representation of the chemical libraries, their overlap with each other, 
and their inclusion into or exclusion from the model development process is summarized. In 
 172 
total, 304 of the 309 chemicals from Phase I of ToxCast were included in the model 
development or external validation process. Only a subset were used in the final model 
development or evaluation process due to filtering based on low quality of MGR or other 
reproductive study or low in vitro activity across all assays. Ultimately, 77 chemicals were 
tested in Phase II of ToxCast, not in Phase I, at the NCGC as part of Tox21, and that had 
quality reproductive study data.  This chemical set was used as the primary forward 
validation chemical set. 
 
Figure 5.2. Estimation of AC50 values and determining active calls across the cell-free 
assays used in the initial predictive model compare to the final AC50 values and hit calls 
using the full concentration response data from ToxCast Phase I. Comparing the hit calls 
resulted in a 87% balanced accuracy, while the negative log10 AC50 among all 305 true 
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positives resulted in a percent correlation of 76%.  Only 31of 305 chemical-assay 
combinations had estimated AC50 values that were greater than an order of magnitude from 
each other, demonstrating the ability to preliminarily use single concentration screening data 
from ToxCast Phase II in applying the predictive model of reproductive toxicity.  
 
 
Figure 5.3. Decision dashboard for case study 1 represents an application of the predictive 
model of reproductive toxicity to chemicals with the statutory requirement to perform a 
multigeneration reproductive study (MGR). The left side of the dashboard displays specific 
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parameters or decisions that can be tuned or chosen and the right side represents the model 
outputs, including model performance. True positive (TP), false positive (FP), false negative 
(FN), and true negative counts are provided based on the model performance and the number 
of chemicals the model was applied to, which in turn computes sensitivity (Sens), specificity 
(Spec), positive predictivity (PPV), negative predictivity (NPV), balanced accuracy (BA) and 
predictivity (Pred). 
 
 
Figure 5.4. Decision dashboard for case study 2 represents an application of the predictive 
model of reproductive toxicity to chemicals with the statutory capacity to request a 
multigeneration reproductive study (MGR). The left side of the dashboard displays specific 
parameters or decisions that can be tuned or chosen and the right side represents the model 
outputs, including model performance. True positive (TP), false positive (FP), false negative 
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(FN), and true negative counts are provided based on the model performance and the number 
of chemicals the model was applied to, which in turn computes sensitivity (Sens), specificity 
(Spec), positive predictivity (PPV), negative predictivity (NPV), balanced accuracy (BA) and 
predictivity (Pred). 
 
 
Figure 5.5. Decision dashboard for case study 3 represents an application of the predictive 
model of reproductive toxicity to chemicals with little to no statutory to request a 
multigeneration reproductive study (MGR). The left side of the dashboard displays specific 
parameters or decisions that can be tuned or chosen and the right side represents the model 
outputs, including model performance. True positive (TP), false positive (FP), false negative 
(FN), and true negative counts are provided based on the model performance and the number 
of chemicals the model was applied to, which in turn computes sensitivity (Sens), specificity 
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(Spec), positive predictivity (PPV), negative predictivity (NPV), balanced accuracy (BA) and 
predictivity (Pred). 
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CHAPTER 6 
GENERAL DISCUSSION 
The combined results of this research demonstrate that bioactivity profiling from high 
throughput screening (HTS) data can be used to accurately predict reproductive toxicity 
potential and be used to increase chemical testing efficiency. In arriving at a forward 
predictive model of reproductive toxicity with the capacity to change chemical testing 
decision making, foundational work had to be performed to ensure data quality, modeling 
transparency, and repeatability. The foundational methodologies employed included 
standardization of toxicological vocabularies, database development, HTS data analysis and 
informatics, classification modeling, and validation procedures.   
In Vivo – Capturing Traditional Reproductive Toxicity Information 
Reproductive toxicity, as defined in this research, is chemical effects on reproductive 
performance (i.e., fertility and fecundity), the reproductive tract, and/or sexual development. 
Reproductive toxicity has been routinely assessed, using laboratory animal studies, in the 
chemical risk assessment process for over forty years. For environmental chemicals, the 
multi-generation reproduction and fertility study in rats has been the primary tool for 
assessing reproductive toxicity potential in humans. Unfortunately, these expensive and 
animal intensive studies have only been conducted on a fraction of environmentally relevant 
chemicals and the studies have been dispersed across many filing cabinets, computers, and 
file management systems over the years. Limited efforts have been made to make these data 
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useful beyond individual chemical risk assessments and to normalize study design and effect 
nomenclature. Before advancements in reproductive toxicity testing decision-making could 
be made using computational modeling and alternative methods, the scientific community 
needed to fully understand the body of information that existed. The Toxicity Reference 
Database (ToxRefDB) was the first large-scale effort to capture and house the dispersed 
library of reproductive toxicity information in a consistent and transparent manner (as 
described in Chapter 2). 
The ToxRefDB reproductive toxicity study dataset has opened the doors to the broad 
evaluation of the multi-generation reproductive toxicity test with goals of refining the study 
design, reducing animal use with alternative methods, or replacing the study altogether. The 
emphasis on using an accepted controlled vocabulary for capturing the study and effect 
information permits the integration of analyses and the common interpretation of results 
across many laboratories, study authors, study reviewers, study designs, and over forty years 
of data. A retrospective analysis, primarily using ToxRefDB, comparing first and second 
generation relative sensitivity has helped push forward the adoption of an extended one-
generation protocol (Piersma et al., 2010), while a similar description of the data was used in 
defining reproductive toxicants for developing a predictive model (as described in Chapter 
4). In the past, these analyses would not have been connected or comparable in any way, thus 
hindering the ability to evaluate the impact of either analysis on refining toxicity testing 
strategies. As alternative test methods for reproductive toxicity continue to be developed 
(Schenk et al., 2010), transparent and consistent definition and use of chemical training sets 
need to be used in order to adequately and uniformly assess new methods and approaches.   
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In Vitro – Analyzing and Interpreting High Throughput Screening Data 
High throughput screening (HTS) has the ability to tests thousands of chemicals in 
concentration response across hundreds of in vitro molecular and cellular assays for tens of 
thousands of dollars as compared to the hundreds of thousands of dollars to run a single two-
generation reproductive study. Much like structural features, HTS assays provide uniform 
data for which to characterize a large chemical library, but are anchored to molecular and 
cellular events often tied to known biological pathways. HTS, as often performed by the 
pharmaceutical industry, has its own unique challenges including the screening of millions of 
chemicals as opposed to thousands as is being done in HTS application toward toxicity 
testing. However, pharmaceutical screening is not typically performed in concentration 
response and aims to identify a select set of very potent and efficacious chemicals against a 
single molecular target as lead candidates for further evaluation. HTS application toward 
toxicity testing has generated and reinvigorated areas of research including performing broad 
spectrum biological activity profiling, routinely running HTS in concentration response 
mode, and discovering the appropriate informatics and analysis techniques to handle and 
interpret the large quantity of data (as described in Chapter 3). The U.S. EPA ToxCast 
research program has produced the largest publically available broad spectrum HTS dataset 
and a few unique themes and lessons have emerged from this diverse dataset, including the 
difference between statistical and biological relevance and the need for common but flexible 
data analysis workflows. 
Generally, a four-parameter hill model can be fit to the concentration response data 
producing a model that estimates the baseline or bottom response, maximal or top response, 
the slope of the response, and the 50% activity concentration or AC50. Data pre-processing, 
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parameter constraining, confounding, statistical and biological considerations all play a role 
into the final set of conditions used to define active or inactive concentrations of a particular 
chemical-assay combination. Specific considerations include, but are not limited to; data 
normalization methods, positive and negative control performance and availability, baseline 
response adjustments, plate or well variations, response saturation (e.g., full versus partial 
agonist), active concentration extrapolation, outlier detection and removal, response 
directionality, non-monotonic response detection, cytotoxicity filtering and interpretation, 
fluorescence and other artifact detection, statistical versus biological significance, and target 
specificity. Taking into account many of these considerations enables summary statistical 
outputs to be compared appropriately across assays and assay technologies and to be used in 
downstream modeling applications. These complex and often dependent confounders support 
the idea that no single assay is “truth” and that incorporating orthogonal or parallel assays 
provides much needed testing redundancy helping ensure an accurate characterization of a 
chemical’s potential to interact with a particular biological target or pathway. Obtaining 
accurate activity calls and accurately annotating the assays prepares the large data-set for 
integration. Pathway-based analysis has been the focus of many researchers in the genomic-
era. However, mapping roughly 500 assays to genes and then to pathways results in hundreds 
to thousands of potential pathways with high levels of redundancy. To lower the complexity 
of data integration, assays were mapped to gene or aggregated to related gene-sets (e.g., all 
cytochrome P450 inhibition assays) reducing the dataset down from over 500 unique assays 
to less than 100 gene or gene-sets. The result of this data reduction process creates an 
increasingly independent dataset, i.e., decreased correlation between input features, and 
assists in the practical long-term implementation of downstream models and tools. The 
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model’s features are genes or gene-sets and do not necessarily rely on a single assay to be 
available and allows for seamless upgrades to the system as new and improved assay 
technology becomes available. 
Model Development – Combing HTS and Animal Toxicity Data 
Computational modeling is an interface between reference in vivo reproductive 
toxicity data and in vitro assay (i.e. HTS) data. Reproductive toxicity is an aggregated multi-
modal and multi-effect outcome. No single assay has the ability to broadly identify 
reproductive toxicants. Computational modeling allows one to explore the complex 
relationships between in vivo observations and networks of in vitro activity. One of the more 
simplistic computational modeling approaches is the development of a classification model, 
which aims to accurately classify or predict an outcome based a training set with known 
outcomes. The training set for modeling reproductive toxicity was the set of chemicals in the 
ToxCast library with high quality reproductive toxicity data (as described in Chapter 4). The 
initial inputs into the model were the hundreds of ToxCast assays that were collectively 
mapped to genes and the aggregate activity across the assays per gene provided the 
quantitative inputs into the model. The assay-gene combinations were further filtered based 
on a feature selection process that evaluated the statistical association to the training set data. 
The filtered gene set was then weighted in a multivariate model using linear discriminate 
analysis (LDA) and five-fold cross-validation. Many other approaches and methods could 
have been deployed, but our observation has been that using complex machine learning 
algorithms have a tendency to over-fit the data lowering the outputted model’s ability to be 
externally predictive. The resulting internal model performance statistics were greater than or 
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equal to 75% balanced accuracy and there was no significant difference between the training 
and test set accuracies.  
For the purposes of clarity and in the context of the predictive reproductive toxicity 
model, the terms ‘external validation’ and ‘forward validation’ are distinguished from each 
other and defined. External validation is the testing of the predictive model’s performance 
using data generated alongside data used in the training of the model, but not used in the 
developing the initial model. Forward validation is the testing of the predictive model’s 
performance using data generated independent of the data used in the training of the model 
and for which the results were not previously known. Among the chemicals selected for 
external validation, the model provided accurate predictions for 16 of the 21 chemicals. The 
five chemicals with inaccurate predictions provide valuable insight into potential limitations 
or gaps of the model. Interestingly, the 5 chemicals had a common phenotypic profile with 
respect to reproductive toxicity causing reduced early offspring survival, particularly litter 
size decrease with little to no accompanying effects on reproductive performance or 
reproductive tract pathology. The rLOAEL for all 5 chemicals was set at the high dose tested 
based on the early offspring survival effects and the parental and offspring LOAEL were set 
at the lower dose levels. Based on the inclusive definition used for defining a positive for 
reproductive toxicity for model development all 5 were considered positive, but lack 
evidence of specific fertility-related or developmentally sensitive reproductive outcomes. 
Nonetheless, a gap in model predictivity has been identified and could potentially be filled 
using additional assay technologies, physical chemical properties and structural descriptors, 
or acute or short-term in vivo studies. 
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Biological Plausibility – Key Targets and Pathways Identified 
The model development process identified biologically plausible features and 
pathways from over 500 assays mapped to less than 100 genes or gene-sets and spanning 
many reproductive relevant modes-of-action. PPARα activity was clearly associated with 
reproductive toxicity, with all 10 PPARα agonists in the training set causing reproductive 
toxicity. Although a mechanistic link between PPAR activity and fertility or other 
reproductive impairments remains unclear (Peraza et al., 2006), the role of PPAR in steroid 
metabolism and its activity in reproductive tissues infers that it is a plausible target for 
disruption of endocrine signaling and altered gametogenesis. AR and ERα activity was also 
associated with reproductive toxicity. The ToxCast receptor profiling identified most if not 
all the known anti-androgenic and estrogenic chemicals in the current dataset, but the causal 
relationship between reproductive toxicity and steroid receptor activity, absolute and relative 
potency and efficacy, needs to be explored further. CYP enzyme inhibition, as compared to 
gene induction, was significantly more associated with reproductive toxicity. Alterations in 
steroid metabolism through CYP induction have been previously associated with 
reproductive impairment (Goetz et al., 2007), however the non-specific inhibition of CYPs 
may be a surrogate for a chemical’s capacity to disturb steroid metabolism including 
inhibition of key CYPs involved in steroidogenesis (e.g., Cyp19 and Cyp17). Related to CYP 
activity, PXR interestingly displayed a negative correlation/association with reproductive 
toxicity. In general, PXR lowered the false positive rate of the model by lowering the model 
score of chemicals with non-specific and low potency nuclear receptor activity. Robust PXR 
activity is an indication of potent xeno-sensing and potentially rapid metabolism. A major 
component of the model not directly related to nuclear receptor biology and 
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xenobiotic/steroid metabolism was GPCR binding. Numerous GPCR binding assays were 
significantly associated with reproductive toxicity. Those chosen to represent the GPCR 
family were selected for statistical, and not biological, reasons as there is limited literature 
information on their role in reproduction in contrast to their well characterized role in 
nervous system function. Platforms measuring EGFR, TGF-β1 and NF-κB activity were also 
associated with reproductive toxicity. All three gene products have been shown to modulate 
the relative sensitivity of developmental toxicants, especially aryl-hydrocarbon receptor 
signaling (Abbott et al., 2003;  Tian et al., 1999) and may be indicative of altered xenobiotic 
metabolism, cellular proliferation, cell-cell signaling or potential epigenetic effects (Tian, 
2009;  Tian et al., 2002). Overall the key targets in the model identify plausible modes of 
action leading to reproductive toxicity covering anti-androgenic, estrogenic, 
cholesterol/steroid metabolism, limited coverage of disruption of steroidogenesis, and altered 
xenobiotic metabolism modes of action. 
Validation – Evaluating the Developed Model 
Forward validation of the predictive reproductive toxicity model ultimately measures 
the stability of the entire system. The model was previously shown to be stable using cross-
validation (75% accuracy across the test sets) and robust using external validation (75% 
accuracy). Forward validation not only further tests the external predictivity of the model 
across an increasingly diverse chemical set, but also tests the reproducibility and overall 
quality of the input data (i.e., HTS data). The additional 297 chemicals run across the entire 
assay set used in developing the model produced 77 chemicals with high quality reproductive 
toxicity study data. Key differences between the external validation dataset and the forward 
validation dataset included the fact that the cell-free assays were all run in single-point versus 
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full concentration response and the rodent cytochrome P450 inhibition (CYP) assays were 
replaced with human assays due to cost reduction and testing efficiency. These real-world 
factors truly test the applicability of the predictive model and interesting appeared to have 
little impact on model performance. Using ToxCast Phase I data, the single-point activity 
calls were roughly 90% concordant with concentration response activity calls and the human 
CYP assays were roughly 70% correlated to the rodent. Additionally, applying the in vitro 
activity filter of 2% (i.e., 2 out of every 100 assays were active for a particular chemical) 
removed 15 of the 77 chemicals from the forward validation chemical set. In applying the 
model to the forward validation chemical set with and without the activity filter the model 
remained highly accurate with 77% accuracy (72% balanced accuracy) and 70% accuracy 
(69% balanced accuracy), respectively. The maintained high level of accuracy progressing 
from training, to testing, to external validation, and finally to forward validation 
demonstrates the applicability of the model to classify the reproductive toxicity potential of 
chemicals.  
Application – Developing a Tool for Chemical Testing 
There currently is great need for a tool that can inform chemical testing decisions 
especially with regards to reproductive toxicity testing due to heavy animal use, high cost, 
and increasing concern for chemicals effects on reproductive development (Scialli, 2008). 
The forward validated predictive model of reproductive toxicity would undoubtedly be 
improved by incorporation of other available models, alternative test methods and 
institutional knowledge, especially in regards to supplementing recognized weaknesses in the 
model including steroidogenesis and germ-cell mutagenicity (Cordelli et al., 2007;  Hareng et 
al., 2005). The validation status and transparency of the various alternative methods, tools or 
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models varies, but currently would be difficult to integrate due to discordant chemical 
coverage and a lack of data availability at this time. Nonetheless, evaluating the current 
model in isolation gives great insight into its potential impact on chemical testing decision-
making. Three case studies were derived varying the statutory context varying from requiring 
a MGR study, to requesting a MGR study, to no authority to request a study. Using the full 
chemical dataset with reproductive toxicity information (N=381chemicals), the first case 
study tested the ability of the model to accurately identify the most likely negative chemicals 
in order to apply a waiver to those chemicals. Based on optimized model sensitivity and 
negative predictivity, waivers could be applied to 67 chemicals out of the 381 total, a roughly 
20% reduction in reproductive testing and total cost. In contrast, case study 2 has the 
statutory authority to request studies when evidence suggests the need for a study. Therefore, 
the model was optimized to identify most likely positive chemicals resulting in 52 of the 381 
chemicals resulting in MGR study requests. Each study costs upwards of $750,000, but the 
increased efficiency in running studies that result in important positive findings potentially 
being used in chemical risk assessment would save roughly $90,000 per chemical across all 
chemicals that would fall under case study 2. Case study 3 provides the biggest challenge 
because of the limited authority to request studies and the current number of chemicals that 
fall into this category. In starting to tackle the need for assessing these chemicals the model 
was applied by attempting to optimize the confidence in both negative and positive 
predictions. Therefore, the model was applied to the lowest and highest scoring chemicals 
with a high in vitro activity filter resulting in 25% of the chemicals being classified as highly 
likely to be a reproductive toxicant (27 of 28 chemicals positive) or not (59 of 67chemicals 
negative). The remaining 75% of chemicals could be prioritized for further testing or 
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evaluation based on their model scores. The three cases studies cover the statutory context of 
the vast majority of chemicals, in particular environmental chemicals. Application of the 
model to chemicals within each case study showed clear increases in testing efficiency, 
animal use efficiency, cost reduction, and the characterization of previously untested 
chemicals. 
With the availability of a forward validated classification model predicting 
reproductive toxicity, the bottleneck of uncharacterized chemicals can be evaluated either 
through improvements in the overall statutory authority to request MGR studies or in the 
ability to quantitatively identify reproductive toxicants. If the statutory authority to request 
MGR studies were improved, then the current model in concert with other models, 
alternative methods and institutional knowledge could identify with fairly good accuracy and 
efficiency all chemicals that a MGR should be requested. If the latter were improved to the 
point of accurate adverse dose predictions, then the model could drastically decrease the need 
for MGR studies and be used in the assessment of the majority of environmental chemicals. 
To do this, improvements in HTS assay reproducibility, metabolic capacity, mode-of-action 
coverage, reverse toxicokinetics, and overall model accuracy would need to be made. Placing 
the classification model into a systems modeling context will begin to address these next 
generation of research questions. For now, the forward validated predictive model of 
reproductive toxicity can go a long way in improving reproductive chemical testing 
efficiency and decision-making. 
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CHAPTER 7 
FUTURE DIRECTIONS 
The development of a classification model predictive of rodent reproductive toxicity 
has provided the chemical testing community with a tool for prioritizing and targeting testing 
decisions for chemicals with unknown toxicities. Practical implementation of this tool 
requires large scale testing of thousands of chemicals across, at minimum, the assays used in 
the model. As additional models are generated and integrated with each other, hundreds of 
high throughput screening (HTS) assays will be required and be used to test, refine and add 
to the high throughput predictive toolbox. The cost to run over 500 assays in roughly 10 
distinct technologies is roughly $30,000 per chemical in contrast to the greater than twenty 
million dollars it costs to run the battery of animal toxicity studies used in pesticide 
registration.  The nominal costs to run such a large library of assays makes expansion of the 
current assay set reasonable, especially if data generation and analysis costs are shared or 
distributed among government regulatory agencies and chemical companies. The current 
predictive model of reproductive toxicity is a good example of how we will continue to 
refine and expand the model. 
Assay Development to Fill Biological Gaps 
 The predictive model has recognized data gaps in terms of known and unknown 
modes of toxic action, assay coverage, and pathway redundancy. The model contains non-
specific cytochrome P450 inhibition as a feature predictive of reproductive toxicity potential 
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yet provides little specific indication of a chemical’s potential to disrupt steroidogenesis. To 
cover the steroidogenic mode-of-action, multiple assays may be required but a good start 
would be the incorporation of the H295R steroidogenesis assay currently used in the 
Endocrine Disrupter Screening Program (EDSP) and that is currently being converted into a 
higher-throughput 96-well format (Hecker and Giesy, 2008;  Hecker et al., 2011). Another 
identified mode-of-action gap in the current model is the detection of germ-cell mutagens 
and clastogens. Currently, a number of assays are available, but lack throughput for testing 
thousands of chemicals (Cordelli et al., 2007). Future research in advancing the throughput 
and mechanistic coverage of assays or models targeting the identification of germ-cell 
damaging chemicals is needed and is an area in which structure-based modeling may be a 
useful tool (Grindon et al., 2008). The identification and filling of biological gaps in the 
model will only increase the understanding and relationships between features in the model 
and the resulting predictions. An initial step in relating the biological responses, predicted 
outcome and the actual adverse outcome is the use of pharmacokinetic information. The 
assumption would be that the biological features in the model would have to be activated at 
or below concentrations that cause the adverse reproductive outcome.  Currently, a concept 
of reverse pharmacokinetics, a combination of in vitro hepatic clearance, plasma protein 
binding and a simple pharmacokinetic model, is being used to estimate the administered dose 
required to achieve a steady-state concentration in the blood equivalent to the active 
concentrations observed in a particular HTS assay (Rotroff et al., 2010).  In short, one can 
convert micromolar active concentrations to milligram per kilogram of bodyweight per day 
(mg/kg/day). Early work has shown that relationship exist between HTS targets linked to a 
particular mode-of-action  and whole animal toxic outcomes for chemicals with a known 
 195 
modes-of-action (Judson et al., 2011). However, additional research is needed to incorporate 
this reverse toxicokinetic information into the model development process and using the 
information to corroborate and link biological activity with toxicological activity. 
Neuroendocrine Systems Modeling 
 To advance the reproductive modeling effort being classification modeling, the effort 
will need to be put into a system modeling framework. One such approach is the 
development of virtual tissues or systems as is currently being done with the liver and 
embryo. Directly related to the prediction of reproductive outcomes, would be the modeling 
of the hypothalamic-pituitary (HP) axis, the primary initiator of the onset of puberty and key 
in the maintenance of gonadal (G), thyroid (T), and adrenal (A) function. Many of the key 
normal physiological events involved in pubertal onset, sexual maturation, steroidogenesis, 
and oogenesis have been well described based on observed hormonal, protein and gene 
changes (Hoyer, 2010;  Perreault, 2008). However, the exact sequence of these events and 
the ability of chemicals to perturb these well orchestrated feedback mechanisms have yet to 
be elucidated in full. Currently, a variety of in vivo and in vitro assays exist that explore 
chemical perturbations of the HP(GTA)-axis, including estrogenicity, androgenicity, 
aromatase, steroidogenesis, thyroid function, puberty, and sexual maturation and will 
continue to be refined, scaled-up, and validated. The majority of these mechanisms are 
covered in the current predictive model of reproductive toxicity, but dose- and time-
relationships can be explored further within the virtual HP(GTA)-axis. The ultimate goal 
would be to have a working model of the HP(GTA)-axis that would incorporate high-
throughput testing results and other data to make detailed predictions of an uncharacterized 
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chemical’s effect on reproduction and sexual development with life-stage, dose response, and 
mechanistic specificity. 
Extension to Predicting Human and Ecological Reproductive Toxicity 
 The systems modeling approaches also help progress from predicting animal toxicity 
to human toxicity and extrapolating to ecologically-relevant species. Very limited causal 
evidence exists pertaining to chemical effects on human reproduction, thus the inability to 
predict human reproductive toxicity directly, to date. However, through the EPA ToxCast 
research program marketed and failed pharmaceutical compounds have been included into 
the chemical library and the respective pharmaceutical companies have contributed pre-
clinical and clinical data. Efforts are underway to make the clinical data useful and to begin 
to bridge between HTS, pre-clinical, and clinical outcomes. The number of chemicals with 
high quality clinical fertility or other reproductive parameters tested will most likely be 
limited, but nonetheless may provide hints as to the human relevancy of some of the targets 
in the current or future models. In addition to predicting human toxicity, research efforts are 
needed to evaluate the challenges in extending models predictive of mammalian toxicity to 
ecologically-relevant species, including reptiles, amphibians, fish, and birds. Work similar to 
ToxRefDB has been performed for pesticide registration studies for ecological risk 
assessments (Russom, 2002). The data from ECOTOX could provide valuable bridging data 
by comparing, for example, avian reproduction study data to rat multigeneration reproductive 
study data, but additional work is needed to make these data comparable. Much attention has 
been placed on testing for endocrine disruption for both human and ecological risk 
assessments (Ankley et al., 2009). However, few ecologically-relevant species have been the 
target of endocrine screening especially for assays outside of estrogen and androgen receptor 
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activity. Assay development needs to be focused on these other species as well as expanding 
beyond estrogen and androgen assays into screening for HP(GTA) effects (Watanabe et al., 
2009).  Lessons learned from developing predictive reproductive toxicity models of 
ecological species, especially if done so from a population perspective, could have great 
impact on the use of predictive models towards human health risk assessment.  Likewise, 
performing systems modeling determining best practices for specific extrapolation from 
rodent to human in HTS predictive models will greatly impact approaches applied in 
environmental toxicology. Using computational toxicology as the interface between typically 
distinct risk assessment processes should help advance both regulatory sciences or even 
merge them into one with an eye toward full life-cycle assessments. 
Developing an Integrated Testing Strategy 
 An early step toward assessing chemicals in an integrated fashion is the combining of 
predictive toxicity models and alternative test methods as part of an overarching integrated 
testing strategy. Similar efforts to develop predictive models of prenatal developmental 
toxicity using HTS data have shown promise and the compatibility with the predictive model 
of reproductive toxicity will make the integration of the two models straightforward. These 
HTS-derived models will enable the evaluation of the vast majority of environmental 
chemicals with the initial capacity to prioritize chemical testing or make other simple 
chemical testing decisions. In addition to the systems modeling work that needs to be 
performed to add dose, time, and mechanistic relevance to the classification models, equal 
efforts in developing and validating alternative test methods for evaluating developmental 
and reproductive toxicity in alternative test species or medium throughput complex assay 
systems are required. Ideally, the systems modeling and the test method development will 
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feed off of each other with the systems modeling identifying molecular and cellular 
mechanisms to focus assay development and for the complex assay systems to provide data 
feeding systems modeling efforts. As the mechanisms leading to toxicity continue to be 
elucidated and the ability to assay those mechanisms becomes available, the need and 
reliance on animal testing will decline. The focus and usefulness of chemical-by-chemical 
risk assessment will diminish and the integrated evaluation of chemicals in the context of 
pathways, co-exposures, lifestyle and communities will be the drivers of chemical safety 
assessments. 
  
 199 
References 
Ankley, G. T., Bencic, D. C., Breen, M. S., Collette, T. W., Conolly, R. B., Denslow, N. D., 
Edwards, S. W., Ekman, D. R., Garcia-Reyero, N., Jensen, K. M., Lazorchak, J. M., 
Martinovic, D., Miller, D. H., Perkins, E. J., Orlando, E. F., Villeneuve, D. L., Wang, R. L. 
and Watanabe, K. H. (2009). Endocrine disrupting chemicals in fish: developing exposure 
indicators and predictive models of effects based on mechanism of action. Aquat Toxicol 92, 
168-78, S0166-445X(09)00039-3 [pii] 
10.1016/j.aquatox.2009.01.013. 
 
Cordelli, E., Fresegna, A. M., D'Alessio, A., Eleuteri, P., Spano, M., Pacchierotti, F. and 
Villani, P. (2007). ReProComet: a new in vitro method to assess DNA damage in mammalian 
sperm. Toxicol Sci 99, 545-52, kfm191 [pii] 
10.1093/toxsci/kfm191. 
 
Grindon, C., Combes, R., Cronin, M. T., Roberts, D. W. and Garrod, J. F. (2008). Integrated 
decision-tree testing strategies for developmental and reproductive toxicity with respect to 
the requirements of the EU REACH legislation. Altern Lab Anim 36, 65-80. 
 
Hecker, M. and Giesy, J. P. (2008). Novel trends in endocrine disruptor testing: the H295R 
Steroidogenesis Assay for identification of inducers and inhibitors of hormone production. 
Anal Bioanal Chem 390, 287-91, 10.1007/s00216-007-1657-5. 
 
Hecker, M., Hollert, H., Cooper, R., Vinggaard, A. M., Akahori, Y., Murphy, M., 
Nellemann, C., Higley, E., Newsted, J., Laskey, J., Buckalew, A., Grund, S., Maletz, S., 
Giesy, J. and Timm, G. (2011). The OECD validation program of the H295R steroidogenesis 
assay: Phase 3. Final inter-laboratory validation study. Environ Sci Pollut Res Int 18, 503-15, 
10.1007/s11356-010-0396-x. 
 
Hoyer, P. B. (2010). Female Reproductive Toxicology. pp. 339-345. Elsevier, Oxford. 
 
Judson, R. S., Kavlock, R. J., Setzer, R. W., Hubal, E. A., Martin, M. T., Knudsen, T. B., 
Houck, K. A., Thomas, R. S., Wetmore, B. A. and Dix, D. J. (2011). Estimating toxicity-
related biological pathway altering doses for high-throughput chemical risk assessment. 
Chem Res Toxicol 24, 451-62, 10.1021/tx100428e. 
 
Perreault, S. D., Klinefelter G.R., Clegg E. (2008). Assessment of Male Reproductive 
Toxicity. Informa Healthcare, USA. 
 
Rotroff, D. M., Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., 
LeCluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., Sochaski, M. A., Kavlock, R. 
J., Boellmann, F., Martin, M. T., Reif, D. M., Wambaugh, J. F. and Thomas, R. S. (2010). 
Incorporating Human Dosimetry and Exposure into High-Throughput In Vitro Toxicity 
Screening. Toxicol Sci 117, 348-358, DOI 10.1093/toxsci/kfq220. 
 
 200 
Russom, C. L. (2002). Mining environmental toxicology information: web resources. 
Toxicology 173, 75-88, S0300483X02000239 [pii]. 
 
Watanabe, K. H., Li, Z., Kroll, K. J., Villeneuve, D. L., Garcia-Reyero, N., Orlando, E. F., 
Sepulveda, M. S., Collette, T. W., Ekman, D. R., Ankley, G. T. and Denslow, N. D. (2009). 
A computational model of the hypothalamic-pituitary-gonadal axis in male fathead minnows 
exposed to 17alpha-ethinylestradiol and 17beta-estradiol. Toxicol Sci 109, 180-92, kfp069 
[pii] 
10.1093/toxsci/kfp069. 
 
 
 
